Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
34100.0 | 2014-12-30 00:00:00 UTC | Health Care Sector Update for 12/30/2014: XNPT,BGMD,CTSO | ABT | https://www.nasdaq.com/articles/health-care-sector-update-12302014-xnptbgmdctso-2014-12-30 | nan | nan | Top Health Care Stocks
JNJ +0.17%
PZE +0.13%
MRK +0.50%
ABT -0.01%
AMGN -1.05%
Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group.
In company news, shares of XenoPort Inc. ( XNPT ) sprang sharply higher Tuesday after a RBC Capital Markets analyst late yesterday named the biotech company working to develop treatments for neurological disorders as his sleeper pick for the upcoming year.
During a late afternoon appearance on CNBC, Michael Yee said XNPT was an "under the radar play" for 2015, igniting an after-market buying spree that has spilled over into today's trade.
XNPT was up more than 8% at $9.01 each in recent trade, earlier climbing to within 3 cents of its recent two-year high at $9.24 a share. Heading into today's session, the stock already had risen over 49% over the past 12 months.
In other sector news,
(+) BGMD, (+62.5%) FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer.
(-) CTSO, (-6.6%) Submits Investigational Device Exemption application to begin clinical testing of its CytoSorb filter in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) BGMD, (+62.5%) FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. In company news, shares of XenoPort Inc. ( XNPT ) sprang sharply higher Tuesday after a RBC Capital Markets analyst late yesterday named the biotech company working to develop treatments for neurological disorders as his sleeper pick for the upcoming year. During a late afternoon appearance on CNBC, Michael Yee said XNPT was an "under the radar play" for 2015, igniting an after-market buying spree that has spilled over into today's trade. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news, (+) BGMD, (+62.5%) FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group. | In other sector news, (+) BGMD, (+62.5%) FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group. In company news, shares of XenoPort Inc. ( XNPT ) sprang sharply higher Tuesday after a RBC Capital Markets analyst late yesterday named the biotech company working to develop treatments for neurological disorders as his sleeper pick for the upcoming year. | In other sector news, (+) BGMD, (+62.5%) FDA authorizes first automated version of galectin-3 testing for chronic heart failure with 510(k) clearance for the company's BGM Galectin-3 blood test for use with the Abbott ( ABT ) ARCHITECT immunoassay analyzer. Top Health Care Stocks Health care stocks were narrowly lower this afternoon with the NYSE Health Care Sector Index declining about 0.2% and shares of health care companies in the S&P 500 also down about 0.2% as a group. |
34101.0 | 2014-12-29 00:00:00 UTC | Novartis' Cosentyx Approved in Japan for Psoriatic Arthritis - Analyst Blog | ABT | https://www.nasdaq.com/articles/novartis-cosentyx-approved-in-japan-for-psoriatic-arthritis-analyst-blog-2014-12-29 | nan | nan | Novartis ( NVS ) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Cosentyx (secukinumab) for the treatment of both psoriasis vulgaris and psoriatic arthritis (PsA) in adults who have failed to respond adequately to systemic therapies (except for biologics).
The approval was based on positive safety and efficacy results from more than 10 phase II and phase III studies and supported by two pivotal phase III studies, FUTURE 1 and FUTURE 2.
The studies demonstrated a favorable safety profile for Cosentyx, with similar incidence and severity of adverse events across the different treatment arms.
Meanwhile, Cosentyx has obtained a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). In Nov 2014, the CHMP recommended Cosentyx as a first-line treatment of moderate-to-severe psoriasis.
In Oct 2014, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) unanimously voted in favor of approving Cosentyx for the treatment of moderate-to-severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy. The DODAC's recommendation was based on safety and efficacy data from 10 phase II/III studies in patients suffering from moderate-to-severe plaque psoriasis.
A response from the FDA regarding the approval of Cosentyx should be out in early 2015.
Novartis is also evaluating Cosentyx for the treatment of ankylosing spondylitis (AS) and rheumatoid arthritis (RA).
The approval of Cosentyx in Japan will be a major boost for Novartis as it will further strengthen the company's dermatology portfolio. The company already has Xolair in its dermatology portfolio, which is approved both in the EU and the U.S. While the treatment is labeled as refractory chronic spontaneous urticaria in the EU it is known as refractory chronic idiopathic urticaria in the U.S.
The successful development and commercialization of the pipeline is important for the company as it faces generic competition for several key drugs such as Gleevec, Zometa and Diovan.
Novartis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader health care sector include AbbVie ( ABBV ), Allergan ( AGN ) and Abbott Inc ( ABT ). All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ALLERGAN INC (AGN): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader health care sector include AbbVie ( ABBV ), Allergan ( AGN ) and Abbott Inc ( ABT ). Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis ( NVS ) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Cosentyx (secukinumab) for the treatment of both psoriasis vulgaris and psoriatic arthritis (PsA) in adults who have failed to respond adequately to systemic therapies (except for biologics). | Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader health care sector include AbbVie ( ABBV ), Allergan ( AGN ) and Abbott Inc ( ABT ). In Oct 2014, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) unanimously voted in favor of approving Cosentyx for the treatment of moderate-to-severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy. | Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader health care sector include AbbVie ( ABBV ), Allergan ( AGN ) and Abbott Inc ( ABT ). Novartis ( NVS ) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Cosentyx (secukinumab) for the treatment of both psoriasis vulgaris and psoriatic arthritis (PsA) in adults who have failed to respond adequately to systemic therapies (except for biologics). | Some better-ranked stocks in the broader health care sector include AbbVie ( ABBV ), Allergan ( AGN ) and Abbott Inc ( ABT ). Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In Oct 2014, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) unanimously voted in favor of approving Cosentyx for the treatment of moderate-to-severe plaque psoriasis in adult patients suitable for systemic therapy or phototherapy. |
34102.0 | 2014-12-18 00:00:00 UTC | Does China Have an Unfair Competitive Advantage Over U.S. Companies? | ABT | https://www.nasdaq.com/articles/does-china-have-unfair-competitive-advantage-over-us-companies-2014-12-18 | nan | nan | Best Buy is taking a fast boat out of China, selling its stake in a local appliance retailer and essentially ending its presence in the country. Photo: Wikimedia Commons.
Can U.S. companies beat China, let alone survive or thrive there?
Best Buy became the latest casualty to surrender to seeming Chinese superiority. It announced last week it was throwing in the towel, selling its Jiangsu Five Star Appliance division to local real estate outfit Jiayuan Group and largely exiting the Chinese market. In doing so, the electronics retailer joins a growing number of U.S. and multinational corporations that have similarly concluded they can't beat China at its own game.
Yahoo! , Revlon , Home Depot , and U.K. supermarket chain Tesco are just a few of the companies that slinked out of China after finding they could not compete effectively against local businesses.
I'll buy that
Yet it shouldn't be this way. The demographics of China's economy are a retailer's dream. Its cities are growing, income is rising, and the new wealth has created a Chinese middle class willing to spend more. In fact, the Chinese markets are geared more toward consumerism than at any time before.
The Economist reported China more than any other country contributed to growth in global consumption over the last two years and is "poised to become the next consumption superpower." China's $3.3 trillion in private consumption represents just 8% of the world's total, butis large enough to make it the second-largest global consumer-oriented society.
With more than a century of honing our consumerist skills, shouldn't U.S. business have easily marched in and taken over?
The great firewall
Sure, the Chinese government has thrown roadblocks in front of a number of Internet businesses, hampering their ability to compete. Facebook , Twitter , Google , and even Amazon.com have all been blocked or banned at times.
But U.S. retailers generally haven't encountered such problems since Deng Xiaoping opened up the country to foreign investment 35 years or so ago. Some U.S. industries even perform quite well.
Recent tainted-food scandals notwithstanding, global fast-food chains like KFC remain as popular as ever in China.
Fast-food dominates the landscape, with McDonald's operating some 2,000 restaurants in China that account for 10% of total company revenue, while Yum! Brands runs 4,400 KFC restaurants and 1,100 Pizza Hut locations. China represented half of its revenue and 40% of its operating profit last year.
Others have capitalized on local scandals to build their business. Memories of tainted milk that killed dozens of children and sickened thousands has Chinese mothers gladly paying inflated prices for dairy products from Abbott Laboratories , Mead Johnson Nutrition , and Nestle rather than buy from local suppliers.
Apple generated 16% of its total revenue this fiscal year from China, where sales jumped 17% from 2013. That was faster than any other region and was ahead of the company's growth overall. And Ford is seeing the increase in Chinese car sales outpace auto industry growth as a whole.
Enter the dragon
Best Buy, though, couldn't get it right from the beginning. It entered China in 2006 with a small chain of branded stores and did nothing with them. After five years it had only opened nine Best Buy stores that were easily overwhelmed by leading Chinese chain Gome, which operates over 1,000 stores. Best Buy subsequently closed those locations in favor of a partnership with Jiangsu Five Star. Now it wants nothing to do with that investment, either.
Part of the problem is cultural. Best Buy operated its Chinese stores the way it does here, buying all its products from suppliers and distributors and selling them itself. Chinese consumer electronics retailers, on the other hand, tend to lease out space to suppliers and let their employees do the sales, something like a store-in-store boutique, but on a grander scale . Value-added services like delivery, installation and assembly, and maintenance are also often free in China, but Best Buy charged for them.
A new American century
The consumer electronic giant is not completely quitting China. It promises to keep a small presence through its private-label business that includes brands like Insignia and Rocketfish. But the announcement is recognition that breaking into this insular market is not easy.Still, U.S. businesses should have the competitive edge. Chinese consumers often seek out foreign name brands because they associate them with quality. Retailers that account for local sensibilities ought to be able to capitalize on that advantage and take a victory lap instead of waving the white flag of defeat.
Best Buy could not figure that out. Apple, McDonald's, and others have. There is no innate competitive superiority for Chinese companies. U.S. businesses just need to learn how to climb the wall of success there rather than simply believing that if they build it, Chinese consumers will come.
You can't afford to miss this
"Made in China" -- an all too familiar phrase. But not for much longer: There's a radical new technology out there, one that's already being employed by the U.S. Air Force, BMW and even Nike. Respected publications like The Economist have compared this disruptive invention to the steam engine and the printing press; Business Insider calls it "the next trillion dollar industry." Watch The Motley Fool's shocking video presentation to learn about the next great wave of technological innovation, one that will bring an end to "Made In China" for good. Click here !
The article Does China Have an Unfair Competitive Advantage Over U.S. Companies? originally appeared on Fool.com.
FollowRich Duprey 's coverage of all the most important news and developments inretail and consumer goods. He has no position in any stocks mentioned. The Motley Fool recommends Amazon.com, Apple, Facebook, Ford, Google (C shares), Home Depot, McDonald's, Twitter, and Yahoo. The Motley Fool owns shares of Amazon.com, Apple, Facebook, Ford, Google (C shares), Microsoft, Twitter, and Yahoo. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | It announced last week it was throwing in the towel, selling its Jiangsu Five Star Appliance division to local real estate outfit Jiayuan Group and largely exiting the Chinese market. Memories of tainted milk that killed dozens of children and sickened thousands has Chinese mothers gladly paying inflated prices for dairy products from Abbott Laboratories , Mead Johnson Nutrition , and Nestle rather than buy from local suppliers. Watch The Motley Fool's shocking video presentation to learn about the next great wave of technological innovation, one that will bring an end to "Made In China" for good. | Fast-food dominates the landscape, with McDonald's operating some 2,000 restaurants in China that account for 10% of total company revenue, while Yum! The Motley Fool recommends Amazon.com, Apple, Facebook, Ford, Google (C shares), Home Depot, McDonald's, Twitter, and Yahoo. The Motley Fool owns shares of Amazon.com, Apple, Facebook, Ford, Google (C shares), Microsoft, Twitter, and Yahoo. | Best Buy is taking a fast boat out of China, selling its stake in a local appliance retailer and essentially ending its presence in the country. Best Buy operated its Chinese stores the way it does here, buying all its products from suppliers and distributors and selling them itself. The Motley Fool recommends Amazon.com, Apple, Facebook, Ford, Google (C shares), Home Depot, McDonald's, Twitter, and Yahoo. | I'll buy that Yet it shouldn't be this way. But U.S. retailers generally haven't encountered such problems since Deng Xiaoping opened up the country to foreign investment 35 years or so ago. Best Buy operated its Chinese stores the way it does here, buying all its products from suppliers and distributors and selling them itself. |
34103.0 | 2014-12-17 00:00:00 UTC | Better Big Pharma Spinoff: Zoetis Inc. or AbbVie Inc.? | ABT | https://www.nasdaq.com/articles/better-big-pharma-spinoff-zoetis-inc-or-abbvie-inc-2014-12-17 | nan | nan | We're approaching two years after Abbott Labs spun off its pharmaceutical division AbbVie and a little less since Zoetis , Pfizer 's animal health division, separated from its patent company.
Seems like a good time to see which spinoff has performed better. Let's take a look at a couple of metrics.
Returns Winner: AbbVie
Measuring by stock price. AbbVie clearly wins. The following chart begins when Zoetis went public. AbbVie is up 98% since inception, more than double the 41% increase that the S&P 500 managed. | We're approaching two years after Abbott Labs spun off its pharmaceutical division AbbVie and a little less since Zoetis , Pfizer 's animal health division, separated from its patent company. Returns Winner: AbbVie Measuring by stock price. AbbVie is up 98% since inception, more than double the 41% increase that the S&P 500 managed. | We're approaching two years after Abbott Labs spun off its pharmaceutical division AbbVie and a little less since Zoetis , Pfizer 's animal health division, separated from its patent company. Seems like a good time to see which spinoff has performed better. Let's take a look at a couple of metrics. | We're approaching two years after Abbott Labs spun off its pharmaceutical division AbbVie and a little less since Zoetis , Pfizer 's animal health division, separated from its patent company. Seems like a good time to see which spinoff has performed better. Let's take a look at a couple of metrics. | We're approaching two years after Abbott Labs spun off its pharmaceutical division AbbVie and a little less since Zoetis , Pfizer 's animal health division, separated from its patent company. Seems like a good time to see which spinoff has performed better. Let's take a look at a couple of metrics. |
34104.0 | 2014-12-15 00:00:00 UTC | Daily Dividend Report: GE, PFE, ABT, BXMT, AES, ZMH | ABT | https://www.nasdaq.com/articles/daily-dividend-report-ge-pfe-abt-bxmt-aes-zmh-2014-12-15 | nan | nan | GE ( GE ) raised the Company's quarterly dividend 5%, or $0.01 per outstanding share of the Company's common stock, to $0.23 per outstanding share of the Company's common stock. The Board declared that the dividend is payable January 26, 2015 to shareowners of record at the close of business on December 22, 2014. The ex-dividend date is December 18, 2014.
Pfizer declared a 28-cent first-quarter 2015 dividend on the company's common stock, payable March 3, 2015, to shareholders of record at the close of business on February 6, 2015. Pfizer increased the dividend by approximately 8 percent, to 28 cents from 26 cents per share.
Abbott ( ABT ) increased the company's quarterly common dividend to $0.24 per share from $0.22 per share. The cash dividend is payable Feb. 13, 2015, to shareholders of record at the close of business on Jan. 15, 2015.
Blackstone Mortgage Trust ( BXMT ) declared a dividend of $0.52 per share of class A common stock with respect to the fourth quarter of 2014. This dividend is payable on January 15, 2015 to stockholders of record as of the close of business on December 31, 2014.
The AES Corporation ( AES ) approved a 100% increase in the Company's quarterly common stock dividend, to $0.10 per share from $0.05 per share. The Board of Directors declared a quarterly common stock dividend of $0.10 per share payable on February 17, 2015, to shareholders of record at the close of business on February 3, 2015.
And, Zimmer Holdings ( ZMH ) has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2014. The cash dividend of $0.22 per share will be paid on or about January 30, 2015, to stockholders of record as of the close of business on December 29, 2014.
VIDEO: Daily Dividend Report: GE, PFE, ABT, BXMT, AES, ZMH
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott ( ABT ) increased the company's quarterly common dividend to $0.24 per share from $0.22 per share. VIDEO: Daily Dividend Report: GE, PFE, ABT, BXMT, AES, ZMH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Board declared that the dividend is payable January 26, 2015 to shareowners of record at the close of business on December 22, 2014. | VIDEO: Daily Dividend Report: GE, PFE, ABT, BXMT, AES, ZMH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) increased the company's quarterly common dividend to $0.24 per share from $0.22 per share. GE ( GE ) raised the Company's quarterly dividend 5%, or $0.01 per outstanding share of the Company's common stock, to $0.23 per outstanding share of the Company's common stock. | Abbott ( ABT ) increased the company's quarterly common dividend to $0.24 per share from $0.22 per share. VIDEO: Daily Dividend Report: GE, PFE, ABT, BXMT, AES, ZMH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. GE ( GE ) raised the Company's quarterly dividend 5%, or $0.01 per outstanding share of the Company's common stock, to $0.23 per outstanding share of the Company's common stock. | Abbott ( ABT ) increased the company's quarterly common dividend to $0.24 per share from $0.22 per share. VIDEO: Daily Dividend Report: GE, PFE, ABT, BXMT, AES, ZMH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Pfizer declared a 28-cent first-quarter 2015 dividend on the company's common stock, payable March 3, 2015, to shareholders of record at the close of business on February 6, 2015. |
34105.0 | 2014-12-13 00:00:00 UTC | Can These Top Dividend-Paying Stocks Soar in 2015? | ABT | https://www.nasdaq.com/articles/can-these-top-dividend-paying-stocks-soar-2015-2014-12-13 | nan | nan | Searching for the top dividend paying stocks is easy. Use any screening tool -- The Motley Fool has one here -- and search for dividend yields above a certain threshold.
But any experienced investor knows there's more to a dividend-paying stock than its yield. Dividend yields are often high because the share price has sunk because investors aren't confident the payout can be sustained.
Rather than characterizing the top dividend-paying stocks as those with the highest yield, let's define them as stocks that can provide the best return -- dividend yield plus growth in share price -- to give us healthy companies with strong cash flow that can help raise the dividend in the future.
Here are three healthcare stocks I | Use any screening tool -- The Motley Fool has one here -- and search for dividend yields above a certain threshold. Dividend yields are often high because the share price has sunk because investors aren't confident the payout can be sustained. Rather than characterizing the top dividend-paying stocks as those with the highest yield, let's define them as stocks that can provide the best return -- dividend yield plus growth in share price -- to give us healthy companies with strong cash flow that can help raise the dividend in the future. | Searching for the top dividend paying stocks is easy. Use any screening tool -- The Motley Fool has one here -- and search for dividend yields above a certain threshold. Rather than characterizing the top dividend-paying stocks as those with the highest yield, let's define them as stocks that can provide the best return -- dividend yield plus growth in share price -- to give us healthy companies with strong cash flow that can help raise the dividend in the future. | Searching for the top dividend paying stocks is easy. Dividend yields are often high because the share price has sunk because investors aren't confident the payout can be sustained. Rather than characterizing the top dividend-paying stocks as those with the highest yield, let's define them as stocks that can provide the best return -- dividend yield plus growth in share price -- to give us healthy companies with strong cash flow that can help raise the dividend in the future. | Searching for the top dividend paying stocks is easy. Use any screening tool -- The Motley Fool has one here -- and search for dividend yields above a certain threshold. But any experienced investor knows there's more to a dividend-paying stock than its yield. |
34106.0 | 2014-12-11 00:00:00 UTC | Diamond Hill Adds Two Companies to Portfolio in Third Quarter | ABT | https://www.nasdaq.com/articles/diamond-hill-adds-two-companies-portfolio-third-quarter-2014-12-11 | nan | nan | At its web site , Diamond Hill Capital ( Trades , Portfolio ) Management calls itself "an independent investment management firm headquartered in Columbus, Ohio."
In its summary of its investment philosophy, Diamond Hill writes, "We focus on the fundamentals of intrinsic value, which are far less volatile than market price, and our actions are ultimately dictated by the price to intrinsic value relationship."
That seems to work pretty well. In the last five years, Diamond Hill's average annual return has been 18.3%. Since its inception in 2000, its average annual return has been better than 12%.
Dodge & Cox Undervalued Stocks
Dodge & Cox Top Growth Companies
Dodge & Cox High Yield stocks
IVA International Fund Undervalued Stocks
IVA International Fund Top Growth Companies
IVA International Fund High Yield stocks
Diamond Hill Capital Undervalued Stocks
Diamond Hill Capital Top Growth Companies
Diamond Hill Capital High Yield stocks
In the third quarter, Diamond Hill Capital (Trades, Portfolio) bought two stocks that are new to its portfolio - Goodyear Tire & Rubber Co ( GT ) and StrykerCorporation ( SYK ).
The firm bought 3,182,158 shares of Goodyear, a tire manufacturer based in Ohio, for an average price of $25.67 per share. The purchase had a 0.55% impact on the firm's portfolio.
Diamond Hill also bought 425,344 shares of Stryker, a Michigan-based medical technology company, for an average price of $82.29. That transaction had a 0.27% impact on the portfolio.
The company added to its existing stakes in 29 companies - Twenty-First Century Fox Inc ( FOX ), Abbott Laboratories ( ABT ), Juniper Networks Inc ( JNPR ), Alere Inc (ALR), Cimarex Energy Co (XEC), Praxair Inc (PX), International Business Machines Corp (IBM), Devon Energy Corp (DVN), TJX Companies (TJX), Willis Group Holdings PLC (WSH), United Technologies Corp (UTX), Pfizer Inc (PFE), Jarden Corp (JAH), Citigroup Inc (C), Boston Scientific Inc (BSX), Parker Hannifin Corp (PH), Whirlpool Corp (WHR), Kimberly-Clark Corp (KMB), Brown & Brown Inc (BRO), Post Holdings Inc (POST), Aircastle Ltd (AYR), Hub Group Inc (HUBG), Live Nation Entertainment Inc (LYV), Fortress Investment Group LLC (FIG), Aaron's Inc (AAN), Molson Coors Brewing C o (TAP), Contango Oil & Gas Co (MCF), State Bank Financial Corp (STBZ) and SunTrust Banks Inc (STI).
Diamond Hill's purchase of 2,445,959 shares of Twenty-First Century Fox, a New York-based mass media company, for an average price of $33.42 per share had an impact of 0.63% on the firm's portfolio.
The additions to Diamond Hill's holdings in Abbott Laboratories, a North Chicago-based pharmaceuticals and healthcare products company, and Juniper Networks, a California-based manufacturer of networking equipment, each had a 0.38% impact on Diamond Hill's portfolio.
Diamond Hill purchased 1,202,099 shares of Abbott for an average price of $42.32 per share.
The company bought 2,207,861 shares of Juniper Networks for an average price of $23.45 per share.
Divestitures and reductions
Diamond Hill sold all its holdings in nine companies - Bank of New York Mellon Corp (BK), WGL Holdings Inc (WGL), KeyCorp (KEY), General Mills Inc (GIS), Air Products & Chemicals Inc (APD), ConAgra Foods Inc (CAG), Quest Diagnostics Inc (DGX), Liquidity Service Inc (LQDT) and Southwest Airlines Co (LUV).
The divestiture of 2,497,295 shares of General Mills, a food products company based in Minnesota, for an average price of $52.47 per share had a -1% impact on the firm's portfolio.
Diamond Hill reduced its holdings in seven companies - Dollar General Corp (DG), Medtronic Inc (MDT), McDonald's Corp (MCD), Occidental Petroleum Corp (OXY), Avis Budget Group Inc (CAR), GlaxoSmithKline PLC (GSK) and XPO Logistics Inc (XPO).
To view the portfolios of more gurus, visit theList of Guruspage. Not a premium member of GuruFocus?Try it free for 7 days.
About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. This value investing site offers stock screeners and valuation tools. And publishes daily articles tracking the latest moves of the world's best investors. GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .
This article first appeared on GuruFocus .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The company added to its existing stakes in 29 companies - Twenty-First Century Fox Inc ( FOX ), Abbott Laboratories ( ABT ), Juniper Networks Inc ( JNPR ), Alere Inc (ALR), Cimarex Energy Co (XEC), Praxair Inc (PX), International Business Machines Corp (IBM), Devon Energy Corp (DVN), TJX Companies (TJX), Willis Group Holdings PLC (WSH), United Technologies Corp (UTX), Pfizer Inc (PFE), Jarden Corp (JAH), Citigroup Inc (C), Boston Scientific Inc (BSX), Parker Hannifin Corp (PH), Whirlpool Corp (WHR), Kimberly-Clark Corp (KMB), Brown & Brown Inc (BRO), Post Holdings Inc (POST), Aircastle Ltd (AYR), Hub Group Inc (HUBG), Live Nation Entertainment Inc (LYV), Fortress Investment Group LLC (FIG), Aaron's Inc (AAN), Molson Coors Brewing C o (TAP), Contango Oil & Gas Co (MCF), State Bank Financial Corp (STBZ) and SunTrust Banks Inc (STI). Diamond Hill also bought 425,344 shares of Stryker, a Michigan-based medical technology company, for an average price of $82.29. The additions to Diamond Hill's holdings in Abbott Laboratories, a North Chicago-based pharmaceuticals and healthcare products company, and Juniper Networks, a California-based manufacturer of networking equipment, each had a 0.38% impact on Diamond Hill's portfolio. | The company added to its existing stakes in 29 companies - Twenty-First Century Fox Inc ( FOX ), Abbott Laboratories ( ABT ), Juniper Networks Inc ( JNPR ), Alere Inc (ALR), Cimarex Energy Co (XEC), Praxair Inc (PX), International Business Machines Corp (IBM), Devon Energy Corp (DVN), TJX Companies (TJX), Willis Group Holdings PLC (WSH), United Technologies Corp (UTX), Pfizer Inc (PFE), Jarden Corp (JAH), Citigroup Inc (C), Boston Scientific Inc (BSX), Parker Hannifin Corp (PH), Whirlpool Corp (WHR), Kimberly-Clark Corp (KMB), Brown & Brown Inc (BRO), Post Holdings Inc (POST), Aircastle Ltd (AYR), Hub Group Inc (HUBG), Live Nation Entertainment Inc (LYV), Fortress Investment Group LLC (FIG), Aaron's Inc (AAN), Molson Coors Brewing C o (TAP), Contango Oil & Gas Co (MCF), State Bank Financial Corp (STBZ) and SunTrust Banks Inc (STI). At its web site , Diamond Hill Capital ( Trades , Portfolio ) Management calls itself "an independent investment management firm headquartered in Columbus, Ohio." Dodge & Cox Undervalued Stocks Dodge & Cox Top Growth Companies Dodge & Cox High Yield stocks IVA International Fund Undervalued Stocks IVA International Fund Top Growth Companies IVA International Fund High Yield stocks Diamond Hill Capital Undervalued Stocks Diamond Hill Capital Top Growth Companies Diamond Hill Capital High Yield stocks In the third quarter, Diamond Hill Capital (Trades, Portfolio) bought two stocks that are new to its portfolio - Goodyear Tire & Rubber Co ( GT ) and StrykerCorporation ( SYK ). | The company added to its existing stakes in 29 companies - Twenty-First Century Fox Inc ( FOX ), Abbott Laboratories ( ABT ), Juniper Networks Inc ( JNPR ), Alere Inc (ALR), Cimarex Energy Co (XEC), Praxair Inc (PX), International Business Machines Corp (IBM), Devon Energy Corp (DVN), TJX Companies (TJX), Willis Group Holdings PLC (WSH), United Technologies Corp (UTX), Pfizer Inc (PFE), Jarden Corp (JAH), Citigroup Inc (C), Boston Scientific Inc (BSX), Parker Hannifin Corp (PH), Whirlpool Corp (WHR), Kimberly-Clark Corp (KMB), Brown & Brown Inc (BRO), Post Holdings Inc (POST), Aircastle Ltd (AYR), Hub Group Inc (HUBG), Live Nation Entertainment Inc (LYV), Fortress Investment Group LLC (FIG), Aaron's Inc (AAN), Molson Coors Brewing C o (TAP), Contango Oil & Gas Co (MCF), State Bank Financial Corp (STBZ) and SunTrust Banks Inc (STI). Dodge & Cox Undervalued Stocks Dodge & Cox Top Growth Companies Dodge & Cox High Yield stocks IVA International Fund Undervalued Stocks IVA International Fund Top Growth Companies IVA International Fund High Yield stocks Diamond Hill Capital Undervalued Stocks Diamond Hill Capital Top Growth Companies Diamond Hill Capital High Yield stocks In the third quarter, Diamond Hill Capital (Trades, Portfolio) bought two stocks that are new to its portfolio - Goodyear Tire & Rubber Co ( GT ) and StrykerCorporation ( SYK ). Diamond Hill's purchase of 2,445,959 shares of Twenty-First Century Fox, a New York-based mass media company, for an average price of $33.42 per share had an impact of 0.63% on the firm's portfolio. | The company added to its existing stakes in 29 companies - Twenty-First Century Fox Inc ( FOX ), Abbott Laboratories ( ABT ), Juniper Networks Inc ( JNPR ), Alere Inc (ALR), Cimarex Energy Co (XEC), Praxair Inc (PX), International Business Machines Corp (IBM), Devon Energy Corp (DVN), TJX Companies (TJX), Willis Group Holdings PLC (WSH), United Technologies Corp (UTX), Pfizer Inc (PFE), Jarden Corp (JAH), Citigroup Inc (C), Boston Scientific Inc (BSX), Parker Hannifin Corp (PH), Whirlpool Corp (WHR), Kimberly-Clark Corp (KMB), Brown & Brown Inc (BRO), Post Holdings Inc (POST), Aircastle Ltd (AYR), Hub Group Inc (HUBG), Live Nation Entertainment Inc (LYV), Fortress Investment Group LLC (FIG), Aaron's Inc (AAN), Molson Coors Brewing C o (TAP), Contango Oil & Gas Co (MCF), State Bank Financial Corp (STBZ) and SunTrust Banks Inc (STI). Diamond Hill purchased 1,202,099 shares of Abbott for an average price of $42.32 per share. The divestiture of 2,497,295 shares of General Mills, a food products company based in Minnesota, for an average price of $52.47 per share had a -1% impact on the firm's portfolio. |
34107.0 | 2014-12-04 00:00:00 UTC | This Pet Food Supplier Is Still In the Hunt for Growth | ABT | https://www.nasdaq.com/articles/pet-food-supplier-still-hunt-growth-2014-12-04 | nan | nan | It's been the dog days for pet supplies industry. Data: American Pet Products Association
The wave of consolidation washing over the pet supplies industry may claim yet another company in PetSmart, and Petco's acquisition of Drs. Foster & Smith for an undisclosed sum shows its ability and willingness to participate in the M&A game.
As much bite as bark these days
Although a lot of the stocks gains PetSmart has made over the year can probably be attributed to the strategic moves it has been forced to undertake, its most recent quarterly performance was a reason for investors to purr with delight. Net sales continued improving, rising at low single digit rates, and comparable stores were flat, which for a company experiencing falling comps for much of the year, it was a welcome change.
It still needs to get control over comparable transactions, which continued to fall, but it maintains a trajectory that's beating analyst expectations while producing profit margins that are decent considering the promotional economic environment it's operating in.
With planned cost reductions totaling $200 million for 2015, comps in the low single digits, and a mid-teen increase in EPS, PetSmart may be strong enough to withstand the challenge hedge fund operator Jana Partners promises will result if it doesn't approve of the strategic alternative analysis that emerges. The P/E firm says it has five candidates it will nominate for the pet supplier's board.
Chomping at the bit
A PetSmart acquisition could make its acquirer the top dog in the industry. However, there seems to be more risk than reward in its stock at the moment. An offer has been largely priced in, and if a buyout deal doesn't materialize, its stock could deflate.
With the industry being shaped by the ebb and flow of mergers and acquisitions, and as e-commerce and online shopping continue to alter the landscape further, the major industry retailers will need to devise new strategies to come up with a competitive edge other than simply buying out their rivals if they want to unleash growth.
1 great stock to buy for 2015 and beyond
2015 is shaping up to be another great year for stocks. But if you want to make sure that 2015 is your best investing year ever, you need to know where to start. That's why The Motley Fool's chief investment officer just published a brand-new research report that reveals his top stock for the year ahead. To get the full story on this year's stock -- completely free -- simply click here .
The article This Pet Food Supplier Is Still In the Hunt for Growth originally appeared on Fool.com.
FollowRich Duprey 's coverage of all theretailing industry'smost important news and developments. He owns shares of Pfizer. The Motley Fool recommends Amazon.com and PetSmart. The Motley Fool owns shares of Amazon.com. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | As much bite as bark these days Although a lot of the stocks gains PetSmart has made over the year can probably be attributed to the strategic moves it has been forced to undertake, its most recent quarterly performance was a reason for investors to purr with delight. It still needs to get control over comparable transactions, which continued to fall, but it maintains a trajectory that's beating analyst expectations while producing profit margins that are decent considering the promotional economic environment it's operating in. With planned cost reductions totaling $200 million for 2015, comps in the low single digits, and a mid-teen increase in EPS, PetSmart may be strong enough to withstand the challenge hedge fund operator Jana Partners promises will result if it doesn't approve of the strategic alternative analysis that emerges. | It's been the dog days for pet supplies industry. The Motley Fool owns shares of Amazon.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Data: American Pet Products Association The wave of consolidation washing over the pet supplies industry may claim yet another company in PetSmart, and Petco's acquisition of Drs. As much bite as bark these days Although a lot of the stocks gains PetSmart has made over the year can probably be attributed to the strategic moves it has been forced to undertake, its most recent quarterly performance was a reason for investors to purr with delight. That's why The Motley Fool's chief investment officer just published a brand-new research report that reveals his top stock for the year ahead. | It's been the dog days for pet supplies industry. Net sales continued improving, rising at low single digit rates, and comparable stores were flat, which for a company experiencing falling comps for much of the year, it was a welcome change. The Motley Fool owns shares of Amazon.com. |
34108.0 | 2014-12-03 00:00:00 UTC | Bulls can't get enough of Abbott Labs | ABT | https://www.nasdaq.com/articles/bulls-cant-get-enough-abbott-labs-2014-12-03 | nan | nan | For the second day in a row, traders anticipate a rally in Abbott Laboratories.
optionMONSTER's Heat Seeker monitoring program detected the purchase of more than 5,000 February 46 calls for $0.98 today. Volume was more than twice the previous open interest in the strike, which indicates that new money was put to work.
Long calls lock in the price where investors can buy a stock, positioning them to benefit from a rally for limited cost. Cheap option premiums help control risk and can produce significant leverage on a percentage basis. (See our Education section)
Today's activity follows buying yesterday in the December 46 calls , which are already up more than 30 percent. We've also had a winning trade recently AbbVie , which was spun off from ABT two years ago.
ABT is up 1.04 percent to $45.69 in afternoon trading and is in all-time record territory. The provider of medical products has been marching steadily higher for the last month despite falling on a weak revenue number in late October.
Total option volume in the name is already quadruple its full-session average so far today, according to the Heat Seeker. Overall ABT calls outnumber puts by a bullish 19-to-1 ratio.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We've also had a winning trade recently AbbVie , which was spun off from ABT two years ago. ABT is up 1.04 percent to $45.69 in afternoon trading and is in all-time record territory. Overall ABT calls outnumber puts by a bullish 19-to-1 ratio. | Overall ABT calls outnumber puts by a bullish 19-to-1 ratio. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. We've also had a winning trade recently AbbVie , which was spun off from ABT two years ago. | We've also had a winning trade recently AbbVie , which was spun off from ABT two years ago. ABT is up 1.04 percent to $45.69 in afternoon trading and is in all-time record territory. Overall ABT calls outnumber puts by a bullish 19-to-1 ratio. | We've also had a winning trade recently AbbVie , which was spun off from ABT two years ago. ABT is up 1.04 percent to $45.69 in afternoon trading and is in all-time record territory. Overall ABT calls outnumber puts by a bullish 19-to-1 ratio. |
34109.0 | 2014-12-03 00:00:00 UTC | Abbott Labs attracts bullish trades | ABT | https://www.nasdaq.com/articles/abbott-labs-attracts-bullish-trades-2014-12-03 | nan | nan | AbbVie has rallied, and now the bulls are turning to former parent Abbott Laboratories.
optionMONSTER's Heat Seeker tracking program detected the purchase of about 7,500 December 46 calls yesterday, most of which priced for $0.37. Volume was 20 times the strike's previous open interest, which indicates that new money was put to work.
Long calls lock in the price where investors can buy shares in the maker of health-care products. The cheap cost of the options lets traders position for profits from a rally at limited risk while also creating the possibility for significant leverage if the stock pushes higher. (See our Education section)
ABT rose 2.03 percent to $45.22 yesterday and at one point hit an all-time high of $45.62 in the session. The stock has been steadily working higher for more than three years and is up about 15 percent since the broader market bottomed in mid-October.
Overall option volume in Abbott was 8 times greater than its daily average for the last month, with calls accounting for a bullish three-quarters of the total.
Calls in AbbVie, which was spun off in late 2012, have already handed investors profits of about 50 percent after triggering alerts on our InsideOptions Pro subscription service one week ago.
(A version of this post appeared on InsideOptions Pro yesterday.)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright © 2010 OptionMonster® Holdings, Inc. All Rights Reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (See our Education section) ABT rose 2.03 percent to $45.22 yesterday and at one point hit an all-time high of $45.62 in the session. The cheap cost of the options lets traders position for profits from a rally at limited risk while also creating the possibility for significant leverage if the stock pushes higher. Overall option volume in Abbott was 8 times greater than its daily average for the last month, with calls accounting for a bullish three-quarters of the total. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (See our Education section) ABT rose 2.03 percent to $45.22 yesterday and at one point hit an all-time high of $45.62 in the session. (A version of this post appeared on InsideOptions Pro yesterday.) | (See our Education section) ABT rose 2.03 percent to $45.22 yesterday and at one point hit an all-time high of $45.62 in the session. The cheap cost of the options lets traders position for profits from a rally at limited risk while also creating the possibility for significant leverage if the stock pushes higher. Overall option volume in Abbott was 8 times greater than its daily average for the last month, with calls accounting for a bullish three-quarters of the total. | (See our Education section) ABT rose 2.03 percent to $45.22 yesterday and at one point hit an all-time high of $45.62 in the session. AbbVie has rallied, and now the bulls are turning to former parent Abbott Laboratories. optionMONSTER's Heat Seeker tracking program detected the purchase of about 7,500 December 46 calls yesterday, most of which priced for $0.37. |
34110.0 | 2014-11-18 00:00:00 UTC | UPRO, ABT, ACT, ADT: ETF Outflow Alert | ABT | https://www.nasdaq.com/articles/upro-abt-act-adt-etf-outflow-alert-2014-11-18 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $38.8 million dollar outflow -- that's a 4.0% decrease week over week (from 7,550,000 to 7,250,000). Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Actavis plc (Symbol: ACT) is up about 5.4%, and ADT Corp (Symbol: ADT) is lower by about 0.4%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $79.47 per share, with $131.15 as the 52 week high point - that compares with a last trade of $130.64. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Actavis plc (Symbol: ACT) is up about 5.4%, and ADT Corp (Symbol: ADT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $38.8 million dollar outflow -- that's a 4.0% decrease week over week (from 7,550,000 to 7,250,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Actavis plc (Symbol: ACT) is up about 5.4%, and ADT Corp (Symbol: ADT) is lower by about 0.4%. For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $79.47 per share, with $131.15 as the 52 week high point - that compares with a last trade of $130.64. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Actavis plc (Symbol: ACT) is up about 5.4%, and ADT Corp (Symbol: ADT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $38.8 million dollar outflow -- that's a 4.0% decrease week over week (from 7,550,000 to 7,250,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $79.47 per share, with $131.15 as the 52 week high point - that compares with a last trade of $130.64. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.5%, Actavis plc (Symbol: ACT) is up about 5.4%, and ADT Corp (Symbol: ADT) is lower by about 0.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $38.8 million dollar outflow -- that's a 4.0% decrease week over week (from 7,550,000 to 7,250,000). For a complete list of holdings, visit the UPRO Holdings page » The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $79.47 per share, with $131.15 as the 52 week high point - that compares with a last trade of $130.64. |
34111.0 | 2014-11-18 00:00:00 UTC | Zoetis to Buy Abbott's Animal Health Assets for $255 Million - Analyst Blog | ABT | https://www.nasdaq.com/articles/zoetis-to-buy-abbotts-animal-health-assets-for-%24255-million-analyst-blog-2014-11-18 | nan | nan | Zoetis Inc. ( ZTS ) was up 2.5% after the company announced that it has entered into an agreement with Abbott Laboratories ( ABT ) to purchase the latter's animal health assets. The deal is valued at $255 million. The transaction is expected to close in the first quarter of 2015.
Abbott Animal Health - focused on the veterinary surgical suite - is a companion animal health business operating in nearly 20 countries.
The acquisition of Abbott's animal health assets will add several interesting products to Zoetis' portfolio. These include PropoFlo (general anesthesia), Simbadol (a feline pain reliever) and AlphaTRAK (a glucose monitoring system). Zoetis' pipeline will also be boosted by several cancer and pain candidates.
We note that Mylan ( MYL ) is set to acquire Abbott's branded specialty and generics business in the developed ex-U.S. markets. This deal is also expected to close in the first quarter of 2015.
Our Take
We are pleased with Zoetis' decision to acquire Abbott's animal health assets. The transaction will boost Zoetis' companion animal product portfolio and expand its diagnostics business. We expect to see more such acquisitions/deals at Zoetis in the near future as the company continues to focus on its strategy of acquiring complementary businesses and products.
Meanwhile, Valeant Pharmaceuticals International, Inc. ( VRX ) is rumored to be interested in acquiring Zoetis.
Zoetis carries a Zack Rank #3 (Hold). Mylan is a better-ranked stock in the health care sector sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
VALEANT PHARMA (VRX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
ZOETIS INC (ZTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Zoetis Inc. ( ZTS ) was up 2.5% after the company announced that it has entered into an agreement with Abbott Laboratories ( ABT ) to purchase the latter's animal health assets. Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. These include PropoFlo (general anesthesia), Simbadol (a feline pain reliever) and AlphaTRAK (a glucose monitoring system). | Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis Inc. ( ZTS ) was up 2.5% after the company announced that it has entered into an agreement with Abbott Laboratories ( ABT ) to purchase the latter's animal health assets. The transaction will boost Zoetis' companion animal product portfolio and expand its diagnostics business. | Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis Inc. ( ZTS ) was up 2.5% after the company announced that it has entered into an agreement with Abbott Laboratories ( ABT ) to purchase the latter's animal health assets. Abbott Animal Health - focused on the veterinary surgical suite - is a companion animal health business operating in nearly 20 countries. | Zoetis Inc. ( ZTS ) was up 2.5% after the company announced that it has entered into an agreement with Abbott Laboratories ( ABT ) to purchase the latter's animal health assets. Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition of Abbott's animal health assets will add several interesting products to Zoetis' portfolio. |
34112.0 | 2014-11-11 00:00:00 UTC | DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog | ABT | https://www.nasdaq.com/articles/dexcom-scales-52-week-high-on-product-pipeline-strength-analyst-blog-2014-11-11 | nan | nan | Shares of DexCom, Inc. ( DXCM ) closed at a new 52-week high of $53.50 on Nov 10, translating into a solid one-year return of roughly 62%. In fact, shares of this CA-based glucose monitoring systems provider have been on the rise since the beginning of this year, posting an impressive year-to-date return of around 51%.
DexCom has a market cap of around $4 billion while average volume of shares traded over the last three months stands at roughly 0.6 million.
Catalysts for Growth
Impressive third-quarter 2014 results indicating double-digit top-line growth, a string of U.S. Food and Drug Administration (FDA) approvals for its new products over the last few months along with a robust product pipeline contribute to the growth trajectory of this company, creating good momentum for 2015 as well.
This week, FDA approved a new algorithm designed for DexCom's G4 Platinum Continuous Glucose Monitoring (CGM) system, following which shares of the company shot up around 14%. With this new technology, the G4 Platinum system approaches a MARD (Mean Absolute Relative Difference) measurement of 9%, making it the first and only CGM system in the market with a single-digit MARD.
Last month, the FDA cleared DexCom's CGM remote mobile communications device - DexCom SHARE, which enables wireless transmission of a patient's glucose information to the G4 Platinum receiver. Following the approval, DexCom launched the device, making significant advances toward extending CGM to mobile devices.
In the recently reported third-quarter 2014, the company's losses remained flat on a year-over-year- basis. Revenues, on the other hand, surged 60.8% driven by continued growth in the installed base of customers using the G4 Platinum system.
Gross margins also expanded primarily due to greater sales of the high margin G4 Platinum system. Higher gross margin base, along with strong revenue growth further led to narrower operating losses in the quarter.
Going forward, DexCom expects to drive greater sales volume and improved margins as it makes significant investments and launches new products. It is extremely optimistic with regard to its G4 Platinum system which has been driving superior product revenue growth.
However, the company continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind.
Currently, DexCom carries a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, the company continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, shares of this CA-based glucose monitoring systems provider have been on the rise since the beginning of this year, posting an impressive year-to-date return of around 51%. | Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, the company continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. This week, FDA approved a new algorithm designed for DexCom's G4 Platinum Continuous Glucose Monitoring (CGM) system, following which shares of the company shot up around 14%. | Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, the company continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. This week, FDA approved a new algorithm designed for DexCom's G4 Platinum Continuous Glucose Monitoring (CGM) system, following which shares of the company shot up around 14%. | Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report DEXCOM INC (DXCM): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, the company continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. This week, FDA approved a new algorithm designed for DexCom's G4 Platinum Continuous Glucose Monitoring (CGM) system, following which shares of the company shot up around 14%. |
34113.0 | 2014-11-10 00:00:00 UTC | DexCom G4 Platinum Software Gains FDA Nod, Shares Surge - Analyst Blog | ABT | https://www.nasdaq.com/articles/dexcom-g4-platinum-software-gains-fda-nod-shares-surge-analyst-blog-2014-11-10 | nan | nan | DexCom, Inc. ( DXCM ) recently revealed the U.S. Food and Drug Administration (FDA) approval for a new algorithm designed for its G4 PLATINUM Continuous Glucose Monitoring (CGM) system. Following the announcement, shares of DexCom shot up nearly 14.12% to close at $50.93 in the last trading session.
This latest software enhancement to DexCom G4 Platinum will make the performance level of blood glucose monitoring comparable to finger stick meters, the traditional standard-of-care for the same. With this new technology, the G4 Platinum system approaches a MARD (Mean Absolute Relative Difference) measurement of 9%, making it the first and only CGM system in the market with a single-digit MARD.
The new algorithm will be made available free of charge to existing adult patients using G4 Platinum and will be preloaded onto the new DexCom receivers. The combination of the latest software with CGM advantages of real-time trends, speed and direction, will allow healthcare providers, patients and caregivers to have a complete picture of the patient's glucose activity.
Management is extremely optimistic with regard to the new algorithm for the G4 Platinum system, which according to them, represents a significant potential to support the company's ultimate goal of replacing finger-sticks altogether.
In fact, since its launch in Oct 2012, the G4 Platinum CGM system has been driving superior product revenue growth at DexCom. Notably, DexCom's average year over year quarterly revenue growth has been approximately 63% since the launch.
The recently reported third-quarter 2014 also saw a significant 60% rise in product revenues, on the back of continued growth in the installed base of customers using the G4 Platinum system. Other highlights of the quarter are provided below.
Third-Quarter Results
DexCom reported a loss of 8 cents per share in the third-quarter of 2014, wider than the Zacks Consensus Estimate of a loss of 5 cents. However, losses during the quarter remained flat on a year-over-year basis.
DexCom's total revenue surged 60.8% to $69 million, topping the Zacks Consensus Estimate of $61 million. The upside was driven by an impressive 60% rise in product revenues to $68 million and a $0.7 million increase in development grant and other revenues to $1.1 million.
Gross margin expanded 450 basis points year over year to 69.5%, primarily due to increased revenue and greater sales of the high margin G4 Platinum system.
Both selling, general and administrative (SG&A) and research and development (R&D) expenses rose 56% and 56.8% year over year, respectively, owing to higher cost of sales, increased marketing expenses, additional payroll and consulting costs and other key expenses for commercial infrastructure.
Despite the increase in both R&D and SG&A expenses, operating loss narrowed to $5 million from the year-ago level of $5.8 million, riding on strong revenue growth and higher gross margin base.
DexCom had cash and cash equivalents of $63.2 million as of Sep 31, 2014, higher than $49.5 million as of Jun 30, 2014. Total long-term debt went down to $5.2 million from $5.8 million as of Jun 30, 2014.
Our Take
We are encouraged with DexCom's revenue beat and narrower operating losses in the third quarter. DexCom also boasts a robust product pipeline with the recent launch of DexCom SHARE - the first FDA-approved mobile remote monitoring system - and the new software for its G4 Platinum CGM System.
However, DexCom continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind.
Currently, DexCom carries a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DEXCOM INC (DXCM): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | However, DexCom continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. DexCom, Inc. ( DXCM ) recently revealed the U.S. Food and Drug Administration (FDA) approval for a new algorithm designed for its G4 PLATINUM Continuous Glucose Monitoring (CGM) system. | Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, DexCom continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. Both selling, general and administrative (SG&A) and research and development (R&D) expenses rose 56% and 56.8% year over year, respectively, owing to higher cost of sales, increased marketing expenses, additional payroll and consulting costs and other key expenses for commercial infrastructure. | Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, DexCom continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. The upside was driven by an impressive 60% rise in product revenues to $68 million and a $0.7 million increase in development grant and other revenues to $1.1 million. | Click to get this free report DEXCOM INC (DXCM): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. However, DexCom continues to face stiff competition from Johnson and Johnson ( JNJ ) Abbott Laboratories ( ABT ) and Medtronic ( MDT ), which remains a headwind. The recently reported third-quarter 2014 also saw a significant 60% rise in product revenues, on the back of continued growth in the installed base of customers using the G4 Platinum system. |
34114.0 | 2014-10-31 00:00:00 UTC | Mylan Beats, Raises Earnings Guidance; Abbott Deal on Track - Analyst Blog | ABT | https://www.nasdaq.com/articles/mylan-beats-raises-earnings-guidance-abbott-deal-on-track-analyst-blog-2014-10-31 | nan | nan | Mylan 's ( MYL ) third-quarter 2014 earnings (excluding special items) of $1.16 per share beat the Zacks Consensus Estimate by 2 cents. Earnings in the third quarter of 2014 increased 41.5% from the year-ago quarter. Earnings benefited from higher revenues and better gross margins. We expect investors to react positively to the news.
Mylan Inc - Earnings Surprise | FindTheBest
On a reported basis (including special items) third-quarter 2014 earnings tripled (increased 215%) to $1.26 per share. Revenues climbed 17.9% to $2.08 billion, marginally above the Zacks Consensus Estimate of $2.06 billion. Mylan recorded year-over-year growth on the back of double-digit revenue growth in the Specialty segment, North America and rest of the world.
Third Quarter in Details
Generics third-party net sales, derived from sales in North America, Europe and rest of the world, climbed 15% to $1.61 billion. Segmental third-party net sales grew 19% to $841.8 million in North America. New product launches and capitalizing on unanticipated market opportunities aided revenues.
Third-party net sales from the European market increased slightly by 1% to $351.5 million aided by higher volumes in Italy and France and new product launches which were partially offset by lower pricing throughout Europe. Third party net sales from rest of the world rose 19% to $414.1 million. Segmental performance improved on the back of increased sales of its antiretroviral products in India. Performance in Australia was also strong during the quarter.
Third-party net sales in the Specialty segment jumped 29% to $462 million. Specialty segment sales were boosted by the strong performance of its flagship product - EpiPen Auto-Injector - for severe allergic reactions. Sales of the product improved due to increased volume and favorable pricing. Mylan expects the product to generate more than $1 billion in 2014.
Adjusted gross margin during the third quarter of 2014 expanded to 54% from 51% in the year-ago quarter on the back of strong sales of EpiPen Auto-Injector and new products.
2014 Outlook
Mylan increased its guidance for 2014 earnings based on strong performance in the third quarter. The company now expects adjusted earnings per share in the range of $3.54 to $3.60 (old guidance: $3.44 to $3.54). Mylan tweaked its revenue guidance. The company expects revenues in the range of $7.7 billion to $7.8 billion (old guidance: $7.8 billion to $8.0 billion). The projection does not include the potential launches of the generic versions of Copaxone and Lidoderm. The Zacks Consensus Estimate for 2014 is pegged at earnings of $3.48 per share on revenues of approximately $7.73 billion.
The company expects adjusted earnings per share in the band of $1.03 to $1.09 in the third quarter of 2014, much above the year-ago earnings of 78 cents. The anticipated increase is attributed to new product launches in North America and continued growth in the Specialty segment. The guidance is above the Zacks Consensus Estimate of 99 cents.
Our Take
Mylan's third-quarter results were better than expected with the company beating on both earnings and revenues driven by strong sales in North America and the Specialty segment. We are looking forward to the potential launch of generic versions of Copaxone and Lidoderm, which should boost revenues further.
We remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets, which is expected to close in the first quarter of 2015. On Oct 21, 2014, Mylan amended the agreement, which is expected to result in additional accretion. The deal is expected to be immediately and significantly accretive to the company.
Mylan said that it expects to achieve the 2018 earnings guidance of at least $6 per share even earlier.
Mylan carries a Zacks Rank #1 (Strong Buy). Other well-ranked stocks in the health care sector include Mallinckrodt ( MNK ) and Actavis ( ACT ). While Mallinckrodt carries a Zacks Rank #2 (Buy), Actavis carries the same rank as Mylan.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
MALLINCKRODT PL (MNK): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets, which is expected to close in the first quarter of 2015. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Third-party net sales from the European market increased slightly by 1% to $351.5 million aided by higher volumes in Italy and France and new product launches which were partially offset by lower pricing throughout Europe. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. We remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets, which is expected to close in the first quarter of 2015. Mylan 's ( MYL ) third-quarter 2014 earnings (excluding special items) of $1.16 per share beat the Zacks Consensus Estimate by 2 cents. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. We remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets, which is expected to close in the first quarter of 2015. The company expects revenues in the range of $7.7 billion to $7.8 billion (old guidance: $7.8 billion to $8.0 billion). | We remain positive on Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets, which is expected to close in the first quarter of 2015. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Third Quarter in Details Generics third-party net sales, derived from sales in North America, Europe and rest of the world, climbed 15% to $1.61 billion. |
34115.0 | 2014-10-28 00:00:00 UTC | 3 Generics Stocks to Buy Now - Analyst Blog | ABT | https://www.nasdaq.com/articles/3-generics-stocks-buy-now-analyst-blog-2014-10-28 | nan | nan | The pharma sector experienced one of its most significant turning points 30 years ago when the Hatch-Waxman Act was signed into law, clearing the way for the launch of generic drugs which changed the pharma business forever. Since then, complicated regulations have been reinterpreted and revised.
Compliance has also increased for the industry. However, generic makers have also found new avenues of growth which make them a particularly viable investment choice.
Impressive Growth
The original legislation was intended to address the interests of innovative drug companies as well as generics makers. Protection was provided to innovators while they awaited patent approval. Additionally, a period was provided during which they could reap the fruits of their efforts.
After some initial hiccups, primarily caused by attempts to secure drug approval in haste, the generics segment has grown at a rapid pace. To illustrate just how fast this growth has been, data from market research firm IMS Health reveals that generics made up just 19% of U.S. prescription in 1984. This share had grown to 86% in 2013.
Geographic Expansion and M&As
Even though the Hatch-Waxman Act was a domestic legislation, its impact has been global. Global generics sales amounted to $260 million in 2012. According to IMS Health, this has occurred because of the need for cheaper medication in foreign markets as well as numerous patent expirations. This has helped generics firms expand geographically.
The global generics business is a fragmented one. However, the four biggest companies contribute over 40% of combined sales of 60 largest companies. This has been revealed in a report from market research company EvaluatePharma. This has been achieved by a series of mergers and acquisitions.
Inversion Wave
Another reason for such consolidation has been the series of foreign acquisitions undertaken to benefit from an easier tax regime. At 35%, the U.S. corporate tax rate is one of the highest rates in the world. A tax inversion involves the acquisition of a foreign company and subsequently adopting its home country's domicile. Alternatively, the combined entity can create a holding company in a country whose tax rate is lower.
Last month, the U.S. Treasury Department made several change to tax regulations pertaining to such mergers. New regulations make it tougher to gain tax benefits from an inversion. As a result, some companies such as Chicago-based AbbVie Inc. ( ABBV ) have pulled out of such deals.
On the other hand, Mylan, Inc. ( MYL ) and Abbott Laboratories ( ABT ) have decided to continue with their $5.3 billion deal. Per the deal, Mylan will acquire Abbott Laboratories' branded specialty and generics business in developed ex-U.S. markets. However, they have changed the terms of the transaction. This indicates that further mergers and acquisitions will continue in the sector.
Our Choices
Below we present three stocks which will gain from these trends, each of which also has a good Zacks Rank.
Actavis plc ( ACT ) is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The company, which was previously known as Watson Pharmaceuticals, Inc., became the third largest generics pharma company in the world following its Oct 2012 acquisition of Actavis Group.
Actavis holds a Zacks Rank #1 (Strong Buy) and has expected earnings growth of 40.2%. The forward price-to-earnings ratio (P/E) for the current financial year (F1) is 18.04.
Mylan, Inc. specializes in the development, manufacture, marketing, and distribution of generic, branded, and branded generic pharmaceutical products, as well as active pharmaceutical ingredients (APIs). The company, which operates in about 140 countries and territories, is one of the leading generic and specialty pharmaceutical companies in the world. The company derives the majority of its revenues from the generics segment.
Apart from a Zacks Rank #1 (Strong Buy), the company has expected earnings growth of 18.7%. It has a P/E (F1) of 14.93x.
Mallinckrodt plc ( MNK ) is involved in drug development, manufacturing, marketing and distribution. This includes both branded and generic specialty drugs, active pharmaceutical ingredients and agents used in diagnostic imaging. The company has two operating segments, specialty pharmaceuticals and global medical imaging. Mallinckrodt has a large generics portfolio with a focus on pain management drugs.
Mallinckrodt holds a Zacks Rank #2 (Buy) and has expected earnings growth of 39.6%. It has a P/E (F1) of 13x.
Data from IMS health show that 29% of expenditure on prescription drugs in the U.S. can be attributed to generics. With the advent of products like biosimilars, generics companies now have new avenues of growth. This is why these stocks would make good additions to your portfolio.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
MALLINCKRODT PL (MNK): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On the other hand, Mylan, Inc. ( MYL ) and Abbott Laboratories ( ABT ) have decided to continue with their $5.3 billion deal. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Impressive Growth The original legislation was intended to address the interests of innovative drug companies as well as generics makers. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, Mylan, Inc. ( MYL ) and Abbott Laboratories ( ABT ) have decided to continue with their $5.3 billion deal. Actavis plc ( ACT ) is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, Mylan, Inc. ( MYL ) and Abbott Laboratories ( ABT ) have decided to continue with their $5.3 billion deal. Actavis plc ( ACT ) is a specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. | On the other hand, Mylan, Inc. ( MYL ) and Abbott Laboratories ( ABT ) have decided to continue with their $5.3 billion deal. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Last month, the U.S. Treasury Department made several change to tax regulations pertaining to such mergers. |
34116.0 | 2014-10-27 00:00:00 UTC | IYH, GILD, ABT, AGN: Large Inflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iyh-gild-abt-agn-large-inflows-detected-etf-2014-10-27 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $254.3 million dollar inflow -- that's a 9.2% increase week over week in outstanding units (from 20,150,000 to 22,000,000). Among the largest underlying components of IYH, in trading today Gilead Sciences, Inc. (Symbol: GILD) is trading flat, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Allergan, Inc (Symbol: AGN) is lower by about 0.6%. The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $109.79 per share, with $137.81 as the 52 week high point - that compares with a last trade of $137.16. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Gilead Sciences, Inc. (Symbol: GILD) is trading flat, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Allergan, Inc (Symbol: AGN) is lower by about 0.6%. The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $109.79 per share, with $137.81 as the 52 week high point - that compares with a last trade of $137.16. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IYH, in trading today Gilead Sciences, Inc. (Symbol: GILD) is trading flat, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Allergan, Inc (Symbol: AGN) is lower by about 0.6%. The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $109.79 per share, with $137.81 as the 52 week high point - that compares with a last trade of $137.16. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Gilead Sciences, Inc. (Symbol: GILD) is trading flat, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Allergan, Inc (Symbol: AGN) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $254.3 million dollar inflow -- that's a 9.2% increase week over week in outstanding units (from 20,150,000 to 22,000,000). The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $109.79 per share, with $137.81 as the 52 week high point - that compares with a last trade of $137.16. | Among the largest underlying components of IYH, in trading today Gilead Sciences, Inc. (Symbol: GILD) is trading flat, Abbott Laboratories (Symbol: ABT) is down about 0.3%, and Allergan, Inc (Symbol: AGN) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $254.3 million dollar inflow -- that's a 9.2% increase week over week in outstanding units (from 20,150,000 to 22,000,000). The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $109.79 per share, with $137.81 as the 52 week high point - that compares with a last trade of $137.16. |
34117.0 | 2014-10-22 00:00:00 UTC | Abbott Labs' (ABT) Earnings Up Y/Y in Q3, Guidance Updated - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-earnings-up-y-y-in-q3-guidance-updated-analyst-blog-2014-10-22 | nan | nan | Abbott Laboratories ( ABT ) reported third-quarter 2014 earnings of 54 cents per share, up 22.7% from the year-ago quarter.
We note that Abbott Labs agreed to sell its developed markets generics pharmaceutical business to Mylan ( MYL ) in Jul 2015. Hence, this business has been reported as discontinued operations. The deal is expected to close in the first quarter of 2015.
Including the discontinued operations, earnings came in at 62 cents, up 12.7% year over year. The Zacks Consensus Estimate was 60 cents.
Abbott Labs generated sales of $5.1 billion in the third quarter of 2014, up 5.8% year over year (on a reported basis). Sales were impacted unfavorably by foreign exchange movements to the tune of 0.9% during the quarter. Quarterly sales were below the Zacks Consensus Estimate of $5.6 billion.
Sales from emerging markets, accounting for almost 50% of the total sales, were up 13.8% year over year on a reported basis.
Third Quarter in Detail
Abbott Labs operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.
EPD sales were up 11.5% to $771 million including a negative impact of 1.4% due to currency fluctuations. Sales in key emerging markets climbed 10.2% on an operational basis (excluding foreign currency fluctuations) driven by growth in India, Russia, Mexico and Vietnam. We note that Abbott Labs completed its acquisition of CFR Pharmaceuticals in September 2014, thereby more than doubling its branded generics pharmaceuticals presence in Latin America.
The Medical Devices business generated sales of $1.4 billion, down 1% year over year (0.6% on an operational basis). Diabetes Care sales were down 5.8%. The impact of the implementation of CMS or the competitive bidding for Medicare patients in the U.S moderated during the quarter. The Vascular business was down 2.4%, impacted by a decline in drug-eluting stent sales.
The Medical Optics business was up 8.3%. Cataract sales, accounting for almost 70% of total Medical Optics sales, outpaced the overall market and recorded double-digit growth propelled by multiple new product launches.
The Nutrition business improved 9.3% year over year to $1.8 billion. Pediatric Nutrition sales were up 8% during the quarter fueled by market uptake of recently launched products, including new infant formula products, Eleva and Similac QINTI, which were launched earlier this year in China. Adult Nutrition sales grew 10.8%, driven by solid growth of its key brand Ensure and continued expansion in international markets.
Diagnostics business sales increased 4.9% year over year to $1.2 billion. Key areas of focus in this division include the Core Laboratory Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses. Core Laboratory sales increased 5.2% and Point of Care Diagnostics rose 6.7%. Worldwide sales of Molecular Diagnostics were up 0.9%.
2014 Earnings Outlook Updated
Abbott Labs now expects earnings per share in the range of $2.25 to $2.27 in 2014 (old guidance $2.19 to $2.29). The guidance includes the sale of branded generics business to Mylan. The Zacks Consensus Estimate currently stands at $2. 25 per share .
Our Take
Abbott Labs currently carries a Zacks Rank #4 (Sell).
We expect the sale of branded generics business to positively impact the top line and bottom line as Abbott Labs will now focus primarily on the branded generics pharmaceuticals business in emerging markets. The improved performance of the nutrition business should also impact results positively and boost investor confidence.
Some better-ranked stocks in the broader health care sector include Allergan ( AGN ) and Lannett, Inc ( LCI ). While Allergan is a Zacks Rank #2 (Buy) stock, Lannett sports a Zacks Rank #1 (Strong Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) reported third-quarter 2014 earnings of 54 cents per share, up 22.7% from the year-ago quarter. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Third Quarter in Detail Abbott Labs operates through four segments, namely, Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) reported third-quarter 2014 earnings of 54 cents per share, up 22.7% from the year-ago quarter. Key areas of focus in this division include the Core Laboratory Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) reported third-quarter 2014 earnings of 54 cents per share, up 22.7% from the year-ago quarter. Abbott Labs generated sales of $5.1 billion in the third quarter of 2014, up 5.8% year over year (on a reported basis). | Abbott Laboratories ( ABT ) reported third-quarter 2014 earnings of 54 cents per share, up 22.7% from the year-ago quarter. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Quarterly sales were below the Zacks Consensus Estimate of $5.6 billion. |
34118.0 | 2014-10-22 00:00:00 UTC | Amgen Gains as Third Point Suggests Split - Analyst Blog | ABT | https://www.nasdaq.com/articles/amgen-gains-as-third-point-suggests-split-analyst-blog-2014-10-22 | nan | nan | Amgen Inc. ( AMGN ) jumped 4.79% as Third Point, a hedge fund firm, increased its stake in the company. Third Point also discussed the company's position and even suggested that Amgen split into two, at an investor conference and in its third quarter letter to the investors.
Amgen issued a statement in response stating that it appreciates all the views of its shareholders including Third Point. However, the company did not discuss specifics and said that it will provide an insight into its strategic priorities and restructuring plans on Oct 28, 2014. In Jul 2014, Amgen had announced a restructuring plan which involved reducing 12%-15% of its total work force.
Third Point mentioned in its letter that it is now one of Amgen's highest stakeholders. The hedge fund suggested that Amgen should consider separating into two companies - a mature company (containing legacy assets which will be valued on its dividend yield and will focus on efficiency and cash flow), and a growth company (comprising a promising pipeline focusing on product development and innovation).
As per Third Point, such a split would create a value of almost $249 per share in two years, far above (approximately 81%) Amgen's undisturbed price before Third Point's views reached the market. Third Point believes that concerns about potential revenue erosion for certain products in Amgen's portfolio are overstated and the company's pipeline is under appreciated.
Apart from the split, Third Point also made a few other recommendations to Amgen for enhancing its value. The hedge fund suggested that Amgen should focus on its research and development efforts and provide long-term margin guidance reflecting its restructuring initiatives. Third Point also stated that Amgen should provide more visibility on shareholder returns.
Our Take
We believe that investors would react positively if Amgen takes Third Point's advice of splitting into two companies. We have seen several splits in the past few years. Last year, Abbott Laboratories ( ABT ) separated its research-based pharmaceuticals business by creating a new company. More recently, Theravance Inc. ( THRX ) split into two companies.
For now, we expect investor focus to remain on Amgen's third quarter results and an update on its strategic initiatives.
Amgen carries a Zacks Rank #3 (Hold). Ligand Pharmaceuticals Inc. ( LGND ) is a better-ranked stock in the biotech sector with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AMGEN INC (AMGN): Free Stock Analysis Report
THERAVANCE INC (THRX): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
LIGAND PHARMA-B (LGND): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Last year, Abbott Laboratories ( ABT ) separated its research-based pharmaceuticals business by creating a new company. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Third Point believes that concerns about potential revenue erosion for certain products in Amgen's portfolio are overstated and the company's pipeline is under appreciated. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Last year, Abbott Laboratories ( ABT ) separated its research-based pharmaceuticals business by creating a new company. Third Point also discussed the company's position and even suggested that Amgen split into two, at an investor conference and in its third quarter letter to the investors. | Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Last year, Abbott Laboratories ( ABT ) separated its research-based pharmaceuticals business by creating a new company. Third Point also discussed the company's position and even suggested that Amgen split into two, at an investor conference and in its third quarter letter to the investors. | Last year, Abbott Laboratories ( ABT ) separated its research-based pharmaceuticals business by creating a new company. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Third Point also discussed the company's position and even suggested that Amgen split into two, at an investor conference and in its third quarter letter to the investors. |
34119.0 | 2014-10-21 00:00:00 UTC | Pre-Market Earnings Report for October 22, 2014 : BA, BIIB, USB, ABT, DOW, EMC, SPG, TMO, GD, NSC, NOC, BSX | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-october-22-2014-ba-biib-usb-abt-dow-emc-spg-tmo-gd-nsc-noc-bsx | nan | nan | The following companies are expected to report earnings prior to market open on 10/22/2014. Visit our Earnings Calendar for a full list of expected earnings releases.
Boeing Company ( BA ) is reporting for the quarter ending September 30, 2014. The aerospace and defense company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.98. This value represents a 10.00% increase compared to the same quarter last year. In the past year BA has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 19.8%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BA is 15.05 vs. an industry ratio of 16.60.
Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending September 30, 2014. The biomedical (gene) company's consensus earnings per share forecast from the 2 analysts that follow the stock is $3.22. This value represents a 37.61% increase compared to the same quarter last year. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2014 by -5.04%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BIIB is 24.60 vs. an industry ratio of -3.40, implying that they will have a higher earnings growth than their competitors in the same industry.
U.S. Bancorp ( USB ) is reporting for the quarter ending September 30, 2014. The bank company's consensus earnings per share forecast from the 15 analysts that follow the stock is $0.78. This value represents a 2.63% increase compared to the same quarter last year. In the past year USB has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for USB is 12.74 vs. an industry ratio of 14.70.
Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2014. The large cap pharmaceutical company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.60. This value represents a 9.09% increase compared to the same quarter last year. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.43 vs. an industry ratio of 33.30.
Dow Chemical Company ( DOW ) is reporting for the quarter ending September 30, 2014. The chemical company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.67. This value represents a 34.00% increase compared to the same quarter last year. DOW missed the consensus earnings per share in the 3rd calendar quarter of 2013 by -7.41%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for DOW is 15.98 vs. an industry ratio of 16.50.
EMC Corporation ( EMC ) is reporting for the quarter ending September 30, 2014. The computer storage company's consensus earnings per share forecast from the 7 analysts that follow the stock is $0.37. This value represents a 15.63% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for EMC is 17.39 vs. an industry ratio of 1.40, implying that they will have a higher earnings growth than their competitors in the same industry.
Simon Property Group, Inc. ( SPG ) is reporting for the quarter ending September 30, 2014. The reit company's consensus earnings per share forecast from the 10 analysts that follow the stock is $2.02. This value represents a 8.60% decrease compared to the same quarter last year. In the past year SPG has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 0.93%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for SPG is 18.91 vs. an industry ratio of 15.80, implying that they will have a higher earnings growth than their competitors in the same industry.
Thermo Fisher Scientific Inc ( TMO ) is reporting for the quarter ending September 30, 2014. The medical instruments company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.69. This value represents a 30.00% increase compared to the same quarter last year. In the past year TMO has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 6.17%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for TMO is 16.52 vs. an industry ratio of 3.00, implying that they will have a higher earnings growth than their competitors in the same industry.
General Dynamics Corporation ( GD ) is reporting for the quarter ending September 30, 2014. The aerospace and defense company's consensus earnings per share forecast from the 13 analysts that follow the stock is $1.91. This value represents a 3.80% increase compared to the same quarter last year. In the past year GD has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 6.82%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for GD is 16.09 vs. an industry ratio of 16.60.
Norfolk Souther Corporation ( NSC ) is reporting for the quarter ending September 30, 2014. The transportation (rail) company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.83. This value represents a 19.61% increase compared to the same quarter last year. In the past year NSC has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 2.87%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for NSC is 16.45 vs. an industry ratio of 21.10.
Northrop Grumman Corporation ( NOC ) is reporting for the quarter ending September 30, 2014. The aerospace and defense company's consensus earnings per share forecast from the 12 analysts that follow the stock is $2.16. This value represents a 9.64% increase compared to the same quarter last year. NOC missed the consensus earnings per share in the 2nd calendar quarter of 2014 by -7.27%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for NOC is 13.31 vs. an industry ratio of 16.60.
Boston Scientific Corporation ( BSX ) is reporting for the quarter ending September 30, 2014. The medical products company's consensus earnings per share forecast from the 13 analysts that follow the stock is $0.20. This value represents a 17.65% increase compared to the same quarter last year. In the past year BSX has beat the expectations every quarter. The highest one was in the 2nd calendar quarter where they beat the consensus by 5%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BSX is 14.16 vs. an industry ratio of -1.20, implying that they will have a higher earnings growth than their competitors in the same industry.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.43 vs. an industry ratio of 33.30. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.43 vs. an industry ratio of 33.30. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.43 vs. an industry ratio of 33.30. | Abbott Laboratories ( ABT ) is reporting for the quarter ending September 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.43 vs. an industry ratio of 33.30. |
34120.0 | 2014-10-20 00:00:00 UTC | Will Abbott Labs (ABT) Miss on Earnings This Quarter? - Analyst Blog | ABT | https://www.nasdaq.com/articles/will-abbott-labs-abt-miss-on-earnings-this-quarter-analyst-blog-2014-10-20 | nan | nan | Abbott Laboratories ( ABT ) is scheduled to report third-quarter 2014 results before the opening bell on Oct 22, 2014.
Last quarter, Abbott Labs reported a positive earnings surprise of 5.9%. On average, Abbott Labs has posted a 10.3% positive surprise in the last four quarters. Let's see how things are shaping up for the third quarter.
Factors to Influence 3Q Results
Abbott Labs is an extremely diversified company with its presence in the diagnostics, nutrition, generics and medical devices markets after having separated its pharmaceutical business into a new company called AbbVie ( ABBV ) in Jan 2013.
However, the adoption of austerity measures by developed markets has been affecting revenues over the past few quarters. Unfavorable currency fluctuations along with the disruption in international pediatric nutrition sales in China also impacted sales and we expect to see an impact on the third quarter as well from the same.
Meanwhile, the company's Established Pharmaceuticals Division continues to be impacted by lower-than-expected growth rates and we expect further deceleration of growth in this segment in 2014.
In our view, all these factors should impact third-quarter results notwithstanding Abbott Labs' positive earnings streak in the last 12 months.
Earnings Whispers?
Our proven model conclusively shows that Abbott Labs is likely to miss earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 to likely have earnings beat. That is not the case here as you will see below.
Zacks ESP : The ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -1.67%. This is because the Most Accurate Estimate currently stands at 59 cents while the Zacks Consensus Estimate currently stands at 60 cents.
Zacks Rank #4 (Sell) : Abbott Labs currently carries a Zacks Rank #4. We caution against stocks with Zacks Ranks #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing a negative estimate revision momentum.
Stocks to Consider
Here are some stocks in the broader healthcare sector that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this season:
Teva Pharmaceutical Industries Ltd. ( TEVA ) has an earnings ESP of +5.8% and carries a Zacks Rank #2 (Buy). It is scheduled to report its third-quarter results on Oct 30.
Ligand Pharmaceuticals Inc. ( LGND ) has an earnings ESP of +30.00% and carries a Zacks Rank #1 (Strong Buy). The company is scheduled to release its third-quarter results on Oct 27.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
TEVA PHARM ADR (TEVA): Free Stock Analysis Report
LIGAND PHARMA-B (LGND): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is scheduled to report third-quarter 2014 results before the opening bell on Oct 22, 2014. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In our view, all these factors should impact third-quarter results notwithstanding Abbott Labs' positive earnings streak in the last 12 months. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is scheduled to report third-quarter 2014 results before the opening bell on Oct 22, 2014. In our view, all these factors should impact third-quarter results notwithstanding Abbott Labs' positive earnings streak in the last 12 months. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is scheduled to report third-quarter 2014 results before the opening bell on Oct 22, 2014. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 to likely have earnings beat. | Abbott Laboratories ( ABT ) is scheduled to report third-quarter 2014 results before the opening bell on Oct 22, 2014. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, Abbott Labs reported a positive earnings surprise of 5.9%. |
34121.0 | 2014-10-10 00:00:00 UTC | VGK, RXL: Big ETF Outflows | ABT | https://www.nasdaq.com/articles/vgk-rxl-big-etf-outflows-2014-10-10 | nan | nan | Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Vanguard FTSE Europe ETF ( VGK ), where 4,998,080 units were destroyed, or a 2.0% decrease week over week. Among the largest underlying components of VGK, in morning trading today Nestle ( NSRGY ) is down about 0.3%, and Novartis ( NVS ) is lower by about 0.9%.
And on a percentage change basis, the ETF with the biggest outflow was the Proshares Ultra Health Care ( RXL ), which lost 750,000 of its units, representing a 39.0% decline in outstanding units compared to the week prior. Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is up about 1.1%, and Abbvie (ABBV) is lower by about 1.4%.
VIDEO: VGK, RXL: Big ETF Outflows
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is up about 1.1%, and Abbvie (ABBV) is lower by about 1.4%. Among the largest underlying components of VGK, in morning trading today Nestle ( NSRGY ) is down about 0.3%, and Novartis ( NVS ) is lower by about 0.9%. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Ultra Health Care ( RXL ), which lost 750,000 of its units, representing a 39.0% decline in outstanding units compared to the week prior. | Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is up about 1.1%, and Abbvie (ABBV) is lower by about 1.4%. Among the largest underlying components of VGK, in morning trading today Nestle ( NSRGY ) is down about 0.3%, and Novartis ( NVS ) is lower by about 0.9%. VIDEO: VGK, RXL: Big ETF Outflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is up about 1.1%, and Abbvie (ABBV) is lower by about 1.4%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Vanguard FTSE Europe ETF ( VGK ), where 4,998,080 units were destroyed, or a 2.0% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Ultra Health Care ( RXL ), which lost 750,000 of its units, representing a 39.0% decline in outstanding units compared to the week prior. | Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is up about 1.1%, and Abbvie (ABBV) is lower by about 1.4%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Vanguard FTSE Europe ETF ( VGK ), where 4,998,080 units were destroyed, or a 2.0% decrease week over week. Among the largest underlying components of VGK, in morning trading today Nestle ( NSRGY ) is down about 0.3%, and Novartis ( NVS ) is lower by about 0.9%. |
34122.0 | 2014-10-10 00:00:00 UTC | Notable ETF Inflow Detected - VTV, BRK.B, HPQ, ABT | ABT | https://www.nasdaq.com/articles/notable-etf-inflow-detected-vtv-brkb-hpq-abt-2014-10-10 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $103.2 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 190,661,854 to 191,961,941). Among the largest underlying components of VTV, in trading today Berkshire Hathaway Inc. (Symbol: BRK.B) is up about 1%, Hewlett-Packard Co (Symbol: HPQ) is down about 1.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.1%. The chart below shows the one year price performance of VTV, versus its 200 day moving average:
Looking at the chart above, VTV's low point in its 52 week range is $68.68 per share, with $83.89 as the 52 week high point - that compares with a last trade of $79.03. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTV, in trading today Berkshire Hathaway Inc. (Symbol: BRK.B) is up about 1%, Hewlett-Packard Co (Symbol: HPQ) is down about 1.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.1%. The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $68.68 per share, with $83.89 as the 52 week high point - that compares with a last trade of $79.03. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VTV, in trading today Berkshire Hathaway Inc. (Symbol: BRK.B) is up about 1%, Hewlett-Packard Co (Symbol: HPQ) is down about 1.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.1%. The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $68.68 per share, with $83.89 as the 52 week high point - that compares with a last trade of $79.03. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VTV, in trading today Berkshire Hathaway Inc. (Symbol: BRK.B) is up about 1%, Hewlett-Packard Co (Symbol: HPQ) is down about 1.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $103.2 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 190,661,854 to 191,961,941). The chart below shows the one year price performance of VTV, versus its 200 day moving average: Looking at the chart above, VTV's low point in its 52 week range is $68.68 per share, with $83.89 as the 52 week high point - that compares with a last trade of $79.03. | Among the largest underlying components of VTV, in trading today Berkshire Hathaway Inc. (Symbol: BRK.B) is up about 1%, Hewlett-Packard Co (Symbol: HPQ) is down about 1.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Value ETF (Symbol: VTV) where we have detected an approximate $103.2 million dollar inflow -- that's a 0.7% increase week over week in outstanding units (from 190,661,854 to 191,961,941). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. |
34123.0 | 2014-10-10 00:00:00 UTC | Amgen, Inc. Gives AbbVie Inc the Highest Form of Flattery | ABT | https://www.nasdaq.com/articles/amgen-inc-gives-abbvie-inc-highest-form-flattery-2014-10-10 | nan | nan | Amgen 's Enbrel hasn't been able to keep pace with AbbVie 's Humira, managing $4.2 billion in U.S. sales last year compared to Humira's $5.2 billion. So what's Amgen to do? Make a copycat of Humira, of course.
You're not seeing double.Source: AbbVie.
Unlike small-molecule generics, copycats of biologic drugs, called biosimilars, will have to undergo clinical trials to show that they're as efficacious as the original drug. This week. Amgen released the first data for ABP 501, its biosimilar of Humira, showing that the two drugs performed similarly in patients with plaque psoriasis.
Amgen didn't release any data, but noted that, "At week 16, the PASI percent improvement from baseline was within the prespecified equivalence margin for ABP 501 compared to adalimumab." PASI stands for Psoriasis Area and Severity Index, and is the standard measurement for severity of plaque psoriasis. Adalimumab is the chemical name for Humira.
Patients who responded well to ABP 501 after 16 weeks will continue on the drug for another 32 weeks. Those who responded to Humira will be rerandomized to take either Humira or ABP501. The extended trial will give Amgen more safety data for ABP501, and a chance to show that switching from Humira to ABP501 doesn't make patients' psoriasis worse. Given the large number of patients taking Humira, patient switching could be more lucrative than capturing new-to-therapy patients.
Amgen is also testing ABP 501 in rheumatoid arthritis, which Humira is also approved for. If that trial proves successful, look for Amgen to launch ABP 501 in 2017 after Humira's patents start expiring in late 2016.
That's if the FDA allows it
Biosimilars is a relatively new field in the U.S. Biologic drugs used to have de facto exclusivity after their patents expire because there wasn't a way to get a copycat drug approved without running full clinical trials equivalent to what was required for the brand-name drug. Considering the cost of the clinical trials, it wasn't worth the effort.
While some biosimilars have been approved in Europe for a few years, the Food and Drug Administration only recently wrote rules on how to get biosimilars approved after Congress included a pathway to approve biosimilars as part of the Affordable Care Act.
Small-molecule generic drugs generally only have to show equivalent dosing in a handful of patients before being approved. Because biosimilars are more complex, the Food and Drug Administration wants trials that actually show efficacy.
Fortunately, the trials are still much smaller than the originator had to run. Amgen enrolled 350 patients in the ABP 501 trial; to get Humira approved for plaque psoriasis, Abbott Labs , which ran the trials before splitting off its drug division AbbVie, evaluated 1,212 patients in the pivotal trial, and another 147 patients in a second trial.
While I'm sure Amgen ran the clinical trial design by the FDA before performing the trials, investors should realize that Amgen and the rest of the companies developing biosimilars are entering uncharted territory that's apt to change as the FDA digs into the data that companies are generating to show equivalence.
Amgen is making a big move into biosimilars with five other molecules in development. The ABP 501 data is a good start; but it remains to be seen how easy it will be to gain FDA approval, and how much the biosimilars will be used by doctors.
Biosimilars or not, at least both Amgen and AbbVie have this in common
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here .
The article Amgen, Inc. Gives AbbVie Inc the Highest Form of Flattery originally appeared on Fool.com.
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Amgen didn't release any data, but noted that, "At week 16, the PASI percent improvement from baseline was within the prespecified equivalence margin for ABP 501 compared to adalimumab." The extended trial will give Amgen more safety data for ABP501, and a chance to show that switching from Humira to ABP501 doesn't make patients' psoriasis worse. Biosimilars or not, at least both Amgen and AbbVie have this in common The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. | Amgen released the first data for ABP 501, its biosimilar of Humira, showing that the two drugs performed similarly in patients with plaque psoriasis. That's if the FDA allows it Biosimilars is a relatively new field in the U.S. Biologic drugs used to have de facto exclusivity after their patents expire because there wasn't a way to get a copycat drug approved without running full clinical trials equivalent to what was required for the brand-name drug. Amgen enrolled 350 patients in the ABP 501 trial; to get Humira approved for plaque psoriasis, Abbott Labs , which ran the trials before splitting off its drug division AbbVie, evaluated 1,212 patients in the pivotal trial, and another 147 patients in a second trial. | Amgen released the first data for ABP 501, its biosimilar of Humira, showing that the two drugs performed similarly in patients with plaque psoriasis. Amgen enrolled 350 patients in the ABP 501 trial; to get Humira approved for plaque psoriasis, Abbott Labs , which ran the trials before splitting off its drug division AbbVie, evaluated 1,212 patients in the pivotal trial, and another 147 patients in a second trial. While I'm sure Amgen ran the clinical trial design by the FDA before performing the trials, investors should realize that Amgen and the rest of the companies developing biosimilars are entering uncharted territory that's apt to change as the FDA digs into the data that companies are generating to show equivalence. | So what's Amgen to do? Amgen released the first data for ABP 501, its biosimilar of Humira, showing that the two drugs performed similarly in patients with plaque psoriasis. Amgen enrolled 350 patients in the ABP 501 trial; to get Humira approved for plaque psoriasis, Abbott Labs , which ran the trials before splitting off its drug division AbbVie, evaluated 1,212 patients in the pivotal trial, and another 147 patients in a second trial. |
34124.0 | 2014-10-09 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for October 10, 2014 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-october-10-2014-2014-10-09 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 10, 2014. A cash dividend payment of $0.22 per share is scheduled to be paid on November 15, 2014. Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. This marks the 4th quarter that ABT has paid the same dividend. At the current stock price of $42.14, the dividend yield is 2.09%.
The previous trading day's last sale of ABT was $42.14, representing a -4.66% decrease from the 52 week high of $44.20 and a 28.67% increase over the 52 week low of $32.75.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). ABT's current earnings per share, an indicator of a company's profitability, is $1.52. Zacks Investment Research reports ABT's forecasted earnings growth in 2014 as 11.9%, compared to an industry average of %.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
iShares U.S. Medical Devices ETF ( IHI )
Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF )
Schwab U.S. Large-Cap Value ETF ( SCHV )
iShares iBonds Mar 2020 Corporate Term ETF ( IBDC )
Schwab Fundamental U.S. Large Company Index ETF ( FNDX ).
The top-performing ETF of this group is IHI with an increase of 6.91% over the last 100 days. It also has the highest percent weighting of ABT at 9.37%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2014 as 11.9%, compared to an industry average of %. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) Schwab U.S. Large-Cap Value ETF ( SCHV ) iShares iBonds Mar 2020 Corporate Term ETF ( IBDC ) Schwab Fundamental U.S. Large Company Index ETF ( FNDX ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 10, 2014. | Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. The following ETF(s) have ABT as a top-10 holding: iShares U.S. Medical Devices ETF ( IHI ) Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) Schwab U.S. Large-Cap Value ETF ( SCHV ) iShares iBonds Mar 2020 Corporate Term ETF ( IBDC ) Schwab Fundamental U.S. Large Company Index ETF ( FNDX ). | Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. ABT's current earnings per share, an indicator of a company's profitability, is $1.52. Abbott Laboratories ( ABT ) will begin trading ex-dividend on October 10, 2014. |
34125.0 | 2014-10-07 00:00:00 UTC | S&P 500 Analyst Moves: ABT | ABT | https://www.nasdaq.com/articles/sp-500-analyst-moves-abt-2014-10-07 | nan | nan | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #163 analyst pick, moving up by 1 spot.
This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values.
Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 8.9%.
VIDEO: S&P 500 Analyst Moves: ABT
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #163 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 8.9%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #163 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 8.9%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #163 analyst pick, moving up by 1 spot. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 8.9%. | The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Abbott Laboratories ( ABT ) is now the #163 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Abbott Laboratories ( ABT ) is showing a gain of 8.9%. VIDEO: S&P 500 Analyst Moves: ABT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
34126.0 | 2014-10-03 00:00:00 UTC | Jazz Pharmaceuticals Uses New Cash To Buy For Growth | ABT | https://www.nasdaq.com/articles/jazz-pharmaceuticals-uses-new-cash-buy-growth-2014-10-03 | nan | nan | Just a few years ago, one drug generated all but a small slice of revenue for Jazz Pharmaceuticals.
And though the drug, Xyrem, targeted a small patient population of narcolepsy sufferers -- people prone to fall suddenly asleep in the middle of the day -- its high price made the sales effort worthwhile.
Jazz Pharmaceuticals ( JAZZ ) kept raising prices with little resistance. And that helped it generate a long string of double- or triple-digit earnings gains each quarter over the earlier year.
The specialty pharma firm is still raising prices on Xyrem and making lots of money from the drug. Xyrem sales in Q2 jumped 43% over a year ago to $191.4 million. And that was from just 11,750 patients.
But Jazz has more specialty drugs under its helm now, thanks to a series of transactions over the last two years. Three were completed this year alone in sleep medicine and hematology/oncology.
"They are no longer a one-trick pony," said Difei Yang, an analyst with the brokerage R.F. Lafferty.
Greener In Ireland
Deals to expand the product line began not long after Jazz merged with the Irish drug company Azure Pharma in January 2012 and officially moved to Ireland.
The tax inversion lowered its corporate tax rate, giving it more financial means to expand.
"Jazz became an Ireland company when nobody was talking about (tax inversions)," Yang said.
Many drug and medical companies have announced inversion plans over the last year. The pace picked up this year ahead of potential rule changes by the U.S. government to block inversions or make them harder.
Among those currently pursuing tax inversions areAbbVie ( ABBV ) (withShire ( SHPG ),Mylan ( MYL ) (withAbbott Laboratories' ( ABT ) generic drug unit) andMedtronic (MDT), withCovidien (COV), among others.
Specialty biopharma firmHorizon Pharma (HZNP) completed an inversion in mid-September, moving its corporate headquarters to Dublin from Illinois.
Jazz's corporate move to Dublin has paid off, analysts say. In a report over the summer, Deutsche Bank analysts said that Jazz's Irish domicile "allows the company to maximize cash flow and support business development activity."
Jazz's cash tax rate fell from 35% to 40% to the "high teens," the analysts noted.
Yang told IBD that the tax savings allowed Jazz "to do one acquisition after another. And they said they are still looking. I would not be surprised if we see another deal before the year ends."
Three months after the Azur merger and the move to Ireland, Jazz agreed to acquire specialty drug firm Eusa Pharma for $650 million. Eusa's lead product, Erwinaze, is a life-saving treatment for patients with acute lymphoblastic leukemia, which mostly affects children.
The transaction, which closed in June 2012, was expected to add $210 to $230 million in revenue in 2013 and $0.75 to $0.85 in adjusted earnings per share. Jazz's 2013 revenue climbed 49% to $872 million. EPS rose 31% to $6.31.
Jazz has been rumored to be a potential takeover candidate itself, as a way forAllergan (AGN) to thwart a hostile takeover bid fromValeant Pharmaceuticals (VRX).
Jazz's second biggest drug after Xyrem, Erwinaze and its counterpart Erwinase (sold outside the U.S.) took in $47.9 million in sales in Q2, up 7% from the same time last year. It made up 16.4% of total revenue. Xyrem made up 65.7%.
Jazz's total revenue in the quarter grew 40% to $291.2 million.
Full-year revenue is seen rising 33% to nearly $1.16 billion, according to Thomson Reuters. That's more that twice as much as 2012's tally. Earnings are expected to jump 30% to $8.19 a share.
At 7% of revenue, or $20.2 million, the third biggest contributor to sales in Q2 was the drug defibrotide. It treats patients with severe VOD, or hepatic veno-occlusive disease, who undergo stem-cell transplant therapy.
Early this year, Jazz paid $1 billion for indirect majority control of Italian biotech firm Gentium. The acquisition gave Jazz the right to market the drug in the European Union, where it goes by the brand name Defitelio.
In early August, Jazz acquired the rights to defibrotide in the Americas from Sigma-Tau Pharmaceuticals. It's seeking approval from the Food and Drug Administration to target a similar VOD patient population in the U.S.
"The company was able to diversify its revenue stream, but Xyrem still accounts for a significant portion and is still growing significantly," Yang said. "We will have to wait and see on the other products."
JPMorgan analyst Jessica Fye estimates that Xyrem accounts for 80% of Jazz's per-share earnings and remains a key growth driver, fueled by volume and price gains.
In a recent report, she and her associates forecast Xyrem to hit $1.5 billion in sales "over time," since the number of patients treated with the drug is low compared with the overall narcolepsy population.
Protected Turf
Despite challenges, analysts believe Jazz will enjoy patent protections on Xyrem through 2019 at the earliest and up to 2033, when the last of several patents expires. But JPMorgan also expects Jazz to continue to reduce reliance on Xyrem via further acquisitions, aided by up to $3 billion in borrowing capacity plus acquired cash flow.
"In the context of an ongoing wave of consolidation in the specialty pharmaceuticals sector, we see Jazz as well positioned from both an organic growth and (an) acquisition standpoint," Fye wrote.
She likened Jazz to a small biotech company because of its focus on a "very specific" disease area and patient population in narcolepsy and oncology.
"The company's focus on extremely specialized products sets it apart from the majority of its specialty pharma peers," she wrote.
Positive results from clinical trials could expand Jazz's reach. This year, Jazz acquired a stay-awake compound from Aerial BioPharma. Jazz and partnerConcert Pharmaceuticals (CNCE) announced in July the start of a Phase I trial for JZP-386, the active ingredient in Xyrem, for potential new dosing regimens.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among those currently pursuing tax inversions areAbbVie ( ABBV ) (withShire ( SHPG ),Mylan ( MYL ) (withAbbott Laboratories' ( ABT ) generic drug unit) andMedtronic (MDT), withCovidien (COV), among others. And though the drug, Xyrem, targeted a small patient population of narcolepsy sufferers -- people prone to fall suddenly asleep in the middle of the day -- its high price made the sales effort worthwhile. JPMorgan analyst Jessica Fye estimates that Xyrem accounts for 80% of Jazz's per-share earnings and remains a key growth driver, fueled by volume and price gains. | Among those currently pursuing tax inversions areAbbVie ( ABBV ) (withShire ( SHPG ),Mylan ( MYL ) (withAbbott Laboratories' ( ABT ) generic drug unit) andMedtronic (MDT), withCovidien (COV), among others. And though the drug, Xyrem, targeted a small patient population of narcolepsy sufferers -- people prone to fall suddenly asleep in the middle of the day -- its high price made the sales effort worthwhile. Greener In Ireland Deals to expand the product line began not long after Jazz merged with the Irish drug company Azure Pharma in January 2012 and officially moved to Ireland. | Among those currently pursuing tax inversions areAbbVie ( ABBV ) (withShire ( SHPG ),Mylan ( MYL ) (withAbbott Laboratories' ( ABT ) generic drug unit) andMedtronic (MDT), withCovidien (COV), among others. Just a few years ago, one drug generated all but a small slice of revenue for Jazz Pharmaceuticals. Greener In Ireland Deals to expand the product line began not long after Jazz merged with the Irish drug company Azure Pharma in January 2012 and officially moved to Ireland. | Among those currently pursuing tax inversions areAbbVie ( ABBV ) (withShire ( SHPG ),Mylan ( MYL ) (withAbbott Laboratories' ( ABT ) generic drug unit) andMedtronic (MDT), withCovidien (COV), among others. "Jazz became an Ireland company when nobody was talking about (tax inversions)," Yang said. Specialty biopharma firmHorizon Pharma (HZNP) completed an inversion in mid-September, moving its corporate headquarters to Dublin from Illinois. |
34127.0 | 2014-10-02 00:00:00 UTC | Noteworthy ETF Inflows: UPRO, ABT, ABBV, ACN | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-upro-abt-abbv-acn-2014-10-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $185.8 million dollar inflow -- that's a 25.8% increase week over week in outstanding units (from 6,400,000 to 8,050,000). Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, AbbVie Inc. (Symbol: ABBV) is off about 0.3%, and Accenture plc (Symbol: ACN) is lower by about 0.6%. The chart below shows the one year price performance of UPRO, versus its 200 day moving average:
Looking at the chart above, UPRO's low point in its 52 week range is $67.83 per share, with $126.25 as the 52 week high point - that compares with a last trade of $112.43. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, AbbVie Inc. (Symbol: ABBV) is off about 0.3%, and Accenture plc (Symbol: ACN) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $185.8 million dollar inflow -- that's a 25.8% increase week over week in outstanding units (from 6,400,000 to 8,050,000). The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $67.83 per share, with $126.25 as the 52 week high point - that compares with a last trade of $112.43. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, AbbVie Inc. (Symbol: ABBV) is off about 0.3%, and Accenture plc (Symbol: ACN) is lower by about 0.6%. The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $67.83 per share, with $126.25 as the 52 week high point - that compares with a last trade of $112.43. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, AbbVie Inc. (Symbol: ABBV) is off about 0.3%, and Accenture plc (Symbol: ACN) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $185.8 million dollar inflow -- that's a 25.8% increase week over week in outstanding units (from 6,400,000 to 8,050,000). The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $67.83 per share, with $126.25 as the 52 week high point - that compares with a last trade of $112.43. | Among the largest underlying components of UPRO, in trading today Abbott Laboratories (Symbol: ABT) is trading flat, AbbVie Inc. (Symbol: ABBV) is off about 0.3%, and Accenture plc (Symbol: ACN) is lower by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $185.8 million dollar inflow -- that's a 25.8% increase week over week in outstanding units (from 6,400,000 to 8,050,000). The chart below shows the one year price performance of UPRO, versus its 200 day moving average: Looking at the chart above, UPRO's low point in its 52 week range is $67.83 per share, with $126.25 as the 52 week high point - that compares with a last trade of $112.43. |
34128.0 | 2014-09-26 00:00:00 UTC | 3 Reasons AbbVie Inc Stock Could Fall | ABT | https://www.nasdaq.com/articles/3-reasons-abbvie-inc-stock-could-fall-2014-09-26 | nan | nan | Back in early 2013, there was considerable speculation about how Abbott Laboratories' then-new spin-off AbbVie would fare on its own. That speculation was answered by AbbVie's stock performance. Shares have surged around 65% since then. Meanwhile, Abbott Labs' shares climbed around 25% -- not bad, but small in comparison to AbbVie's successful run.
Solid results from blockbuster drug Humira continued to power AbbVie's stock upward this year. However, it could be time for more speculation. Will AbbVie's stock soon begin to slide after the positive momentum experienced over the last couple of years? Perhaps not, but there are three reasons the answer could be yes.
1. Regulatory roadblock
Many celebrated AbbVie's announcement in July that it planned to combine with Shire plc . The company stated that transaction would enable the "new" AbbVie to be domiciled in the United Kingdom and drastically lower its effective tax rate | Back in early 2013, there was considerable speculation about how Abbott Laboratories' then-new spin-off AbbVie would fare on its own. Solid results from blockbuster drug Humira continued to power AbbVie's stock upward this year. The company stated that transaction would enable the "new" AbbVie to be domiciled in the United Kingdom and drastically lower its effective tax rate | That speculation was answered by AbbVie's stock performance. Solid results from blockbuster drug Humira continued to power AbbVie's stock upward this year. Will AbbVie's stock soon begin to slide after the positive momentum experienced over the last couple of years? | Back in early 2013, there was considerable speculation about how Abbott Laboratories' then-new spin-off AbbVie would fare on its own. That speculation was answered by AbbVie's stock performance. Meanwhile, Abbott Labs' shares climbed around 25% -- not bad, but small in comparison to AbbVie's successful run. | That speculation was answered by AbbVie's stock performance. Shares have surged around 65% since then. However, it could be time for more speculation. |
34129.0 | 2014-09-24 00:00:00 UTC | Will New Treasury Rules Contain Tax Inversions? - Analyst Blog | ABT | https://www.nasdaq.com/articles/will-new-treasury-rules-contain-tax-inversions-analyst-blog-2014-09-24 | nan | nan | Late on Monday, the U.S. Treasury Department outlined new rules to deter domestic companies from moving abroad in an attempt to reduce tax payments. Some experts were of the opinion that the changes to the laws will discourage deal making of this nature for a while. Others believe that this may only reduce the speed of such agreements, that too for a limited period of time. However, stocks of companies involved in such deals slumped after the announcement of new rules.
The Basis for Tax Inversion
At 35%, the U.S. corporate tax rate is one of the highest rates in the world. A tax inversion involves the acquisition of a foreign company and subsequently adopting its home country's domicile. Alternatively, the combined entity can create a holding company in a country whose tax rate is lower.
This could help U.S. companies reduce their tax rates to single digits. The conditions attached to such a move specify that 20% of the stock of the resultant entity must be transferred to the shareholders of the company which has been acquired.
Treasury Outlines New Rules
The U.S. Treasury has made changes to five sections of the tax code which are intended to make it tougher for companies to enter into tax inversion deals.
The major changes to the tax code include putting a stop to "hopscotch" loans. This involves U.S. companies issuing loans to a newly created overseas parent company born out of a deal involving tax inversion. The idea is to avoid paying U.S. taxes on foreign earnings which have been repatriated.
A separate change made would prevent companies entering into inversion deals from executing a tax-free transfer of tax or foreign property to the new parent company located abroad from a "controlled foreign corporation." This is intended to prevent companies from undertaking restructuring of foreign subsidiaries to gain access to deferred earnings while avoiding the payment of taxes.
Another loophole which has been plugged involves an existing requirement regarding inversion. This requirement stipulates that a U.S. company can enter into an inversion agreement only if more than 20% of ownership of the new company created as a result of the deal is owned by the foreign "acquirer." Now, U.S. companies will not be able to cut down their size before closing such a deal. This is normally done by issuing large dividends. Additionally, they will be unable to increase the size of the new foreign parent by taking into account passive assets.
Further, new rules stipulate that U.S. companies can no longer move assets to a foreign subsidiary by undertaking inversions of portions of the domestic companies. After such assets are shifted they are "spun off" to shareholders.
Stocks Which Felt the Pinch
The inversion wave has affected the healthcare sector the most. Medical devices and pharma companies are rapidly acquiring smaller foreign competitors. Following the announcement, Medtronic, Inc. ( MDT ) slumped 2.9% yesterday. Irish medical supplies firm Covidien plc ( COV ), which Medtronic is attempting to acquire, lost 2.5%.
Similarly, Abbott Laboratories ( ABT ) lost 2.1%. The company's generic drug business in mature markets is slated to be purchased by Mylan, Inc. ( MYL ). A new company will then be created which will be based out of Netherlands to reduce the tax burden. However, Mylan gained 0.2%.
On the other hand, AbbVie Inc. ( ABBV ), which announced in July that it was acquiring Irish firm Shire plc ( SHPG ), declined 2%. This deal also aims to move its legal address out of the U.S. to reduce tax payments.
Burger King Worldwide, Inc. ( BKW ) lost 2.7%. Near the end of August, the company had agreed to acquire Canadian company Tim Hortons. However, the company said that it will continue with the deal despite the steps taken by the Treasury to reduce tax inversions.
A spokesman from the company said the deal is "moving forward as planned." He also claimed the deal was not aimed at reducing taxes but was instead propelled by long-term growth plans.
Are Changes an Effective Deterrent?
The largest benefit of tax inversion remains untouched. This provides U.S.-based companies with the option of moving domestic profits out of the country to a new foreign parent via interest payments not subject to taxes. Officials said they are still evaluating this option. On the other hand, this means that another regulatory measure is still to be played out.
Legal experts believe that clauses in merger agreements which provide buyers with an exit option would continue to be applicable. Some of them are of the opinion that some pullouts may occur, since inversions may become less lucrative. At the same time, it would not end tax inversion deals altogether.
Other experts are of the opinion that the effect of the new rules may continue only for a short duration. They believe that companies may find new methods of conducting such agreements despite the changes. Deal making could resume soon, some opined. Another group believes that these changes could be circumvented or challenged.
In Conclusion
Many Republicans in Congress are optimistic that the spate of inversions would encourage the Obama administration to reach an agreement on far reaching tax reforms. They believe this would make the U.S. a better place to conduct business. However, the new changes may mean that pressure for the administration to act on this front may have reduced.
At the same time in a statement on Monday, President Obama said he believed that more should be done in order to make tax rules more equitable and increase opportunities in the U.S.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MEDTRONIC (MDT): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
BURGER KING WWD (BKW): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Similarly, Abbott Laboratories ( ABT ) lost 2.1%. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report BURGER KING WWD (BKW): Free Stock Analysis Report To read this article on Zacks.com click here. Late on Monday, the U.S. Treasury Department outlined new rules to deter domestic companies from moving abroad in an attempt to reduce tax payments. | Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report BURGER KING WWD (BKW): Free Stock Analysis Report To read this article on Zacks.com click here. Similarly, Abbott Laboratories ( ABT ) lost 2.1%. Late on Monday, the U.S. Treasury Department outlined new rules to deter domestic companies from moving abroad in an attempt to reduce tax payments. | Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report BURGER KING WWD (BKW): Free Stock Analysis Report To read this article on Zacks.com click here. Similarly, Abbott Laboratories ( ABT ) lost 2.1%. This involves U.S. companies issuing loans to a newly created overseas parent company born out of a deal involving tax inversion. | Similarly, Abbott Laboratories ( ABT ) lost 2.1%. Click to get this free report MEDTRONIC (MDT): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report BURGER KING WWD (BKW): Free Stock Analysis Report To read this article on Zacks.com click here. However, stocks of companies involved in such deals slumped after the announcement of new rules. |
34130.0 | 2014-09-23 00:00:00 UTC | SSO, MMM, ABT, ABBV: ETF Inflow Alert | ABT | https://www.nasdaq.com/articles/sso-mmm-abt-abbv-etf-inflow-alert-2014-09-23 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $153.5 million dollar inflow -- that's a 7.8% increase week over week in outstanding units (from 16,425,000 to 17,700,000). Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 1.1%, and AbbVie Inc. (Symbol: ABBV) is lower by about 2%. The chart below shows the one year price performance of SSO, versus its 200 day moving average:
Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $123.59 as the 52 week high point - that compares with a last trade of $120.14. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 1.1%, and AbbVie Inc. (Symbol: ABBV) is lower by about 2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $153.5 million dollar inflow -- that's a 7.8% increase week over week in outstanding units (from 16,425,000 to 17,700,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $123.59 as the 52 week high point - that compares with a last trade of $120.14. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 1.1%, and AbbVie Inc. (Symbol: ABBV) is lower by about 2%. The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $123.59 as the 52 week high point - that compares with a last trade of $120.14. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 1.1%, and AbbVie Inc. (Symbol: ABBV) is lower by about 2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $153.5 million dollar inflow -- that's a 7.8% increase week over week in outstanding units (from 16,425,000 to 17,700,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $123.59 as the 52 week high point - that compares with a last trade of $120.14. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is off about 0.2%, Abbott Laboratories (Symbol: ABT) is down about 1.1%, and AbbVie Inc. (Symbol: ABBV) is lower by about 2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $153.5 million dollar inflow -- that's a 7.8% increase week over week in outstanding units (from 16,425,000 to 17,700,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. |
34131.0 | 2014-09-22 00:00:00 UTC | Novo Nordisk Reveals Fresh Data on Xultophy for Diabetes - Analyst Blog | ABT | https://www.nasdaq.com/articles/novo-nordisk-reveals-fresh-data-on-xultophy-for-diabetes-analyst-blog-2014-09-22 | nan | nan | Novo Nordisk A/S ( NVO ) announced data from new analyses of the phase IIIa DUAL studies (DUAL I and DUAL II) on Xultophy. Data showed that after four weeks from the initiation of treatment, Xultophy (a once-daily single injection combination of Tresiba and Victoza) led to more rapid and substantial improvement in glycemic control along with a beneficial weight profile in type II diabetes patients (insulin-naive as well as those treated with insulin previously), compared to the individual administration of Tresiba and Victoza.
At week-4 in the DUAL I study, a higher proportion of patients achieved fasting plasma glucose of ≤7.2 mmol/L under treatment with Xultophy (76%) than patients treated with Tresiba or Victoza (62% each). Moreover, 57% of the Xultophy-treated patients achieved glycated hemoglobin (HbA1c) of less than 7% at week-8 compared to 38% and 47% of those treated with Tresiba and Victoza, respectively.
Additionally, Novo Nordisk said that Xultophy-treated patients were more likely to reach pre-prandial (before meal) and post-prandial (after meal) blood glucose targets compared to either Tresiba or Victoza.
Results from the DUAL II study were consistent with that from the DUAL I study with respect to Xultophy and Tresiba. In the DUAL I study, Xultophy led to significant weight loss in patients compared to Tresiba, however, weight loss with Victoza (1.8 mg) alone was higher than that achieved with Xultophy.
Novo Nordisk presented data from the 52-week DUAL I and the 26-week DUAL II studies at the annual meeting of the European Association for the Study of Diabetes (EASD).
We note that late last week, Novo Nordisk had received marketing authorization for Xultophy for the treatment of type II diabetes in adults in the EU. EU approval came shortly after approval in Switzerland. The company intends to launch Xultophy in the EU in the first half of 2015.
Meanwhile, Novo Nordisk also presented data from a 26-week, randomized phase IIIb study on Ryzodeg at the EASD meeting. Results showed that twice-daily Ryzodeg (Tresiba/insulin aspart combination) led to successful glycemic control with fewer injections than a basal-bolus regimen consisting of once-daily Tresiba plus 2−4 injections of insulin aspart.
Although the study did not meet its primary endpoint of non-inferiority, patients on both regimens experienced HbA1c reduction. However, patients treated with Ryzodeg experienced a lower rate of overall and nocturnal confirmed hypoglycemic episodes and gained significantly less weight compared to the basal bolus regimen.
Novo Nordisk carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector are Allergan Inc. ( AGN ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ). While Allergan carries a Zacks Rank #1 (Strong Buy), Abbott and Johnson & Johnson hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector are Allergan Inc. ( AGN ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ). Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Data showed that after four weeks from the initiation of treatment, Xultophy (a once-daily single injection combination of Tresiba and Victoza) led to more rapid and substantial improvement in glycemic control along with a beneficial weight profile in type II diabetes patients (insulin-naive as well as those treated with insulin previously), compared to the individual administration of Tresiba and Victoza. | Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Allergan Inc. ( AGN ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ). In the DUAL I study, Xultophy led to significant weight loss in patients compared to Tresiba, however, weight loss with Victoza (1.8 mg) alone was higher than that achieved with Xultophy. | Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector are Allergan Inc. ( AGN ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ). Data showed that after four weeks from the initiation of treatment, Xultophy (a once-daily single injection combination of Tresiba and Victoza) led to more rapid and substantial improvement in glycemic control along with a beneficial weight profile in type II diabetes patients (insulin-naive as well as those treated with insulin previously), compared to the individual administration of Tresiba and Victoza. | Some better-ranked stocks in the health care sector are Allergan Inc. ( AGN ), Abbott Laboratories ( ABT ) and Johnson & Johnson ( JNJ ). Click to get this free report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. At week-4 in the DUAL I study, a higher proportion of patients achieved fasting plasma glucose of ≤7.2 mmol/L under treatment with Xultophy (76%) than patients treated with Tresiba or Victoza (62% each). |
34132.0 | 2014-09-22 00:00:00 UTC | Novartis' (NVS) Data on Anti-Cancer Drug LBH589 Published - Analyst Blog | ABT | https://www.nasdaq.com/articles/novartis-nvs-data-on-anti-cancer-drug-lbh589-published-analyst-blog-2014-09-22 | nan | nan | Novartis ( NVS ) announced that positive data on its pipeline candidate, LBH589 (panobinostat), was published in The Lancet Oncology .
Data from the study, PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA), showed that patients suffering from relapsed or relapsed and refractory multiple myeloma, when treated with LBH589 in combination with Velcade and Decadron showed a statistically significant and clinically relevant four-month improvement in median progression-free survival (PFS) as compared to placebo plus the same combination.
Moreover, the addition of LBH589 led to clinically meaningful increase in complete and near-complete response rates and the duration of response in the phase III study.
We note that LBH589, a pan-deacetylase (pan-DAC) inhibitor, will be the first in its class of anticancer agents, if approved.
We remind investors that LBH589 was granted priority review by the FDA in May 2014 and a regulatory application was submitted to the European Medicines Agency (EMA).
Novartis is currently facing generic competition for several key drugs such as Gleevec, Zometa and Diovan. Sales of Gleevec edged down 2% in the first half of 2014 due to the loss of patent exclusivity in Canada and lower shipments in the Middle East. Sales of Zometa also declined 63% in the first half of 2014 due to the loss of patent exclusivity and the consequent generic competition.
Therefore, the successful development and commercialization of the pipeline is important for Novartis as it will help restore a part of the revenues lost to generics.
Novartis currently carries a Zacks Rank #3 (Hold). Right now, stocks like Allergan Inc. ( AGN ), Abbott Labs ( ABT ) and Johnson & Johnson ( JNJ ) are worth considering. While Allergan is a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ALLERGAN INC (AGN): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Right now, stocks like Allergan Inc. ( AGN ), Abbott Labs ( ABT ) and Johnson & Johnson ( JNJ ) are worth considering. Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Data from the study, PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA), showed that patients suffering from relapsed or relapsed and refractory multiple myeloma, when treated with LBH589 in combination with Velcade and Decadron showed a statistically significant and clinically relevant four-month improvement in median progression-free survival (PFS) as compared to placebo plus the same combination. | Right now, stocks like Allergan Inc. ( AGN ), Abbott Labs ( ABT ) and Johnson & Johnson ( JNJ ) are worth considering. Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Right now, stocks like Allergan Inc. ( AGN ), Abbott Labs ( ABT ) and Johnson & Johnson ( JNJ ) are worth considering. Data from the study, PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA), showed that patients suffering from relapsed or relapsed and refractory multiple myeloma, when treated with LBH589 in combination with Velcade and Decadron showed a statistically significant and clinically relevant four-month improvement in median progression-free survival (PFS) as compared to placebo plus the same combination. | Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Right now, stocks like Allergan Inc. ( AGN ), Abbott Labs ( ABT ) and Johnson & Johnson ( JNJ ) are worth considering. Sales of Zometa also declined 63% in the first half of 2014 due to the loss of patent exclusivity and the consequent generic competition. |
34133.0 | 2014-09-22 00:00:00 UTC | Study Shows Medtronic's CoreValve TAVR Device Has Consistent And Cost Effective Performance | ABT | https://www.nasdaq.com/articles/study-shows-medtronics-corevalve-tavr-device-has-consistent-and-cost-effective-performance | nan | nan | Medtronic, Inc. 's ( MDT ) CoreValve transcatheter aortic valve replacement (TAVR) system continues to provide efficient treatment at two years for extreme-risk patients, the company announced at the ongoing Transcatheter Cardiovascular Therapeutics (TCT) 2014 Conference in Washington, D.C. Compared to a mortality rate of about 50% (at one year) for high-risk atrial fibrillation patients not undergoing treatment, patients using the CoreValve TAVR system reported a lower all-cause mortality rate of 36.5% and major stroke rate of 5.1% at the end of two years, consistent with the one-year clinical trial results of the device. TAVR therapy is used to replace impaired heart valves in patients who are too weak for traditional open heart surgery. (( CoreValve Two-Year Study-Press Release , Medtronic, Sept 13 2014))
At the conference, the company also announced that the CoreValve TAVR system was more cost-effective compared to traditional surgical aortic valve replacement (SAVR) at one year. The results were based on a number of parameters including resources used compared to procedure time, hospital length of stay, ICU time and rehab requirements post hospitalization. This was the first time that an in-trial cost effectiveness analysis for TAVR had been done for high risk patients by any company.
We expect these results to help Medtronic boost sales of its CoreValve device in the U.S., especially when healthcare costs are increasingly under scrutiny. The CoreValve system received U.S. Food and Drug Administration (FDA) approval for use on patients with extreme-risk and high-risk of surgery in June, and competes with Edwards Lifesciences' ( EW ) Sapien Valve device. Statistics suggest that there are about 100,000 such patients in North America, increasing annually by about 9%. Outside the U.S., CoreValve devices have been implanted in close to 65,000 patients since 2007, and it is currently a leading player in the TAVR device market in Europe.
We currently have a $60 price estimate for Medtronic , implying a slight discount to the current market price.
See our full analysis for Medtronic Inc.
CoreValve U.S. Pivotal Trial Results
Medtronic presented two year results of its CoreValve U.S. pivotal trial for extreme risk patients at the TCT 2014 conference recently. As mentioned above, the two year results were consistent with the one year trial data of the CoreValve system, with all-cause mortality at 36.5% and major stroke chances at 5.1%. The results was also consistent in other performance parameters such as blood flow (hemodynamic) and blood flow resistance.
The study continued to report low levels of paravalvular leaks (PVL), consistent with the rates reported at one year (4.4%). A paravalvular leak is a leakage of blood in the valvular region due to improper fitting of the implanted valve in the cardiac tissue. Results were also consistent for heart failure symptoms (measured by New York Heart Association (NYHA) Classification), with 92% of heart failure patients reporting an improvement by at least one class and 58% by at least two NYHA classes by the end of two years.
Cost Effectiveness Study Results
The first-ever cost effectiveness study of the CoreValve TAVR device for high-risk patients revealed that TAVR therapy had significant benefits over SAVR procedures. TAVR patients reported a procedure time of 61 +/- 35 minutes versus 221 +/- 85 minutes for SAVR, hospital length-of-stay of 8.1 days versus 12.5 days for SAVR, ICU time of 3.1 days versus 4.7 days for SAVR, and only 23% TAVR patients required rehabilitation services post discharge compared to 44% for SAVR. There was also an improvement in the Quality of Life (QoL) of TAVR patients compared to SAVR at one month. However, it was similar at longer time frames of 6 months and one year.
In terms of costs, the initial per patient cost of TAVR therapy was higher than SAVR by about $11,000, which did not fully offset the savings due to the aforementioned benefits such as shorter hospital stays. However, TAVR added 0.24 life years and 0.20 quality-adjusted life years (QALY) per patient. At an incremental cost effectiveness ratio (ICER) of $57,000 per life year gained, this reflects a lifetime incremental cost of about $13,700 for the CoreValve system. Dr. Matthew Reynolds, who presented the findings at TCT 2014, said that the higher cost of TAVR was in a range considered acceptable in the U.S., with the procedure being cheaper than dialysis but slightly expensive than atrial fibrillation ablation.
Global Large Cap | U.S. Mid & Small Cap | European Large & Mid Cap
More Trefis Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The CoreValve system received U.S. Food and Drug Administration (FDA) approval for use on patients with extreme-risk and high-risk of surgery in June, and competes with Edwards Lifesciences' ( EW ) Sapien Valve device. A paravalvular leak is a leakage of blood in the valvular region due to improper fitting of the implanted valve in the cardiac tissue. Dr. Matthew Reynolds, who presented the findings at TCT 2014, said that the higher cost of TAVR was in a range considered acceptable in the U.S., with the procedure being cheaper than dialysis but slightly expensive than atrial fibrillation ablation. | Compared to a mortality rate of about 50% (at one year) for high-risk atrial fibrillation patients not undergoing treatment, patients using the CoreValve TAVR system reported a lower all-cause mortality rate of 36.5% and major stroke rate of 5.1% at the end of two years, consistent with the one-year clinical trial results of the device. See our full analysis for Medtronic Inc. CoreValve U.S. Pivotal Trial Results Medtronic presented two year results of its CoreValve U.S. pivotal trial for extreme risk patients at the TCT 2014 conference recently. TAVR patients reported a procedure time of 61 +/- 35 minutes versus 221 +/- 85 minutes for SAVR, hospital length-of-stay of 8.1 days versus 12.5 days for SAVR, ICU time of 3.1 days versus 4.7 days for SAVR, and only 23% TAVR patients required rehabilitation services post discharge compared to 44% for SAVR. | Compared to a mortality rate of about 50% (at one year) for high-risk atrial fibrillation patients not undergoing treatment, patients using the CoreValve TAVR system reported a lower all-cause mortality rate of 36.5% and major stroke rate of 5.1% at the end of two years, consistent with the one-year clinical trial results of the device. Cost Effectiveness Study Results The first-ever cost effectiveness study of the CoreValve TAVR device for high-risk patients revealed that TAVR therapy had significant benefits over SAVR procedures. TAVR patients reported a procedure time of 61 +/- 35 minutes versus 221 +/- 85 minutes for SAVR, hospital length-of-stay of 8.1 days versus 12.5 days for SAVR, ICU time of 3.1 days versus 4.7 days for SAVR, and only 23% TAVR patients required rehabilitation services post discharge compared to 44% for SAVR. | See our full analysis for Medtronic Inc. CoreValve U.S. Pivotal Trial Results Medtronic presented two year results of its CoreValve U.S. pivotal trial for extreme risk patients at the TCT 2014 conference recently. Cost Effectiveness Study Results The first-ever cost effectiveness study of the CoreValve TAVR device for high-risk patients revealed that TAVR therapy had significant benefits over SAVR procedures. There was also an improvement in the Quality of Life (QoL) of TAVR patients compared to SAVR at one month. |
34134.0 | 2014-09-19 00:00:00 UTC | Dividend Aristocrats: Time to Buy AbbVie Inc Stock? | ABT | https://www.nasdaq.com/articles/dividend-aristocrats-time-buy-abbvie-inc-stock-2014-09-19 | nan | nan | Dividend stocks are a powerful force within a well-balanced portfolio because they can dramatically increase the rate of compounding interest through dividend reinvestment plans.
Not all dividend stocks are great investment vehicles, however. For example, some companies don't increase their total dividends payouts on a regular basis, don't offer attractive yields at current levels, or simply have weak prospects for growth going forward. Companies that offer a compelling mixture of high yields and strong growth prospects have perhaps become harder to find in this aging bull market, but they do exist.
With this in mind, I think AbbVie is a healthcare stock that income and growth investors alike should get to know better. Ever since the company was spun-off as the pharmaceutical segment of Abbott Laboratories in 2013, AbbVie's share price has marched steadily upward, shown by the chart below.
And even though its share price has shot up over the past year, this stock still offers a relatively high dividend yield of 2.83% at current levels, compared to the sector average of 2.69% .
AbbVie's past performance and even its attractive yield are not the reasons why I find this stock so compelling, however. Going forward, the company has some big plans in the works that could unlock a tremendous amount of value for investors over the long term. So, let's take a deeper look at this top dividend stock.
AbbVie is set to diversify its product portfolio in a big way
AbbVie has a problem, albeit a good one in some respects. The company has been reliant on one drug, Humira, for more than half of its top-line growth in recent quarters. That said, Humira's commercial performance has been nothing short of amazing, posting a 26% increase in sales to $3.29 billion in the second quarter of this year compared to a year ago.
The patent cliff has perhaps taught all healthcare investors that over-reliance on any single product for growth can be a major pitfall. AbbVie has thus developed a potent triple-combo therapy indicated for hepatitis C genotype 1 patients that is expected to be approved shortly and launched commercially within the U.S. before year's end. The commercial upside for the drug is up in the air nonetheless, given that it will be competing against Gilead Sciences and Johnson & Johnson 's hepatitis C offerings.
While the Street is expecting first year sales to come in anywhere from from $2 to $3 billion for AbbVie's triple-therapy, I think these estimates are speculative at best. After all, the Street wasn't even close to predicting the sales of either Gilead or J&J's new drugs before they were launched. That having been said, I think it is safe to say that AbbVie's hep-C drug clearly has blockbuster potential and will therefore be an important source of top-line growth down the line.
AbbVie's recent acquisition of Shire has also helped to further diversify its product portfolio. This acquisition gives AbbVie several drugs like Vyvanse, Replagal, Firazyr, and Cinryze that all posted double digit sales growth in the second-quarter , boosting Shire's top line by 20% compared to a year ago. All told, the newly merged entity is expected to easily generate over $25 billion in revenue next year.
Don't forget the tax inversion!
Although Shire has impressive product and clinical portfolios in its own right, the main reason AbbVie was interested in acquiring the Dublin-based company was to lower its effective tax rate.AbbVie's effective tax rate for 2013 was 22.6%, whereas Shire's was only 16.4% . Experts believe that the synergies created by this merger could lower the new entity's effective tax rate to a mere 13%. If this line holds going forward, we can expect AbbVie to save over $2 billion per year on taxes and this number will only increase as revenues climb.
Foolish wrap-up
One of the clear lessons the tax inversion of Actavis plc should teach healthcare investors is that these companies won't be shy about spending their tax savings on new acquisitions to fuel growth. Actavis has been on a spending spree since moving abroad, resulting in a massive 34% increase in total sales year-over year . AbbVie appears to already be following in Actavis' footsteps with its recent deal with Infinity Pharmaceuticals for its blood cancer drug duvelisib. So, you shouldn't be surprised if this trend continues.
From a dividend perspective, these new revenue sources will only increase free cash flows over the long term and should ultimately result in higher total dividend payouts. As such, I think AbbVie should be considered for both its sector-beating dividend yield and strong growth prospects.
Speaking of strong dividends -- Here are the top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here .
The article Dividend Aristocrats: Time to Buy AbbVie Inc Stock? originally appeared on Fool.com.
George Budwell owns shares of Johnson & Johnson. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Companies that offer a compelling mixture of high yields and strong growth prospects have perhaps become harder to find in this aging bull market, but they do exist. And even though its share price has shot up over the past year, this stock still offers a relatively high dividend yield of 2.83% at current levels, compared to the sector average of 2.69% . This acquisition gives AbbVie several drugs like Vyvanse, Replagal, Firazyr, and Cinryze that all posted double digit sales growth in the second-quarter , boosting Shire's top line by 20% compared to a year ago. | For example, some companies don't increase their total dividends payouts on a regular basis, don't offer attractive yields at current levels, or simply have weak prospects for growth going forward. And even though its share price has shot up over the past year, this stock still offers a relatively high dividend yield of 2.83% at current levels, compared to the sector average of 2.69% . The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. | For example, some companies don't increase their total dividends payouts on a regular basis, don't offer attractive yields at current levels, or simply have weak prospects for growth going forward. Although Shire has impressive product and clinical portfolios in its own right, the main reason AbbVie was interested in acquiring the Dublin-based company was to lower its effective tax rate.AbbVie's effective tax rate for 2013 was 22.6%, whereas Shire's was only 16.4% . Speaking of strong dividends -- Here are the top dividend stocks for the next decade The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. | For example, some companies don't increase their total dividends payouts on a regular basis, don't offer attractive yields at current levels, or simply have weak prospects for growth going forward. That said, Humira's commercial performance has been nothing short of amazing, posting a 26% increase in sales to $3.29 billion in the second quarter of this year compared to a year ago. Speaking of strong dividends -- Here are the top dividend stocks for the next decade The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. |
34135.0 | 2014-09-17 00:00:00 UTC | Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-to-initiate-new-trial-on-absorb-analyst-blog-2014-09-17 | nan | nan | Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.
Abbott Labs ( ABT ) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
The trial will evaluate whether Absorb is more cost-effective and offers a higher quality of life than other metallic drug eluting stent (DES).
The randomized heart stent trial will measure angina (chest pain) as the primary endpoint at one year. The other primary endpoint of the ABSORB IV trial is to assess the long-term clinical safety and performance based on the change in target lesion failure (TLF) from one to five years.
Abbott Labs plans to consolidate data from the ABSORB IV trial with that from the ABSORB III trial to create a population of more than 5,000 patients studied in the U.S.
Earlier, Abbott Labs released positive one-year results from the randomized, controlled trial ABSORB II. The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb heart device to Abbott Labs' Xience family of DES in patients suffering from coronary artery disease (CAD).
Data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina compared to those treated with the Xience family of DES.
We note that Absorb obtained the CE mark in Europe in Jan 2011 but is yet to be approved in the U.S.
The vascular business is an important part of Abbott Labs' product portfolio that generated sales of $1.5 billion in the first half of 2014. Of the total vascular sales, approximately $738 million came from the DES and BVS product portfolio. The continued rollout of Absorb and Xience Xpedition along with new products such as Supera stents will further strengthen the company's vascular portfolio in 2014.
Abbott Labs currently carries a Zacks Rank #2 (Buy). Investors may also consider stocks like Allergan ( AGN ), Gilead Sciences ( GILD ) and Shire ( SHPG ). While Allegan and Gilead Sciences carry a Zacks Rank #1 (Strong Buy), Shire is a Zacks Rank #2 stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The trial will evaluate whether Absorb is more cost-effective and offers a higher quality of life than other metallic drug eluting stent (DES). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb. Investors may also consider stocks like Allergan ( AGN ), Gilead Sciences ( GILD ) and Shire ( SHPG ). | Abbott Labs ( ABT ) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs plans to consolidate data from the ABSORB IV trial with that from the ABSORB III trial to create a population of more than 5,000 patients studied in the U.S. | Abbott Labs ( ABT ) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The randomized heart stent trial will measure angina (chest pain) as the primary endpoint at one year. |
34136.0 | 2014-09-15 00:00:00 UTC | Attunity, Ltd. (ATTU) in Focus: Stock Adds 5.2% in Session - Tale of the Tape | ABT | https://www.nasdaq.com/articles/attunity-ltd.-attu-in-focus%3A-stock-adds-5.2-in-session-tale-of-the-tape-2014-09-15 | nan | nan | Attunity, Ltd. ( ATTU ) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 23.39% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Attunity, Ltd. currently has a Zacks Rank #5 (Strong Sell), while its Earnings ESP is 0.00%.
However, some better performing Internet software stocks include DTS Inc. ( DTSI ), Rally Software Development Corp. ( RALY ) and Support.com, Inc. ( SPRT ). All these stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
DTS INC (DTSI): Free Stock Analysis Report
RALLY SOFTWARE (RALY): Free Stock Analysis Report
SUPPORT.COM INC (SPRT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report DTS INC (DTSI): Free Stock Analysis Report RALLY SOFTWARE (RALY): Free Stock Analysis Report SUPPORT.COM INC (SPRT): Free Stock Analysis Report To read this article on Zacks.com click here. Attunity, Ltd. ( ATTU ) was a big mover last session, as the company saw its shares rise more than 5% on the day. This continues the recent uptrend for the company as the stock is now up 23.39% in the past one-month time frame. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report DTS INC (DTSI): Free Stock Analysis Report RALLY SOFTWARE (RALY): Free Stock Analysis Report SUPPORT.COM INC (SPRT): Free Stock Analysis Report To read this article on Zacks.com click here. However, some better performing Internet software stocks include DTS Inc. ( DTSI ), Rally Software Development Corp. ( RALY ) and Support.com, Inc. ( SPRT ). Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report DTS INC (DTSI): Free Stock Analysis Report RALLY SOFTWARE (RALY): Free Stock Analysis Report SUPPORT.COM INC (SPRT): Free Stock Analysis Report To read this article on Zacks.com click here. Click to get this free report >> Want the latest recommendations from Zacks Investment Research? Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report DTS INC (DTSI): Free Stock Analysis Report RALLY SOFTWARE (RALY): Free Stock Analysis Report SUPPORT.COM INC (SPRT): Free Stock Analysis Report To read this article on Zacks.com click here. Attunity, Ltd. ( ATTU ) was a big mover last session, as the company saw its shares rise more than 5% on the day. None of the estimates for this stock were revised over the past 30 days. |
34137.0 | 2014-09-15 00:00:00 UTC | Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-presents-positive-one-year-data-on-absorb-analyst-blog-2014-09-15 | nan | nan | Abbott Laboratories ( ABT ) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb.
The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD).
The data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina (chest pain) compared to those treated with the Xience family of DES.
We note that Absorb obtained the CE mark in Europe in Jan 2011 but is yet to be approved in the U.S.
The vascular portfolio of Abbott Labs boasts of DES such as the Xience series and Absorb.
The portfolio has been further strengthened by a number of recent favorable updates. In Mar 2014, the FDA approved the company's Supera peripheral stent system for the treatment of patients with blocked blood vessels in the upper leg ca | Abbott Laboratories ( ABT ) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb. The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD). The vascular portfolio of Abbott Labs boasts of DES such as the Xience series and Absorb. | Abbott Laboratories ( ABT ) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb. The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD). The vascular portfolio of Abbott Labs boasts of DES such as the Xience series and Absorb. | Abbott Laboratories ( ABT ) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb. The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD). The data from the trial showed that patients treated with Absorb experienced a significantly lower rate of angina (chest pain) compared to those treated with the Xience family of DES. | Abbott Laboratories ( ABT ) announced positive one-year results from the randomized, controlled trial ABSORB II, on its drug-eluting coronary bioresorbable vascular scaffold (BVS) Absorb. The trial, conducted in Europe, compared the safety and efficacy of the dissolving Absorb to Abbott Labs' Xience family of drug-eluting stents (DES) in patients suffering from coronary artery disease (CAD). We note that Absorb obtained the CE mark in Europe in Jan 2011 but is yet to be approved in the U.S. |
34138.0 | 2014-09-15 00:00:00 UTC | Notable ETF Outflow Detected - SSO, MMM, ABT, ABBV | ABT | https://www.nasdaq.com/articles/notable-etf-outflow-detected-sso-mmm-abt-abbv-2014-09-15 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $98.4 million dollar outflow -- that's a 4.8% decrease week over week (from 17,250,000 to 16,425,000). Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and AbbVie Inc. (Symbol: ABBV) is up by about 0.3%. The chart below shows the one year price performance of SSO, versus its 200 day moving average:
Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $122.33 as the 52 week high point - that compares with a last trade of $119.21. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and AbbVie Inc. (Symbol: ABBV) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $98.4 million dollar outflow -- that's a 4.8% decrease week over week (from 17,250,000 to 16,425,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $122.33 as the 52 week high point - that compares with a last trade of $119.21. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and AbbVie Inc. (Symbol: ABBV) is up by about 0.3%. The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $122.33 as the 52 week high point - that compares with a last trade of $119.21. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and AbbVie Inc. (Symbol: ABBV) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $98.4 million dollar outflow -- that's a 4.8% decrease week over week (from 17,250,000 to 16,425,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $122.33 as the 52 week high point - that compares with a last trade of $119.21. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.1%, Abbott Laboratories (Symbol: ABT) is trading flat, and AbbVie Inc. (Symbol: ABBV) is up by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $98.4 million dollar outflow -- that's a 4.8% decrease week over week (from 17,250,000 to 16,425,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $81.01 per share, with $122.33 as the 52 week high point - that compares with a last trade of $119.21. |
34139.0 | 2014-09-12 00:00:00 UTC | AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbvies-humira-positive-in-phase-iii-skin-disease-study-analyst-blog-2014-09-12 | nan | nan | AbbVie Inc. ( ABBV ) announced that Humira met the primary endpoint in a pivotal phase III study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa (HS). The company's shares were up 1.2% on the news.
AbbVie presented data from the first of two pivotal phase III studies. The 36-week, multicenter, randomized, double-blind, two-period PIONEER I (n= 507) study was conducted to evaluate the safety and efficacy of Humira compared to placebo. Results showed that Humira 40 mg demonstrated a significant improvement in HS-related abscesses and inflammatory nodules at 12 weeks compared to placebo (41.8% versus 26%).
These results were presented at the Annual European Society for Dermatological Research (ESDR) Meeting. Meanwhile, the company intends to present data from the second phase III study (PIONEER II) at a forthcoming medical congress.
We note that Humira is the key growth driver at AbbVie. The product generated revenues of $5.9 billion in the first half of 2014.
Humira is already approved for several indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis, ulcerative colitis and juvenile idiopathic arthritis, among others.
Meanwhile, AbbVie is working on expanding Humira's label further into indications like fingernail psoriasis in patients with moderate-to-severe chronic plaque psoriasis.
We are pleased with the encouraging results from the study. Once approved, the new medication will provide significant benefit to patients suffering from HS considering the lack of approved treatments. According to the press release issued by AbbVie, HS affects nearly 1% of the general adult population across the world.
AbbVie is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include Allergan Inc. ( AGN ), Akorn, Inc. ( AKRX ) and Abbott Laboratories ( ABT ). While Allergan and Akorn are Zacks Rank #1 (Strong Buy) stocks, Abbott Laboratories holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
AKORN INC (AKRX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector include Allergan Inc. ( AGN ), Akorn, Inc. ( AKRX ) and Abbott Laboratories ( ABT ). Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AKORN INC (AKRX): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ( ABBV ) announced that Humira met the primary endpoint in a pivotal phase III study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa (HS). | Some better-ranked stocks in the health care sector include Allergan Inc. ( AGN ), Akorn, Inc. ( AKRX ) and Abbott Laboratories ( ABT ). Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AKORN INC (AKRX): Free Stock Analysis Report To read this article on Zacks.com click here. While Allergan and Akorn are Zacks Rank #1 (Strong Buy) stocks, Abbott Laboratories holds a Zacks Rank #2 (Buy). | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AKORN INC (AKRX): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Allergan Inc. ( AGN ), Akorn, Inc. ( AKRX ) and Abbott Laboratories ( ABT ). AbbVie Inc. ( ABBV ) announced that Humira met the primary endpoint in a pivotal phase III study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa (HS). | Some better-ranked stocks in the health care sector include Allergan Inc. ( AGN ), Akorn, Inc. ( AKRX ) and Abbott Laboratories ( ABT ). Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report AKORN INC (AKRX): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ( ABBV ) announced that Humira met the primary endpoint in a pivotal phase III study conducted in patients suffering from moderate-to-severe hidradenitis suppurativa (HS). |
34140.0 | 2014-09-12 00:00:00 UTC | Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-abt-to-repurchase-shares-for-%243b-analyst-blog-2014-09-12 | nan | nan | In an effort to increase shareholder value, Abbott Laboratories ' ( ABT ) board of directors has approved a new share repurchase program.
The board has authorized the repurchase of shares worth up to $3 billion. The new program adds to the $511 million of authorization unused from the prior program, announced in Jun 2013.
The new authorization will leverage Abbott Labs' solid financial position. The company had cash and cash equivalents of $3.6 billion at the end of second-quarter 2014.
Concurrently, Abbott Labs also declared a quarterly common dividend of 22 cents per share which will be paid on Nov 15, 2014 to shareholders of record at the close of business on Oct. 15, 2014.
We note that Abbott Labs had announced a 57% increase in dividends from 14 cents to 22 cents per share in Feb 2014.
We remind investors that Abbott Labs has returned approximately $35 billion to its shareholders through dividends and share repurchases in the last 10 years. The recent increase in dividends and share repurchase program further reinforces the company's commitment to return value to shareholders following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc. ( ABBV ), in Jan 2013.
Abbott Labs reported better-than-expected sales and earnings in the second quarter of 2014, thereby keeping alive its earnings surprise streak. The latest news will further boost investor interest.
Currently, Abbott Labs carries a Zacks Rank #2 (Buy). Other stocks in the health care sector that look attractive include Allergan ( AGN ) and Gilead Sciences ( GILD ). Both carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In an effort to increase shareholder value, Abbott Laboratories ' ( ABT ) board of directors has approved a new share repurchase program. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Concurrently, Abbott Labs also declared a quarterly common dividend of 22 cents per share which will be paid on Nov 15, 2014 to shareholders of record at the close of business on Oct. 15, 2014. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In an effort to increase shareholder value, Abbott Laboratories ' ( ABT ) board of directors has approved a new share repurchase program. Currently, Abbott Labs carries a Zacks Rank #2 (Buy). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In an effort to increase shareholder value, Abbott Laboratories ' ( ABT ) board of directors has approved a new share repurchase program. We remind investors that Abbott Labs has returned approximately $35 billion to its shareholders through dividends and share repurchases in the last 10 years. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In an effort to increase shareholder value, Abbott Laboratories ' ( ABT ) board of directors has approved a new share repurchase program. We remind investors that Abbott Labs has returned approximately $35 billion to its shareholders through dividends and share repurchases in the last 10 years. |
34141.0 | 2014-09-12 00:00:00 UTC | Daily Dividend Report: INTC, ABT, TJX, BXP, RL, SLG, HUN, CBI, DRI, OCR | ABT | https://www.nasdaq.com/articles/daily-dividend-report-intc-abt-tjx-bxp-rl-slg-hun-cbi-dri-ocr-2014-09-12 | nan | nan | Intel declared a quarterly dividend of 22.5 cents per share on the company's common stock. The dividend will be payable on Dec. 1, 2014, to stockholders of record on Nov. 7, 2014.
Abbott ( ABT ) declared a quarterly common dividend of 22 cents per share. The cash dividend is payable Nov. 15, 2014, to shareholders of record at the close of business on Oct. 15, 2014.
The TJX Companies ( TJX ) announced the declaration of a quarterly dividend on its common stock of $.175 per share payable December 4, 2014, to shareholders of record on November 13, 2014.
Boston Properties ( BXP ) declared a regular quarterly cash dividend of $0.65 per share of common stock for the period July 1, 2014 to September 30, 2014 payable on October 31, 2014 to shareholders of record as of the close of business on September 30, 2014.
Ralph Lauren ( RL ) has declared a regular quarterly dividend of $0.45 per share on Ralph Lauren Corporation Common Stock. The dividend is payable on October 10, 2014 to shareholders of record at the close of business on September 26, 2014.
SL Green Realty ( SLG ) has declared the quarterly dividend of $0.50 per share of common stock. The dividend is payable on October 15, 2014 to shareholders of record at the close of business on September 30, 2014.
Huntsman (HUN) has declared a $0.125 per share cash dividend on its common stock. The dividend is payable on September 30, 2014, to stockholders of record as of September 22, 2014.
CB&I (CBI) declared an interim dividend on common stock of $0.07 per share, payable Sept. 30, 2014, to shareholders of record as of Sept. 22, 2014.
Darden declared a quarterly cash dividend of 55 cents per share on the Company's outstanding common stock, equating to a $2.20 per share dividend on an annual basis. The dividend is payable on November 3, 2014 to shareholders of record at the close of business on October 10, 2014.
And, Omnicare (OCR) has approved a quarterly cash dividend of $0.20 per share on the Company's common stock, to be paid on September 29, 2014, to all stockholders of record on September 22, 2014.
VIDEO: Daily Dividend Report: INTC, ABT, TJX, BXP, RL, SLG, HUN, CBI, DRI, OCR
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Daily Dividend Report: INTC, ABT, TJX, BXP, RL, SLG, HUN, CBI, DRI, OCR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 22 cents per share. SL Green Realty ( SLG ) has declared the quarterly dividend of $0.50 per share of common stock. | VIDEO: Daily Dividend Report: INTC, ABT, TJX, BXP, RL, SLG, HUN, CBI, DRI, OCR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott ( ABT ) declared a quarterly common dividend of 22 cents per share. The TJX Companies ( TJX ) announced the declaration of a quarterly dividend on its common stock of $.175 per share payable December 4, 2014, to shareholders of record on November 13, 2014. | Abbott ( ABT ) declared a quarterly common dividend of 22 cents per share. VIDEO: Daily Dividend Report: INTC, ABT, TJX, BXP, RL, SLG, HUN, CBI, DRI, OCR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The TJX Companies ( TJX ) announced the declaration of a quarterly dividend on its common stock of $.175 per share payable December 4, 2014, to shareholders of record on November 13, 2014. | Abbott ( ABT ) declared a quarterly common dividend of 22 cents per share. VIDEO: Daily Dividend Report: INTC, ABT, TJX, BXP, RL, SLG, HUN, CBI, DRI, OCR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Intel declared a quarterly dividend of 22.5 cents per share on the company's common stock. |
34142.0 | 2014-09-11 00:00:00 UTC | FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug | ABT | https://www.nasdaq.com/articles/fda-approves-orexigen-therapeutics-incs-goldilocks-obesity-drug-2014-09-11 | nan | nan | Patients now have a third drug to treat their obesity. Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave .
(The FDA made the same announcement yesterday, but let's give the companies the announcement glory; the approval has been a long time coming after all.)
In 2011, Orexigen was in a tight race with VIVUS and Arena Pharmaceuticals to gain FDA approval of the first new obesity drug. Both of its competitors were rejected and the FDA advisory committee recommended approval of the drug, putting Orexigen in the driver's seat
But the FDA ignored its outside advisors and rejected the application. Adding insult to injury, Orexigen had to run a large clinical trial to rule out heart problems, while VIVUS and Arena Pharmaceuticals were able to fix their deficits relatively quickly and have already launched Qsymia and Belviq respectively. The FDA even made Orexigen wait an extra three months while it worked out issues with post-approval requirements.
"Just right"
Qsymia has the best efficacy of the three, producing a placebo adjusted 8.6% weight loss. But it comes with potential for side effects including birth defects if women take it while pregnant. Belviq is considerably safer, but it doesn't help patients lose nearly as much weight. Contrave's efficacy falls between the two with the biggest side effect worry coming from an antidepressant that's one of the components of Contrave, which is known to increase the potential for suicidal thinking.
Source: FDA
Is efficacy and safety the real issue?
While Orexigen might have the winning combination of efficacy and safety, it's no guarantee that the drug will succeed where Qsymia and Belviq have failed.
Part of the reason VIVUS and Eisai, Arena's marketing partner, have had trouble selling their obesity drugs has more to do with Fen-Phen and Abbott Labs ' Meridia than it does with Qsymia and Belviq. Both Fen-Phen and Meridia were pulled off the market after side effects were discovered. Doctors don't want to repeat the same mistake prescribing the drugs to every overweight person that walks through their doors, potentially putting them at risk for unknown side effects.
Even when doctors are willing to prescribe the drugs, patients may not be willing to pay for them. Many insurers don't cover Qsymia and Belviq, and those that do often put them as a tier 3 drug so patients have to pay large co-pays for the drugs.
Takeda, which plans to launch Contrave this fall, is going to have the same kinds of challenges although adding another player could help all three drugs since their marketing efforts will get doctors thinking about treating obesity.
Takeda will also have an easier time getting insurance coverage since VIVUS and Eisai have done much of the hard work. If an insurer is going to cover one obesity drug, it'll likely cover all three. Gaining tier 2 status with a smaller co-pay will be harder.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article FDA Approves Orexigen Therapeutics Inc.'s Goldilocks Obesity Drug originally appeared on Fool.com.
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Adding insult to injury, Orexigen had to run a large clinical trial to rule out heart problems, while VIVUS and Arena Pharmaceuticals were able to fix their deficits relatively quickly and have already launched Qsymia and Belviq respectively. Part of the reason VIVUS and Eisai, Arena's marketing partner, have had trouble selling their obesity drugs has more to do with Fen-Phen and Abbott Labs ' Meridia than it does with Qsymia and Belviq. Takeda, which plans to launch Contrave this fall, is going to have the same kinds of challenges although adding another player could help all three drugs since their marketing efforts will get doctors thinking about treating obesity. | In 2011, Orexigen was in a tight race with VIVUS and Arena Pharmaceuticals to gain FDA approval of the first new obesity drug. Many insurers don't cover Qsymia and Belviq, and those that do often put them as a tier 3 drug so patients have to pay large co-pays for the drugs. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Today, Orexigen and Takeda Pharmaceuticals announced that the Food and Drug Administration approved its obesity drug Contrave . In 2011, Orexigen was in a tight race with VIVUS and Arena Pharmaceuticals to gain FDA approval of the first new obesity drug. Many insurers don't cover Qsymia and Belviq, and those that do often put them as a tier 3 drug so patients have to pay large co-pays for the drugs. | Patients now have a third drug to treat their obesity. In 2011, Orexigen was in a tight race with VIVUS and Arena Pharmaceuticals to gain FDA approval of the first new obesity drug. Many insurers don't cover Qsymia and Belviq, and those that do often put them as a tier 3 drug so patients have to pay large co-pays for the drugs. |
34143.0 | 2014-09-09 00:00:00 UTC | ACWI, RXL: Big ETF Inflows | ABT | https://www.nasdaq.com/articles/acwi-rxl-big-etf-inflows-2014-09-09 | nan | nan | Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares MSCI ACWI ETF ( ACWI ), which added 11,200,000 units, or a 11.5% increase week over week. Among the largest underlying components of ACWI, in morning trading today Exxon Mobil ( XOM ) is down about 0.3%, and Apple ( AAPL ) is up by about 0.9%.
And on a percentage change basis, the ETF with the biggest increase in inflows was the Proshares Ultra Health Care ( RXL ), which added 375,000 units, for a 33.3% increase in outstanding units. Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is trading flat, and Abbvie (ABBV) is up by about 0.4%.
VIDEO: ACWI, RXL: Big ETF Inflows
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is trading flat, and Abbvie (ABBV) is up by about 0.4%. Among the largest underlying components of ACWI, in morning trading today Exxon Mobil ( XOM ) is down about 0.3%, and Apple ( AAPL ) is up by about 0.9%. And on a percentage change basis, the ETF with the biggest increase in inflows was the Proshares Ultra Health Care ( RXL ), which added 375,000 units, for a 33.3% increase in outstanding units. | Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is trading flat, and Abbvie (ABBV) is up by about 0.4%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares MSCI ACWI ETF ( ACWI ), which added 11,200,000 units, or a 11.5% increase week over week. Among the largest underlying components of ACWI, in morning trading today Exxon Mobil ( XOM ) is down about 0.3%, and Apple ( AAPL ) is up by about 0.9%. | Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is trading flat, and Abbvie (ABBV) is up by about 0.4%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares MSCI ACWI ETF ( ACWI ), which added 11,200,000 units, or a 11.5% increase week over week. And on a percentage change basis, the ETF with the biggest increase in inflows was the Proshares Ultra Health Care ( RXL ), which added 375,000 units, for a 33.3% increase in outstanding units. | Among the largest underlying components of RXL, in morning trading today Abbott Labs ( ABT ) is trading flat, and Abbvie (ABBV) is up by about 0.4%. Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel, the biggest inflow was seen in the iShares MSCI ACWI ETF ( ACWI ), which added 11,200,000 units, or a 11.5% increase week over week. Among the largest underlying components of ACWI, in morning trading today Exxon Mobil ( XOM ) is down about 0.3%, and Apple ( AAPL ) is up by about 0.9%. |
34144.0 | 2014-09-08 00:00:00 UTC | Noteworthy ETF Outflows: SSO, MMM, ABT, ABBV | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-sso-mmm-abt-abbv-2014-09-08 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $447.9 million dollar outflow -- that's a 17.9% decrease week over week (from 20,550,000 to 16,875,000). Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is off about 0.2%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.2%. The chart below shows the one year price performance of SSO, versus its 200 day moving average:
Looking at the chart above, SSO's low point in its 52 week range is $80.40 per share, with $122.33 as the 52 week high point - that compares with a last trade of $121.33. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is off about 0.2%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $447.9 million dollar outflow -- that's a 17.9% decrease week over week (from 20,550,000 to 16,875,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $80.40 per share, with $122.33 as the 52 week high point - that compares with a last trade of $121.33. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is off about 0.2%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.2%. The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $80.40 per share, with $122.33 as the 52 week high point - that compares with a last trade of $121.33. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is off about 0.2%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $447.9 million dollar outflow -- that's a 17.9% decrease week over week (from 20,550,000 to 16,875,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $80.40 per share, with $122.33 as the 52 week high point - that compares with a last trade of $121.33. | Among the largest underlying components of SSO, in trading today 3M Co (Symbol: MMM) is up about 0.4%, Abbott Laboratories (Symbol: ABT) is off about 0.2%, and AbbVie Inc. (Symbol: ABBV) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $447.9 million dollar outflow -- that's a 17.9% decrease week over week (from 20,550,000 to 16,875,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $80.40 per share, with $122.33 as the 52 week high point - that compares with a last trade of $121.33. |
34145.0 | 2014-09-05 00:00:00 UTC | Abbott Labs' FreeStyle Libre Flash Glucose Gets CE Mark - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-freestyle-libre-flash-glucose-gets-ce-mark-analyst-blog-2014-09-05 | nan | nan | Abbott Labs ( ABT ) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe.
Abbott Labs' glucose system eliminates the need for routine finger pricks and challenges of routine glucose monitoring for people suffering from diabetes. This enables them to maintain a better understanding of their glucose levels. Abbott Labs expects the system to be available in seven countries across Europe.
As per estimates from the International Diabetes Federation, approximately 56 million suffering from diabetes live in Europe. The launch of FreeStyle Libre system will boost Diabetes care sales as the segment continues to be impacted by CMS reimbursement reductions and market dynamics. Abbott Labs generated sales of $577 million from its Diabetes care segment, down 10% from a year ago.
We note that Abbott Labs continues to invest in developing innovative technologies in its diabetes care business.
We were impressed by the company's performance in the first half of 2014 and the subsequent increase in guidance. Abbott Labs now expects earnings per share in the range of $2.19 to $2.29 in 2014 (old guidance $2.16 to $2.26). The second half of 2014 should see an improved performance by the company.
We remind investors that Abbott Labs became a diversified medical products company focusing on branded generic pharmaceutical, medical devices, diagnostic and nutritional businesses following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc. ( ABBV ), in Jan 2013.
Abbott Labs currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader healthcare sector include Allergan ( AGN ) and Gilead Sciences ( GILD ). Both the stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The launch of FreeStyle Libre system will boost Diabetes care sales as the segment continues to be impacted by CMS reimbursement reductions and market dynamics. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe. The launch of FreeStyle Libre system will boost Diabetes care sales as the segment continues to be impacted by CMS reimbursement reductions and market dynamics. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe. Abbott Labs' glucose system eliminates the need for routine finger pricks and challenges of routine glucose monitoring for people suffering from diabetes. | Abbott Labs ( ABT ) received positive news when its FreeStyle Libre Flash Glucose Monitoring System obtained CE Mark (Conformite Europeenne) in Europe. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs' glucose system eliminates the need for routine finger pricks and challenges of routine glucose monitoring for people suffering from diabetes. |
34146.0 | 2014-09-04 00:00:00 UTC | Google's Calico in $500M Joint Venture with AbbVie - Analyst Blog | ABT | https://www.nasdaq.com/articles/googles-calico-in-%24500m-joint-venture-with-abbvie-analyst-blog-2014-09-04 | nan | nan | Calico, Google's ( GOOGL ) year-old health startup is collaborating with biotechnology drugmaker, AbbVie ( ABBV ), a spin-off from Abbott Laboratories ( ABT ), for a joint venture to formulate treatments for cancer and Alzheimer's. The project will be worth $500 million.
Google Inc. and AbbVie Inc. are to invest $250 million each. Besides this, another $1 billion may be invested in the project, if required. The entire expenses along with the profits earned by the venture will be shared by both the companies.
During the first five years of the collaboration, Calico will be looking after research and initial development, which will include construction of a world-class facility in the San Francisco Bay Area. In the second phase, AbbVie will be given the choice to take up management and marketing of projects that are ready.
AbbVie will use its pharmaceutical prowess to support Calico in scientific as well as clinical development and will use its commercial competence to make sure that these therapies are brought to the market.
Since Calico is headed by Arthur Levinson, chairman of Apple Inc. ( AAPL ), there are speculations that Google's the entry into healthcare could include a new wearable Apple device.
Such alliances are not uncommon. Intel ( INTC ) and GE together formed Care Innovations in 2011. The joint venture focuses on technology solutions to connect people to their care teams and the ability to live without being dependant on anyone.
Google currently holds a Zacks Rank #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
GOOGLE INC-CL A (GOOGL): Free Stock Analysis Report
INTEL CORP (INTC): Free Stock Analysis Report
APPLE INC (AAPL): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Calico, Google's ( GOOGL ) year-old health startup is collaborating with biotechnology drugmaker, AbbVie ( ABBV ), a spin-off from Abbott Laboratories ( ABT ), for a joint venture to formulate treatments for cancer and Alzheimer's. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report GOOGLE INC-CL A (GOOGL): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. During the first five years of the collaboration, Calico will be looking after research and initial development, which will include construction of a world-class facility in the San Francisco Bay Area. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report GOOGLE INC-CL A (GOOGL): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Calico, Google's ( GOOGL ) year-old health startup is collaborating with biotechnology drugmaker, AbbVie ( ABBV ), a spin-off from Abbott Laboratories ( ABT ), for a joint venture to formulate treatments for cancer and Alzheimer's. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Calico, Google's ( GOOGL ) year-old health startup is collaborating with biotechnology drugmaker, AbbVie ( ABBV ), a spin-off from Abbott Laboratories ( ABT ), for a joint venture to formulate treatments for cancer and Alzheimer's. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report GOOGLE INC-CL A (GOOGL): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Calico, Google's ( GOOGL ) year-old health startup is collaborating with biotechnology drugmaker, AbbVie ( ABBV ), a spin-off from Abbott Laboratories ( ABT ), for a joint venture to formulate treatments for cancer and Alzheimer's. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report GOOGLE INC-CL A (GOOGL): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Google Inc. and AbbVie Inc. are to invest $250 million each. |
34147.0 | 2014-08-22 00:00:00 UTC | PowerTrend Brief: How You Can Use a Technical Analysis of Earnings to Make Smarter Investments | ABT | https://www.nasdaq.com/articles/powertrend-brief-how-you-can-use-technical-analysis-earnings-make-smarter-investments-2014 | nan | nan | One of the easiest and simplest metrics that investors use to screen for, as well as value, stocks is the price-to-earnings ratio, better known as a stock’s P/E. Of course, on its face, a P/E is nothing more than a snapshot in time, but what if I told you it was far more complicated than that?
There are several P/Es that you need to keep in mind. Sure, there is the current P/E, which reflects a stock’s price divided by the current year’s expected earnings per share, but there are also trailing P/Es, as well as price-to-peak-earnings and price-to-trough earnings. Obtaining a stock’s price is fairly simple; after all, there is no shortage of online services -- both free and paid -- that share what I call the basic information about a stock.
That data set includes the company’s name, ticker, share price, traded volume, average traded volume and so on. When I say basic, that’s the information that barely gets you started, and it can be found at Yahoo! Finance or even Google Finance. There is far more data to be found by culling through those and other resources, but I’m talking with you today about P/Es.
Using a simple P/E screen is one way to hunt for cheap stocks or identify overvalued ones, but what if I told you that if you weren’t careful, you could be making a big mistake when using the easy-to-calculate P/E ratio? Making this mistake could mean the difference between finding a truly inexpensive stock and misidentifying one that really isn’t.
Even before you get going on which of the several P/Es to use, you have to have a firm grasp on the earnings-per-share figure you are going to use and whether or not it represents the true growth rate of the company’s business.
You are probably saying to yourself, “What… did… he… just… say??”
Let me come at it from a different perspective.
During the last several quarters, many companies have taken advantage of the Fed’s intentional low-interest-rate environment to float corporate debt and buy back their shares. As they have shrunk their share count, and racked up debt in the process, it gives the illusion that their earnings per share are growing faster than the growth of the actual business.
What you have to remember is that when a company reports the “earnings” that it and Wall Street are talking about, it’s earnings per share, or EPS. Now that we’ve cleared that up, there are a few ways companies can improve their EPS comparisons on a year-on-year and quarter-over-quarter basis. After all, earnings per share equates to earnings, or net income, divided by the outstanding share count (with certain adjustments).
To deliver better-than-expected EPS, a company can grow its net income, which can either reflect a robust core business or something funky beneath the operating line, such as a lower-than-expected quarterly tax rate. The company can also shrink its outstanding share count via a share buyback program, or some combination of the two.
And that’s what corporate America has been busy doing with its excess cash -- step by step -- shrinking its outstanding share count while boosting debt levels.
According to data from Trim Tabs, stock buybacks soared to more than $670 billion in 2013 alone, with more than $230 billion announced so far in 2014. While that sounds like a steep fall-off, corporate America set a record during 1Q 2014 of $138.5 billion for the second-highest amount ever spent in any one quarter. It also shows a dramatic drop to $92.7 billion in the second quarter, which marks the lowest levels in seven quarters. During the first half of 2014, 15 S&P 500 companies, including Apple (AAPL), Intel (INTC), Caterpillar (CAT), Wells Fargo (WFC) and Qualcomm (QCOM), unveiled significant buyback plans.
But just because a company announces a buyback plan doesn’t necessarily mean it was actively buying back shares. In its most recent Buyback Quarterly, FactSet found that “dollar-value share repurchases amounted to $154.5 billion over the first quarter and $535.2 billion for the trailing twelve months.” Among the big buyback spenders, FactSet found Apple, IBM (IBM), FedEx (FDX), Boeing (BA), Abbott Laboratories (ABT), Corning (GLW) and eBay (EBAY). Other notables included Pfizer (PFE) and Home Depot (HD). Sifting through those respective quarterly earnings statements, we find those nine companies on average shrank their June-quarter outstanding share count by 6.5% year over year.
Now, let’s tie it all together, shall we?
Simple calculations show a 6.4% drop in a company’s share count year over year can deliver a 7% increase in its earnings per share, even if its net income is the exact same.
Following a record year of buybacks in 2013 and the second-best buyback quarter ever in 1Q 2014, it stands to reason the aggregate net income growth across the S&P 500 companies was far slower than the 8.4% earnings growth rate from FactSet or the 10% figure offered by S&P Capital IQ.
Now, that’s quite a revelation to be had when the S&P 500 is trading at 16.7x 2014 consensus EPS expectations!
Remember, the stock market rewards true growth, not simulated growth, and that means giving a quick check to a company’s outstanding share count, as well as its reported EPS figures, the next time you look at its earnings press release or skim its 10Q filings.
The added benefit to this is you can recycle all of this work when using a price-to-earnings growth rate, or PEG, analysis, and it also helps you determine whether or not a company’s business is growing its operating earnings faster than the S&P 500. The stock market and Wall Street reward companies that are able to achieve this with premium valuations and punish those that tend to deliver little to no growth.
In the coming weeks, I’ll share my other valuation metrics that help uncover the investing gems and will help you avoid a potential pitfall.
In case you missed it, I encourage you to read my e-letter column from last week about how milk can make you a better investor. I also invite you to comment in the space provided below my Eagle Daily Investor commentary.
Sincerely,
Christopher Versace
Editor, PowerTrend Profits
Editor, PowerTrader
Editor, PowerOptions Trader
Host, PowerTalk
P.S. My colleagues and I just finished putting together a FREE special report to help investors of all stripes navigate the markets – and profit handsomely – through the rest of 2014.
Click here now to claim your free copy of The Top 12 Stocks You Should Buy Right Now.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In its most recent Buyback Quarterly, FactSet found that “dollar-value share repurchases amounted to $154.5 billion over the first quarter and $535.2 billion for the trailing twelve months.” Among the big buyback spenders, FactSet found Apple, IBM (IBM), FedEx (FDX), Boeing (BA), Abbott Laboratories (ABT), Corning (GLW) and eBay (EBAY). To deliver better-than-expected EPS, a company can grow its net income, which can either reflect a robust core business or something funky beneath the operating line, such as a lower-than-expected quarterly tax rate. During the first half of 2014, 15 S&P 500 companies, including Apple (AAPL), Intel (INTC), Caterpillar (CAT), Wells Fargo (WFC) and Qualcomm (QCOM), unveiled significant buyback plans. | In its most recent Buyback Quarterly, FactSet found that “dollar-value share repurchases amounted to $154.5 billion over the first quarter and $535.2 billion for the trailing twelve months.” Among the big buyback spenders, FactSet found Apple, IBM (IBM), FedEx (FDX), Boeing (BA), Abbott Laboratories (ABT), Corning (GLW) and eBay (EBAY). Sure, there is the current P/E, which reflects a stock’s price divided by the current year’s expected earnings per share, but there are also trailing P/Es, as well as price-to-peak-earnings and price-to-trough earnings. That data set includes the company’s name, ticker, share price, traded volume, average traded volume and so on. | In its most recent Buyback Quarterly, FactSet found that “dollar-value share repurchases amounted to $154.5 billion over the first quarter and $535.2 billion for the trailing twelve months.” Among the big buyback spenders, FactSet found Apple, IBM (IBM), FedEx (FDX), Boeing (BA), Abbott Laboratories (ABT), Corning (GLW) and eBay (EBAY). Simple calculations show a 6.4% drop in a company’s share count year over year can deliver a 7% increase in its earnings per share, even if its net income is the exact same. Remember, the stock market rewards true growth, not simulated growth, and that means giving a quick check to a company’s outstanding share count, as well as its reported EPS figures, the next time you look at its earnings press release or skim its 10Q filings. | In its most recent Buyback Quarterly, FactSet found that “dollar-value share repurchases amounted to $154.5 billion over the first quarter and $535.2 billion for the trailing twelve months.” Among the big buyback spenders, FactSet found Apple, IBM (IBM), FedEx (FDX), Boeing (BA), Abbott Laboratories (ABT), Corning (GLW) and eBay (EBAY). Using a simple P/E screen is one way to hunt for cheap stocks or identify overvalued ones, but what if I told you that if you weren’t careful, you could be making a big mistake when using the easy-to-calculate P/E ratio? After all, earnings per share equates to earnings, or net income, divided by the outstanding share count (with certain adjustments). |
34148.0 | 2014-08-21 00:00:00 UTC | SSO, SVXY: Big ETF Outflows | ABT | https://www.nasdaq.com/articles/sso-svxy-big-etf-outflows-2014-08-21 | nan | nan | Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Proshares Ultra S&P500 ( SSO ), where 3,825,000 units were destroyed, or a 15.5% decrease week over week. Among the largest underlying components of SSO, in morning trading today 3M Company ( MMM ) is off about 0.1%, and Abbott Labs ( ABT ) is higher by about 0.5%.
And on a percentage change basis, the ETF with the biggest outflow was the Proshares Short VIX Short-Term Futures ETF ( SVXY ), which lost 900,000 of its units, representing a 19.6% decline in outstanding units compared to the week prior.
VIDEO: SSO, SVXY: Big ETF Outflows
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in morning trading today 3M Company ( MMM ) is off about 0.1%, and Abbott Labs ( ABT ) is higher by about 0.5%. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Short VIX Short-Term Futures ETF ( SVXY ), which lost 900,000 of its units, representing a 19.6% decline in outstanding units compared to the week prior. VIDEO: SSO, SVXY: Big ETF Outflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in morning trading today 3M Company ( MMM ) is off about 0.1%, and Abbott Labs ( ABT ) is higher by about 0.5%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Proshares Ultra S&P500 ( SSO ), where 3,825,000 units were destroyed, or a 15.5% decrease week over week. VIDEO: SSO, SVXY: Big ETF Outflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in morning trading today 3M Company ( MMM ) is off about 0.1%, and Abbott Labs ( ABT ) is higher by about 0.5%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Proshares Ultra S&P500 ( SSO ), where 3,825,000 units were destroyed, or a 15.5% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Short VIX Short-Term Futures ETF ( SVXY ), which lost 900,000 of its units, representing a 19.6% decline in outstanding units compared to the week prior. | Among the largest underlying components of SSO, in morning trading today 3M Company ( MMM ) is off about 0.1%, and Abbott Labs ( ABT ) is higher by about 0.5%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Proshares Ultra S&P500 ( SSO ), where 3,825,000 units were destroyed, or a 15.5% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Short VIX Short-Term Futures ETF ( SVXY ), which lost 900,000 of its units, representing a 19.6% decline in outstanding units compared to the week prior. |
34149.0 | 2014-08-11 00:00:00 UTC | Bet On This Top Ranked Medical Device ETF - ETF News And Commentary | ABT | https://www.nasdaq.com/articles/bet-on-this-top-ranked-medical-device-etf-etf-news-and-commentary-2014-08-11 | nan | nan | Thanks to lackluster global economic activity for most of the year and rising geo-political tensions, sectors less sensitive to economic cycles, including the U.S. healthcare industry, have easily managed to hold out this year. The broad Health Care Select Sector SPDR ( XLV ) has beaten the fund tracking the overall markets - SPDR S&P 500 ( SPY ).
Though that's the case, increased mergers and acquisitions (M&As) are also paving the way for stronger business and diverse offerings. Moreover, new product offerings, increased pipeline visibility and restructuring activities are fuelling confidence in the sector.
A similar trend has been seen in the medical device and equipment sector - a sub sector of the healthcare industry. Several MedTech majors struggling with core businesses are looking to explore potential therapies through collaborations and alliances to focus on their areas of expertise (read: XPH Crushing the Pharma ETFs Competition ).
One of the top companies in the space, Abbott Labs ( ABT ) recently signed a deal with Mylan for the sale of its non-U.S. developed markets specialty and branded generics business.
Medical device companies are coming up with efficient capital allocation plans, expanding their product offerings and investing in emerging geographies in order to survive in the highly regulated medical device industry, which is burdened with stringent and complex procedures (read: Medical Device ETF Investing 101 ).
Given the stepped up M&As and a shift in their business models toward a value-based healthcare structure amid rising pricing pressure and other bottlenecks in the industry, a look at one of the top ranked ETFs in the space could be the way to target the best of the segment with lower levels of risk.
Also, the sector might be a good defensive bet to play the current market turmoil arising from the Argentina debt default, banking problems in Europe and growing geo-political tensions in Israel and Ukraine.
About the Zacks ETF Rank
The Zacks ETF Rank provides a recommendation for the ETF in the context of our outlook for the underlying industry, sector, style box or asset.
The aim of our models is to select the best ETFs within each risk category. We assign each ETF one of the five ranks within each risk bucket. Thus, the Zacks ETF Rank reflects the expected return of an ETF relative to other products with a similar level of risk.
For investors seeking to apply this methodology to their portfolio in the health care space, we have taken a closer look at the top ranked iShares U.S. Medical Devices ETF ( IHI ). This ETF has a Zacks ETF Rank of 2 or 'Buy' and is detailed below (see: all the Top Ranked ETFs ).
IHI in Focus
Launched in May 2006, IHI provides a targeted exposure to the U.S. medical device sector by tracking the Dow Jones U.S. Select Medical Equipment Index. The fund manages an AUM of $687.1 million and trades in light volumes of roughly 60,000 shares a day.
The fund holds a small basket of 49 stocks which are quite concentrated in its top five holdings. Abbott, Medtronic Inc and Thermo Fisher form the top three spots having a combined exposure of more than one-fourth of fund assets. The product has a definite tilt toward large cap securities with 66% of assets, followed by 19% in mid caps and the rest in small caps.
Sector-wise, Medical Equipment occupies the bulk of exposure with three-fourths allocation, followed by 15% allocation to Medical Supplies and 10% allocation to Pharmaceuticals (see: all the Healthcare ETFs here ).
IHI charges a reasonable 43 basis points as expenses. The product has a modest dividend yield of 0.54% but has a good performance track record. IHI has returned 10% in the year-to-date frame, 22% in the past one year and a compounded 67% in the past three years.
Thus, given its impressive track record, solid fundamentals in the space coupled with a favorable Zacks ETF Rank, the fund is expected to continue its winning streak and outperform the broader markets in the near term. Investors can consider adding this fund to their portfolio for a more diversified approach.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
SPDR-SP PHARMA (XPH): ETF Research Reports
ISHARS-US MED D (IHI): ETF Research Reports
SPDR-HLTH CR (XLV): ETF Research Reports
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | One of the top companies in the space, Abbott Labs ( ABT ) recently signed a deal with Mylan for the sale of its non-U.S. developed markets specialty and branded generics business. Click to get this free report SPDR-SP PHARMA (XPH): ETF Research Reports ISHARS-US MED D (IHI): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Given the stepped up M&As and a shift in their business models toward a value-based healthcare structure amid rising pricing pressure and other bottlenecks in the industry, a look at one of the top ranked ETFs in the space could be the way to target the best of the segment with lower levels of risk. | Click to get this free report SPDR-SP PHARMA (XPH): ETF Research Reports ISHARS-US MED D (IHI): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. One of the top companies in the space, Abbott Labs ( ABT ) recently signed a deal with Mylan for the sale of its non-U.S. developed markets specialty and branded generics business. The broad Health Care Select Sector SPDR ( XLV ) has beaten the fund tracking the overall markets - SPDR S&P 500 ( SPY ). | Click to get this free report SPDR-SP PHARMA (XPH): ETF Research Reports ISHARS-US MED D (IHI): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. One of the top companies in the space, Abbott Labs ( ABT ) recently signed a deal with Mylan for the sale of its non-U.S. developed markets specialty and branded generics business. About the Zacks ETF Rank The Zacks ETF Rank provides a recommendation for the ETF in the context of our outlook for the underlying industry, sector, style box or asset. | One of the top companies in the space, Abbott Labs ( ABT ) recently signed a deal with Mylan for the sale of its non-U.S. developed markets specialty and branded generics business. Click to get this free report SPDR-SP PHARMA (XPH): ETF Research Reports ISHARS-US MED D (IHI): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. A similar trend has been seen in the medical device and equipment sector - a sub sector of the healthcare industry. |
34150.0 | 2014-08-08 00:00:00 UTC | After Hours Most Active for Aug 8, 2014 : F, PPL, QQQ, PVA, CAT, ABT, CMCSA, WMB, MSFT, SIRI, AAPL, CSCO | ABT | https://www.nasdaq.com/articles/after-hours-most-active-aug-8-2014-f-ppl-qqq-pva-cat-abt-cmcsa-wmb-msft-siri-aapl-csco | nan | nan | The NASDAQ 100 After Hours Indicator is down -2.51 to 3,885.58. The total After hours volume is currently 15,617,668 shares traded.
The following are the most active stocks for the after hours session :
Ford Motor Company ( F ) is -0.05 at $17.04, with 8,105,114 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2014. The consensus EPS forecast is $0.37. As reported by Zacks, the current mean recommendation for F is in the "buy range".
PPL Corporation ( PPL ) is unchanged at $33.00, with 2 | The total After hours volume is currently 15,617,668 shares traded. The following are the most active stocks for the after hours session : Ford Motor Company ( F ) is -0.05 at $17.04, with 8,105,114 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2014. | The total After hours volume is currently 15,617,668 shares traded. The following are the most active stocks for the after hours session : Ford Motor Company ( F ) is -0.05 at $17.04, with 8,105,114 shares traded. PPL Corporation ( PPL ) is unchanged at $33.00, with 2 | The total After hours volume is currently 15,617,668 shares traded. The following are the most active stocks for the after hours session : Ford Motor Company ( F ) is -0.05 at $17.04, with 8,105,114 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2014. | The NASDAQ 100 After Hours Indicator is down -2.51 to 3,885.58. The total After hours volume is currently 15,617,668 shares traded. The following are the most active stocks for the after hours session : Ford Motor Company ( F ) is -0.05 at $17.04, with 8,105,114 shares traded. |
34151.0 | 2014-08-07 00:00:00 UTC | Mylan Misses Q2 Earnings and Sales Estimates, Adjusts View - Analyst Blog | ABT | https://www.nasdaq.com/articles/mylan-misses-q2-earnings-and-sales-estimates-adjusts-view-analyst-blog-2014-08-07 | nan | nan | Mylan 's ( MYL ) second quarter 2014 earnings (excluding special items) of 69 cents per share fell short of the Zacks Consensus Estimate by a penny. Earnings in the second quarter of 2014 however increased 1.5% from the year-ago quarter. The year-over-year rise was due to higher revenues. On a reported basis (including special items), second quarter 2014 earnings declined 30.4% to 32 cents per share.
Mylan Inc - Earnings Surprise | FindTheBest
Revenues climbed 8% to $1.84 billion, marginally short of the Zacks Consensus Estimate of $1.9 billion. Mylan recorded year-over-year growth on the back of strong sales in the Generics and Specialty segments.
Second Quarter in Details
Generics third-party net sales, derived from sales in North America, Europe and rest of the world, climbed 5% to $1.53 billion. Growth was 6% at constant currency. Segmental third-party net sales grew 3% to $736.6 million in North America. Though newly launched products performed well, sales in the region were adversely affected by sales of existing products due to unfavorable pricing and volume.
Third-party net sales from the European market improved 10% to $395.9 million aided by favorable foreign currency movements. Third party net sales from rest of the world rose 6% to $396 million. Segmental performance improved on the back of increased sales of its antiretroviral products in India. Japanese performance was also strong during the quarter. Excluding the impact of foreign currency movements, segmental sales climbed 11% in the second quarter of 2014.
Third-party net sales in the Specialty segment jumped 22% to $287.8 million. Specialty segment sales were boosted by the strong performance of its flagship product - EpiPen Auto-Injector - for severe allergic reactions. Sales of the product improved due to market expansion and favorable pricing.
Adjusted gross margin during the second quarter of 2014 expanded to 50% from 49% in the year-ago quarter on the back of strong sales of EpiPen Auto-Injector.
2014 Outlook Adjusted
Mylan tweaked its outlook for 2014 both with respect to earnings and revenues. The company now expects adjusted earnings per share in the range of $3.25 to $3.45 (old guidance: $3.25 to $3.60 ). The company expects revenues in the range of $7.8 billion to $8 billion (old guidance: $7.8 billion to $8.2 billion). The projection includes the launches of the generic versions of Copaxone and Celebrex in the final quarter of the year. The Zacks Consensus Estimate for 2014 is pegged at earnings of $3.37 per share on revenues of approximately $7.79 billion.
The company expects adjusted earnings per share in the band of 90 cents to 95 cents in the third quarter of 2014. The guidance is below the Zacks Consensus Estimate of $1.04. Mylan expects the fourth quarter of 2014 to be its strongest this year due to the above generic launches.
Our Take
While impressed by the rebound in the Specialty segment after a disappointing first quarter, we are disappointed by soft generics sales in the U.S. which were down 5.8% sequentially. Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets is a prudent move. The all stock deal is expected to close in the first quarter of 2015. Mylan said that its 2018 earnings guidance (of at least $6.00 per share) could be reached earlier in the event of the deal achieving its desired results.
Nevertheless, the slashing of the top end of the 2014 guidance both for revenues and earnings is disappointing. The lower-than-expected third quarter earnings guidance is also concerning. Consequently, the earnings report failed to find favor with investors and the stock was down in early trading.
Mylan carries a Zacks Rank #3 (Hold). Better-ranked stocks in the health care space include Mallinckrodt ( MNK ) and Celgene Corp. ( CELG ). While Mallinckrodt carries a Zacks Rank #1 (Strong Buy), Celgene is a Zacks Ranked #2 stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MYLAN INC (MYL): Free Stock Analysis Report
MALLINCKRODT PL (MNK): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets is a prudent move. Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan 's ( MYL ) second quarter 2014 earnings (excluding special items) of 69 cents per share fell short of the Zacks Consensus Estimate by a penny. | Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets is a prudent move. Mylan 's ( MYL ) second quarter 2014 earnings (excluding special items) of 69 cents per share fell short of the Zacks Consensus Estimate by a penny. | Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets is a prudent move. Mylan 's ( MYL ) second quarter 2014 earnings (excluding special items) of 69 cents per share fell short of the Zacks Consensus Estimate by a penny. | Mylan's deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets is a prudent move. Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan recorded year-over-year growth on the back of strong sales in the Generics and Specialty segments. |
34152.0 | 2014-08-06 00:00:00 UTC | Will Mylan (MYL) Earnings in Q2 Disappoint Expectations? - Analyst Blog | ABT | https://www.nasdaq.com/articles/will-mylan-myl-earnings-in-q2-disappoint-expectations-analyst-blog-2014-08-06 | nan | nan | Mylan ( MYL ) is set to report second quarter 2014 results on Aug 7 before the market opens. Last quarter, the company had posted a positive earnings surprise of 4.76%. Let's see how things are shaping up for this announcement.
Factors at Play
The Generics segment is expected to perform well in the second quarter of 2014. Mylan has seen quite a few generic launches over the past few quarters. The newly launched products are expected to perform well, driving segmental growth.
Mylan was also in focus recently when it inked an all-stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets (read more: Mylan to Buy Abbott Generic Drug Unit ). We expect some updates on the impending deal at the company's conference call.
We believe that the Specialty segment will rebound in the second quarter of 2014 from a disappointing first quarter led by strong sales of EpiPen Auto-Injector. However, foreign exchange movements are likely to adversely impact the top line. Moreover, increasing operating costs will hurt the bottom line.
Earnings Whispers?
Our proven model does not conclusively show that Mylan is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank of #1, 2 or 3 for this to happen. That is not the case here as you will see below.
Zacks ESP : The Earnings ESP for Mylan is 0.00% since the Most Accurate Estimate stands at $0.70, in line with the Zacks Consensus Estimate.
Zacks Rank #3 (Hold) : Mylan's Zacks Rank #3 when combined with a 0.00% ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some companies you may want to consider as our model shows that they have the right combination of elements: a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or #3
VIVUS Inc. ( VVUS ) has an Earnings ESP of +6.45% and holds a Zacks Rank #3. VIVUS will be reporting second quarter earnings on Aug 7 after market closes.
Myriad Genetics Inc. ( MYGN ) has an earnings ESP of +4.35% and holds a Zacks Rank #1(Strong Buy). Myriad will report fiscal fourth quarter 2014 earnings on Aug 12 after market closes.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
MYLAN INC (MYL): Free Stock Analysis Report
VIVUS INC (VVUS): Free Stock Analysis Report
MYRIAD GENETICS (MYGN): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Mylan was also in focus recently when it inked an all-stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets (read more: Mylan to Buy Abbott Generic Drug Unit ). Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report VIVUS INC (VVUS): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan ( MYL ) is set to report second quarter 2014 results on Aug 7 before the market opens. | Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report VIVUS INC (VVUS): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan was also in focus recently when it inked an all-stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets (read more: Mylan to Buy Abbott Generic Drug Unit ). Other Stocks to Consider Here are some companies you may want to consider as our model shows that they have the right combination of elements: a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or #3 VIVUS Inc. ( VVUS ) has an Earnings ESP of +6.45% and holds a Zacks Rank #3. | Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report VIVUS INC (VVUS): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan was also in focus recently when it inked an all-stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets (read more: Mylan to Buy Abbott Generic Drug Unit ). Zacks ESP : The Earnings ESP for Mylan is 0.00% since the Most Accurate Estimate stands at $0.70, in line with the Zacks Consensus Estimate. | Mylan was also in focus recently when it inked an all-stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in the developed ex-U.S. markets (read more: Mylan to Buy Abbott Generic Drug Unit ). Click to get this free report MYLAN INC (MYL): Free Stock Analysis Report VIVUS INC (VVUS): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play The Generics segment is expected to perform well in the second quarter of 2014. |
34153.0 | 2014-08-05 00:00:00 UTC | Roche to Acquire Santaris Pharma to Expand RNA Portfolio - Analyst Blog | ABT | https://www.nasdaq.com/articles/roche-to-acquire-santaris-pharma-to-expand-rna-portfolio-analyst-blog-2014-08-05 | nan | nan | In a bid to expand the discovery and development of RNA-targeting medicines, Roche ( RHHBY ) announced that it has entered into an agreement to acquire Denmark-based privately-held biopharmaceutical company Santaris Pharma.
Roche will make an upfront cash payment of $250 million to shareholders of Santaris Pharma along with milestone payments of $200 million.
The acquisition is expected to close later in the month. Santaris Pharma's operations in Denmark will be renamed Roche Innovation Center Copenhagen.
By using its proprietary Locked Nucleic Acid (LNA) platform and tissue-targeting expertise, Santaris Pharma is developing a diverse pipeline of LNA therapeutics that influence the production or activity of select RNA targets to address diseases which are difficult-to-treat with conventional drug modalities.
Roche expects Santaris Pharma's next-generation antisense technology and LNA expertise to complement its experience in disease biology, chemistry, drug safety, drug formulation, delivery, and development.
Last month, Roche entered into a definitive agreement to acquire privately-held biotechnology company, Seragon Pharmaceuticals, Inc.
The acquisition will provide Roche rights to Seragon's entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs) for the potential treatment of hormone receptor-positive breast cancer.
Roche is well placed in the oncology market. In particular, Roche is a leader in breast cancer market with its HER2 franchise with strong demand for drugs like Herceptin. The HER2 franchise includes Herceptin along with drugs like Perjeta and Kadcyla.
Apart from providing therapeutic products and services for diverse medical needs, Roche also focuses on innovative diagnostic solutions for the early detection and treatment of diseases.
Roche currently carries a Zacks Rank #3 (Hold). Investors may consider other large cap pharmas like Allergan ( AGN ), AstraZeneca ( AZN ) and Abbott Labs ( ABT ). While Allergan carries a Zacks Rank #1 (Strong Buy), Abbott Labs and AstraZeneca (AZN) carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors may consider other large cap pharmas like Allergan ( AGN ), AstraZeneca ( AZN ) and Abbott Labs ( ABT ). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. In a bid to expand the discovery and development of RNA-targeting medicines, Roche ( RHHBY ) announced that it has entered into an agreement to acquire Denmark-based privately-held biopharmaceutical company Santaris Pharma. | Investors may consider other large cap pharmas like Allergan ( AGN ), AstraZeneca ( AZN ) and Abbott Labs ( ABT ). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. While Allergan carries a Zacks Rank #1 (Strong Buy), Abbott Labs and AstraZeneca (AZN) carry a Zacks Rank #2 (Buy). | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. Investors may consider other large cap pharmas like Allergan ( AGN ), AstraZeneca ( AZN ) and Abbott Labs ( ABT ). Roche expects Santaris Pharma's next-generation antisense technology and LNA expertise to complement its experience in disease biology, chemistry, drug safety, drug formulation, delivery, and development. | Investors may consider other large cap pharmas like Allergan ( AGN ), AstraZeneca ( AZN ) and Abbott Labs ( ABT ). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. By using its proprietary Locked Nucleic Acid (LNA) platform and tissue-targeting expertise, Santaris Pharma is developing a diverse pipeline of LNA therapeutics that influence the production or activity of select RNA targets to address diseases which are difficult-to-treat with conventional drug modalities. |
34154.0 | 2014-07-22 00:00:00 UTC | Abbott Raises Full Year Earnings Guidance On Strong Q2 Results | ABT | https://www.nasdaq.com/articles/abbott-raises-full-year-earnings-guidance-strong-q2-results-2014-07-22 | nan | nan | Healthcare giant Abbott Laboratories ( ABT ) reported a strong set of second quarter 2014 results on Wednesday, July 16. The company's operational sales increased 3% over the prior year quarter to $5.55 billion, beating analysts' estimates of $5.52 billion compiled by Thomson Reuters. Net income increased by 14.6% to $829 million or $0.54 per share, which was higher than the company's own guidance of $0.50-$0.52 for the quarter. These earnings exclude charges for certain items such as amortization, cost-cutting measures and repatriation of ex-U.S. earnings, amounting to $369 million or $0.24 per share. Based on its performance in the quarter, Abbott raised its full year 2014 EPS (earnings per share) guidance from $2.16-$2.26 to $2.19-$2.29.
The Diagnostics division was again the star performer for Abbott, as its operational sales increased 5.5% year-over-year (y-o-y) to about $1.2 billion driven by robust growth in Core Laboratory sales in the U.S. and Point of Care sales in international markets. Nutritionals, the company's largest segment, seems to be finally recovering from the supplier recall that was initiated in international markets in August of last year. It reported an increase of more than 3% in operational sales, excluding a 1.5% negative impact of foreign exchange. Established Pharmaceuticals, which represents the company's generic drug business, also witnessed a turnaround with a 3% y-o-y increase in sales, driven by robust growth in emerging markets. Vascular and Medical Optics reported operational sales growth of 1.4% and 12.2%, respectively, while Diabetes Care sales declined by over 10%. On the cost side, Abbott's adjusted gross margin improved 30 basis points over the prior year quarter to 55.3%, driven by better Diagnostics gross margins and lower product costs in the Vascular business owing to the resolution of an intellectual property matter.
The company expects operational sales to grow in mid-single digits in the third quarter, with gross margins remaining steady around 55%. Its EPS forecast for the next quarter stands at $0.59 to $0.61, excluding a negative impact of certain specified items amounting to about $0.27 per share. We have a price estimate of $40 for Abbott Labs , which is roughly in line with the current market price. We are in the process of updating our model in light of the recent earnings release.
See our full analysis for Abbott Labs
Steady Growth In Diagnostics
Diagnostics has been Abbott's most consistent growth driver, delivering high single-digit operational sales growth for the past three years. Worldwide sales in this segment grew by 5.5% in Q2 on a constant currency basis, driven by Core Laboratory (6.8%) and Point of Care (3.8%). In the Core Laboratory diagnostic business, sales in the U.S. market grew by over 11% y-o-y driven by greater acceptance of Abbott's integrated and flexible solutions for large scale laboratory testing. International sales grew by 5.8% on the back of strong demand in emerging markets. Contrary to its robust performance in the past year, Molecular Diagnostics sales decreased by about 3% in the quarter, but the company expects the business to bounce back to positive growth in the second half of the year on the back of some expected new orders.
We expect Abbott's Diagnostics sales to continue increasing over the next few years as it launches innovative Diagnostic products. In the Core laboratory diagnostics, Abbott plans to broaden its ARCHITECT assay menu and expand its presence in both developed as well as emerging markets.
Nutritionals Gaining Traction
Nutritionals is Abbott's largest business division, contributing slightly over 30% of the company's value, according to our estimates. It has been under pressure since August of last year when regulators in China, Vietnam and Saudi Arabia asked the company to recall some of its baby formula products on concerns that they contained bacteria that cause food poisoning. Although no health issues were detected during later investigations, the recalls caused significant disruption to the company's sales in these countries. Abbott estimates that the August supplier recall impacted its global nutritional operational sales by about $40 million in Q2 2014.
The company undertook several new initiatives to turn around the business in the past couple of quarters, and they seem to be bearing fruit. Global Pediatric nutrition sales grew about 1% on a constant currency basis this quarter to $963 million, with about 60% of sales generated in international markets. In addition to the Similac Simple Pack launched late last year, Abbott introduced a new infant formula, Elova, in China in the last quarter.
In the adult nutrition business, sales increased 5.7% y-o-y globally, including 10% in international markets in the second quarter. Sales were driven by strong performance of the company's flagship product Ensure and robust uptake in emerging markets. The company expects sales to further improve going forward as it launches new products in existing markets and expands its presence in emerging economies such as India, China, Russia and Brazil. It recently launched a new product, Enovo, in Japan, which is its largest adult nutrition market outside the U.S.
Generic Pharma Business Set For Growth
Established Pharmaceuticals sales have seen a low-to-mid single-digit decline in the last few years, owing to pricing pressure in developed markets such as Europe and Japan. The company announced several deals in the last quarter to streamline this business and focus on high growth areas. In Q2 2014, sales grew 2.3% on a constant currency basis, driven by almost 10% growth in emerging markets, partially offset by 4.7% decline in developed regions.
Abbott sold off the developed market assets of its generic drug business to specialty pharma major Mylan ( MYL ) last week. The deal, expected to close in the first quarter of 2015, is in line with the company's strategy of focusing on emerging markets to revive growth in the business. By divesting its generic pharma business in established markets (which generated sales of about $2 billion in 2013), the company has re-positioned itself from a player in the low-margin, low-growth generic drug market in developed regions to one focused on the high-growth opportunity in emerging markets such as India, China and Latin America.
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Healthcare giant Abbott Laboratories ( ABT ) reported a strong set of second quarter 2014 results on Wednesday, July 16. Established Pharmaceuticals, which represents the company's generic drug business, also witnessed a turnaround with a 3% y-o-y increase in sales, driven by robust growth in emerging markets. It has been under pressure since August of last year when regulators in China, Vietnam and Saudi Arabia asked the company to recall some of its baby formula products on concerns that they contained bacteria that cause food poisoning. | Healthcare giant Abbott Laboratories ( ABT ) reported a strong set of second quarter 2014 results on Wednesday, July 16. The Diagnostics division was again the star performer for Abbott, as its operational sales increased 5.5% year-over-year (y-o-y) to about $1.2 billion driven by robust growth in Core Laboratory sales in the U.S. and Point of Care sales in international markets. On the cost side, Abbott's adjusted gross margin improved 30 basis points over the prior year quarter to 55.3%, driven by better Diagnostics gross margins and lower product costs in the Vascular business owing to the resolution of an intellectual property matter. | Healthcare giant Abbott Laboratories ( ABT ) reported a strong set of second quarter 2014 results on Wednesday, July 16. The Diagnostics division was again the star performer for Abbott, as its operational sales increased 5.5% year-over-year (y-o-y) to about $1.2 billion driven by robust growth in Core Laboratory sales in the U.S. and Point of Care sales in international markets. It recently launched a new product, Enovo, in Japan, which is its largest adult nutrition market outside the U.S. Generic Pharma Business Set For Growth Established Pharmaceuticals sales have seen a low-to-mid single-digit decline in the last few years, owing to pricing pressure in developed markets such as Europe and Japan. | Healthcare giant Abbott Laboratories ( ABT ) reported a strong set of second quarter 2014 results on Wednesday, July 16. The Diagnostics division was again the star performer for Abbott, as its operational sales increased 5.5% year-over-year (y-o-y) to about $1.2 billion driven by robust growth in Core Laboratory sales in the U.S. and Point of Care sales in international markets. See our full analysis for Abbott Labs Steady Growth In Diagnostics Diagnostics has been Abbott's most consistent growth driver, delivering high single-digit operational sales growth for the past three years. |
34155.0 | 2014-07-22 00:00:00 UTC | Tuesday's ETF with Unusual Volume: BSCF | ABT | https://www.nasdaq.com/articles/tuesdays-etf-unusual-volume-bscf-2014-07-22 | nan | nan | The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 2.9 million shares traded versus three month average volume of about 100,000. Shares of BSCF were up about 0.1% on the day.
Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading up about 0.1% with over 25.4 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 0.2% on volume of over 2.8 million shares. Marsh & Mclennan Companies ( MMC ) is the component faring the best Tuesday, up by about 0.6% on the day, while Dominion Resources ( D ) is lagging other components of the Guggenheim BulletShares 2015 Corporate Bond ETF, trading relatively unchanged.
VIDEO: Tuesday's ETF with Unusual Volume: BSCF
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading up about 0.1% with over 25.4 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 0.2% on volume of over 2.8 million shares. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 2.9 million shares traded versus three month average volume of about 100,000. Marsh & Mclennan Companies ( MMC ) is the component faring the best Tuesday, up by about 0.6% on the day, while Dominion Resources ( D ) is lagging other components of the Guggenheim BulletShares 2015 Corporate Bond ETF, trading relatively unchanged. | Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading up about 0.1% with over 25.4 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 0.2% on volume of over 2.8 million shares. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 2.9 million shares traded versus three month average volume of about 100,000. Marsh & Mclennan Companies ( MMC ) is the component faring the best Tuesday, up by about 0.6% on the day, while Dominion Resources ( D ) is lagging other components of the Guggenheim BulletShares 2015 Corporate Bond ETF, trading relatively unchanged. | Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading up about 0.1% with over 25.4 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 0.2% on volume of over 2.8 million shares. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 2.9 million shares traded versus three month average volume of about 100,000. VIDEO: Tuesday's ETF with Unusual Volume: BSCF The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading up about 0.1% with over 25.4 million shares changing hands so far this session, and Abbott Labs ( ABT ), up about 0.2% on volume of over 2.8 million shares. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 2.9 million shares traded versus three month average volume of about 100,000. Shares of BSCF were up about 0.1% on the day. |
34156.0 | 2014-07-17 00:00:00 UTC | #PreMarket Primer: Thursday, July 17: Russia Hit With New Sanctions | ABT | https://www.nasdaq.com/articles/premarket-primer-thursday-july-17-russia-hit-new-sanctions-2014-07-17 | nan | nan | Russia has been slapped with a new set of sanctions designed to economically isolate the nation as President Vladimir Putin has ignored calls from the U.S. and the EU to use Moscow's influence to end the conflict in Ukraine.
The new round of sanctions steps up U.S. efforts to hurt the Russian economy by targeting businesses linked to the conflict rather than just individuals tied to Putin's government. The sanctions affect big businesses including Rosneft, Russia's largest oil producer, and Novatek, the nation's second largest gas company.
Top News
In other news around the markets:
The deal between long time rivals Apple and IBM to sell iPads and iPhones to IBM's business customers was a major blow to BlackBerry as it will likely take over much of the company's customer base. Blackberry was slowly overcoming its troubled past this year and the company's stock was up over 50 percent on Tuesday before news of the Apple-IBM agreement dimmed BlackBerry's prospects. Reuters reported that General Motors has found that the ignition switches responsible for turning off engines and airbags in some cars are safe in certain other models. A spokesperson for GM said there were several other design factors affecting the safety of the switches, making them dangerous only in some models. The media space is rife with takeover deals and 21st Century Fox is getting in on the action. The company confirmed that it had attempted to acquire Time Warner Inc last week with an $80 billion cash and stock offer. Time Warner rejected the bid, but if Fox comes through with an offer sweet enough, it could help the company survive at a time when customers are likely to start cutting off their pay-TV subscriptions to opt for online versions. General Electric is working to find a buyer for its appliance business as the company tries to shift its focus more towards more profitable products like heavy industrial equipment. CEO Jeff Immelt said he is looking to sell around $4 billion worth of assets each year to streamline GE's profits.
Asian Markets
Asian markets were lower with the exception of South Korea's KOSPI, which gained 0.37 percent. The NIKKEI lost 0.06 percent, the Shanghai composite was down 0.57 percent and the Shenzhen composite fell 0.60 percent.
European Markets
European markets began the day on a low note; the FTSE was down 0.34 percent, the STOXX 600 was down 0.42 percent, the DAX lost 0.35 percent, the CAC 40 was down 0.46 percent and the MIB fell 0.85 percent.
Commodities
Energy futures were higher; Brent futures were up 0.35 percent and WTI futures rose 0.87 percent. Gold and silver gained 0.37 percent and 0.43 percent, and industrial metals were also higher with the exception of tin, which lost 0.34 percent. Copper was up 0.03 percent, aluminum gained 0.51 percent and zinc rose 0.17 percent.
Currencies
The euro was steady at $1.3536, while the dollar declined 0.19 percent against the yen, 0.10 percent against the franc and 0.02 percent against the Canadian dollar. However, the greenback gained 0.14 percent against the pound.
Earnings
Notable earnings released on Wednesday included:
Bank of America (NYSE: BAC ) reported second quarter EPS of $0.41 on revenue of $21.96 billion, compared to last year's EPS of $0.32 on revenue of $22.73 billion. eBay (NASDAQ: EBAY ) reported second quarter EPS of $0.69 on revenue of $4.40 billion, compared to last year's EPS of $0.63 on revenue of $3.88 billion. Abbott Laboratories (NYSE: ABT ) reported second quarter EPS of $0.54 on revenue of $5.55 billion, compared to last year's EPS of $0.46 on revenue of $5.45 billion. U.S. Bankcorp (NYSE: USB ) reported second quarter EPS of $0.78, compared to last year's EPS of $0.76 on revenue of $4.95 billion. PNC Financial Services (NYSE: PNC ) reported second quarter EPS of $1.85 on revenue of $3.81 billion, compared to last year's EPS of $1.99 on revenue of $4.06 billion.
Pre-Market Movers
Stocks moving in the Premarket included:
Morgan Stanley (NYSE: MS ) was up 0.74 percent in premarket trade after gaining 1.56 percent on Wednesday. Apple (NASDAQ: AAPL ) gained 0.12 percent in premarket trade after losing 0.57 percent on Wednesday. SanDisk (NASDAQ: SNDK ) was down 9.39 percent in premarket trade after climbing 2.43 percent over the past five days. Micron Technology (NASDAQ: MU ) fell 1.53 percent in premarket trade after gaining 5.32 percent over the past week.
Notable earnings releases expected on Thursday include:
UnitedHealth Group (NYSE: UNH ) is expected to report second quarter EPS of $1.26 on revenue of $31.98 billion, compared to last year's EPS of $1.40 on revenue of $30.41 billion. Novartis AG (NYSE: NVS ) is expected to report second quarter EPS of $1.42 on revenue of $14.81 billion, compared to last year's EPS of $1.28 on revenue of $14.49 billion. Schlumberger N.V. (NYSE: SLB ) is expected to report second quarter EPS of $1.36 on revenue of $11.92 billion, compared to last year's EPS of $1.15 on revenue of $11.18 billion. Morgan Stanley (NYSE: MS ) is expected to report second quarter EPS of $0.58 on revenue of $8.39 billion, compared to last year's EPS of $0.45 on revenue of $8.33 billion. Philip Morris (NYSE: PM ) is expected to report second quarter EPS of $1.24 on revenue of $7.52 billion, compared to last year's EPS of $1.30 on revenue of $7.92 billion.
Economics
U.S. economic data will dominate Thursday'seconomic calendarwith releases including initial and continuing jobless claims, housing starts, building permits and FOMC member James Bullard is set to speak.
For a recap of Wednesday's market action, click .
Tune into Benzinga's #PreMarket Prep today to hear Fari Hamzei, Peter Tchir, Dirk Friczewsky & Riad Younes by clicking here !
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Free Trading Education - Check out the free events taking place on Marketfy this week. Spaces are limited. Sign up today.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories (NYSE: ABT ) reported second quarter EPS of $0.54 on revenue of $5.55 billion, compared to last year's EPS of $0.46 on revenue of $5.45 billion. Russia has been slapped with a new set of sanctions designed to economically isolate the nation as President Vladimir Putin has ignored calls from the U.S. and the EU to use Moscow's influence to end the conflict in Ukraine. The new round of sanctions steps up U.S. efforts to hurt the Russian economy by targeting businesses linked to the conflict rather than just individuals tied to Putin's government. | Abbott Laboratories (NYSE: ABT ) reported second quarter EPS of $0.54 on revenue of $5.55 billion, compared to last year's EPS of $0.46 on revenue of $5.45 billion. Earnings Notable earnings released on Wednesday included: Bank of America (NYSE: BAC ) reported second quarter EPS of $0.41 on revenue of $21.96 billion, compared to last year's EPS of $0.32 on revenue of $22.73 billion. Notable earnings releases expected on Thursday include: UnitedHealth Group (NYSE: UNH ) is expected to report second quarter EPS of $1.26 on revenue of $31.98 billion, compared to last year's EPS of $1.40 on revenue of $30.41 billion. | Abbott Laboratories (NYSE: ABT ) reported second quarter EPS of $0.54 on revenue of $5.55 billion, compared to last year's EPS of $0.46 on revenue of $5.45 billion. European Markets European markets began the day on a low note; the FTSE was down 0.34 percent, the STOXX 600 was down 0.42 percent, the DAX lost 0.35 percent, the CAC 40 was down 0.46 percent and the MIB fell 0.85 percent. Earnings Notable earnings released on Wednesday included: Bank of America (NYSE: BAC ) reported second quarter EPS of $0.41 on revenue of $21.96 billion, compared to last year's EPS of $0.32 on revenue of $22.73 billion. | Abbott Laboratories (NYSE: ABT ) reported second quarter EPS of $0.54 on revenue of $5.55 billion, compared to last year's EPS of $0.46 on revenue of $5.45 billion. Russia has been slapped with a new set of sanctions designed to economically isolate the nation as President Vladimir Putin has ignored calls from the U.S. and the EU to use Moscow's influence to end the conflict in Ukraine. European Markets European markets began the day on a low note; the FTSE was down 0.34 percent, the STOXX 600 was down 0.42 percent, the DAX lost 0.35 percent, the CAC 40 was down 0.46 percent and the MIB fell 0.85 percent. |
34157.0 | 2014-07-16 00:00:00 UTC | Stock Futures Get Boost From Upbeat Earnings, Bullish Chinese GDP; Time Warner Rejects Fox | ABT | https://www.nasdaq.com/articles/stock-futures-get-boost-upbeat-earnings-bullish-chinese-gdp-time-warner-rejects-fox-2014 | nan | nan | Stock futures are higher as upbeat Chinese growth data and strong corporate earnings fuels another positive day on Wall Street. An above-consensus gain in June PPI failed to put much of a dent on the bullish tone this morning, leaving equities in the black for the fourth consecutive day.
Shares of Time Warner ( TWX ) are leading the pack higher after the media conglomerate rejected an $80 billion offer from Rupert Murdoch's Twenty-First Century Fox ( FOX ), driving shares of TWX more than 15% higher before the opening bell. Also, Apple ( AAPL ) and IBM ( IBM ) shares are higher after announcing their collaboration to provide IBM applications on new iPhones and iPads, Abbott Labs ( ABT ) beat earnings estimates, but Yahoo (YHOO) is causing the Nasdaq to underperform after announcing disappointing Q2 results.
In economic news, producer prices increased 0.4% last month led by gains in the energy sector, beating estimates for a 0.3% gain. Excluding the volatile food and fuel segment, wholesale prices rose 0.2%, matching consensus estimates.
Also on tap for today is industrial production and capacity utilization, the Atlanta Fed inflation expectations index, NAHB housing market index, and the Federal Reserves Beige Book at 2:00ET.
-Dow Jones Industrial up 0.39%
-S&P 500 futures up 0.44%
-Nasdaq 100 futures up 0.68%
SENTIMENT
Nikkei down 0.10%
Hang Seng up 0.27%
Shanghai Composite down 0.15%
FTSE-100 up 1.17%
DAX-30 up 1.38%
PRE-MARKET SECTOR WATCH
(+) Large cap tech: higher
(+) Chip stocks: higher
(+) Software stocks: higher
(+) Hardware stocks: higher
(+/-) Internet stocks: mixed
(+) Drug stocks: higher
(+) Financial stocks: higher
(+/-) Retail stocks: mixed
(+) Industrial stocks: higher
(+) Airlines: higher
(+) Autos higher
UPSIDE MOVERS:
(+) TWX (15.67%) Rejected 21-Century Fox ( FOX ) $80 billion buyout offer
(+) IGT (+9.48%) Agreed to $6.4 billion merger with Gtech (GTKYY)
(+) CNCE (+5.67%) FDA lifts partial clinical hold on its CTP-354 drug candidate for spasticity
DOWNSIDE MOVERS:
(-) YHOO (-3.00%) Missed earnings estimates by $0.01
(-) BIOA (-15.97%) Plans to sell 2.8 mln shares at discounted $12 per share
(-) BBRY, BB.TO (-4.67%) IBM/Apple partnership expected to increase competition
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also, Apple ( AAPL ) and IBM ( IBM ) shares are higher after announcing their collaboration to provide IBM applications on new iPhones and iPads, Abbott Labs ( ABT ) beat earnings estimates, but Yahoo (YHOO) is causing the Nasdaq to underperform after announcing disappointing Q2 results. Stock futures are higher as upbeat Chinese growth data and strong corporate earnings fuels another positive day on Wall Street. An above-consensus gain in June PPI failed to put much of a dent on the bullish tone this morning, leaving equities in the black for the fourth consecutive day. | Also, Apple ( AAPL ) and IBM ( IBM ) shares are higher after announcing their collaboration to provide IBM applications on new iPhones and iPads, Abbott Labs ( ABT ) beat earnings estimates, but Yahoo (YHOO) is causing the Nasdaq to underperform after announcing disappointing Q2 results. (+) Large cap tech: higher (+) Chip stocks: higher (+) Software stocks: higher (+) Hardware stocks: higher (+/-) Internet stocks: mixed (+) Drug stocks: higher (+) Financial stocks: higher (+/-) Retail stocks: mixed (+) Industrial stocks: higher (+) Airlines: higher (+) Autos higher (+) TWX (15.67%) Rejected 21-Century Fox ( FOX ) $80 billion buyout offer (+) IGT (+9.48%) Agreed to $6.4 billion merger with Gtech (GTKYY) (+) CNCE (+5.67%) FDA lifts partial clinical hold on its CTP-354 drug candidate for spasticity | Also, Apple ( AAPL ) and IBM ( IBM ) shares are higher after announcing their collaboration to provide IBM applications on new iPhones and iPads, Abbott Labs ( ABT ) beat earnings estimates, but Yahoo (YHOO) is causing the Nasdaq to underperform after announcing disappointing Q2 results. Shares of Time Warner ( TWX ) are leading the pack higher after the media conglomerate rejected an $80 billion offer from Rupert Murdoch's Twenty-First Century Fox ( FOX ), driving shares of TWX more than 15% higher before the opening bell. (+) Large cap tech: higher (+) Chip stocks: higher (+) Software stocks: higher (+) Hardware stocks: higher (+/-) Internet stocks: mixed (+) Drug stocks: higher (+) Financial stocks: higher (+/-) Retail stocks: mixed (+) Industrial stocks: higher (+) Airlines: higher (+) Autos higher | Also, Apple ( AAPL ) and IBM ( IBM ) shares are higher after announcing their collaboration to provide IBM applications on new iPhones and iPads, Abbott Labs ( ABT ) beat earnings estimates, but Yahoo (YHOO) is causing the Nasdaq to underperform after announcing disappointing Q2 results. Stock futures are higher as upbeat Chinese growth data and strong corporate earnings fuels another positive day on Wall Street. Shares of Time Warner ( TWX ) are leading the pack higher after the media conglomerate rejected an $80 billion offer from Rupert Murdoch's Twenty-First Century Fox ( FOX ), driving shares of TWX more than 15% higher before the opening bell. |
34158.0 | 2014-07-16 00:00:00 UTC | #PreMarket Primer: Wednesday, July 16: Yellen Hints At Sooner Than Expected Rate Hike | ABT | https://www.nasdaq.com/articles/premarket-primer-wednesday-july-16-yellen-hints-sooner-expected-rate-hike-2014-07-16 | nan | nan | U.S. employment figures became a lot more important on Tuesday after Federal Reserve Chair Janet Yellen said the US central bank would consider raising its interest rate sooner if the job market improves ahead of expectations.
Speaking before Congress, Yellen defended the bank's accommodative stance, saying that the U.S.' recovery was still in progress and that the economy was not yet ready to stand on its own.
However, Yellen did admit that the bank was open to a sooner than expected rate hike if jobs data improves more quickly than anticipated.
Top News
In other news around the markets:
European policymakers will meet on Wednesday to discuss whether | U.S. employment figures became a lot more important on Tuesday after Federal Reserve Chair Janet Yellen said the US central bank would consider raising its interest rate sooner if the job market improves ahead of expectations. Speaking before Congress, Yellen defended the bank's accommodative stance, saying that the U.S.' recovery was still in progress and that the economy was not yet ready to stand on its own. However, Yellen did admit that the bank was open to a sooner than expected rate hike if jobs data improves more quickly than anticipated. | U.S. employment figures became a lot more important on Tuesday after Federal Reserve Chair Janet Yellen said the US central bank would consider raising its interest rate sooner if the job market improves ahead of expectations. However, Yellen did admit that the bank was open to a sooner than expected rate hike if jobs data improves more quickly than anticipated. Top News In other news around the markets: European policymakers will meet on Wednesday to discuss whether | U.S. employment figures became a lot more important on Tuesday after Federal Reserve Chair Janet Yellen said the US central bank would consider raising its interest rate sooner if the job market improves ahead of expectations. However, Yellen did admit that the bank was open to a sooner than expected rate hike if jobs data improves more quickly than anticipated. Top News In other news around the markets: European policymakers will meet on Wednesday to discuss whether | U.S. employment figures became a lot more important on Tuesday after Federal Reserve Chair Janet Yellen said the US central bank would consider raising its interest rate sooner if the job market improves ahead of expectations. Speaking before Congress, Yellen defended the bank's accommodative stance, saying that the U.S.' recovery was still in progress and that the economy was not yet ready to stand on its own. However, Yellen did admit that the bank was open to a sooner than expected rate hike if jobs data improves more quickly than anticipated. |
34159.0 | 2014-07-15 00:00:00 UTC | Mylan to Buy Abbott Generic Drug Unit - Analyst Blog | ABT | https://www.nasdaq.com/articles/mylan-to-buy-abbott-generic-drug-unit-analyst-blog-2014-07-15 | nan | nan | In a bid to further strengthen its portfolio, enhance geographical reach and save taxes, Mylan ( MYL ) inked an all stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in developed ex-U.S. markets for $5.3 billion (based on Mylan's closing price of $50.20 per share last Friday). The all stock deal, which has been cleared by Mylan's board of directors, is expected to close in the first quarter of 2015. The news impacted Mylan's stock price positively.
Deal Structure
According to the terms of the deal, Abbott will receive 105 million shares of the merged entity following the closure of the deal and own approximately 21% of the new company. Post merger, the new company will comprise Mylan's existing business and the generic pharmaceuticals business of Abbott in all developed ex-U.S. markets such as Europe, Japan, Canada, Australia and New Zealand.
Financials to Get a Boost
The new company, organized in the Ne | In a bid to further strengthen its portfolio, enhance geographical reach and save taxes, Mylan ( MYL ) inked an all stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in developed ex-U.S. markets for $5.3 billion (based on Mylan's closing price of $50.20 per share last Friday). The all stock deal, which has been cleared by Mylan's board of directors, is expected to close in the first quarter of 2015. Post merger, the new company will comprise Mylan's existing business and the generic pharmaceuticals business of Abbott in all developed ex-U.S. markets such as Europe, Japan, Canada, Australia and New Zealand. | In a bid to further strengthen its portfolio, enhance geographical reach and save taxes, Mylan ( MYL ) inked an all stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in developed ex-U.S. markets for $5.3 billion (based on Mylan's closing price of $50.20 per share last Friday). The news impacted Mylan's stock price positively. Post merger, the new company will comprise Mylan's existing business and the generic pharmaceuticals business of Abbott in all developed ex-U.S. markets such as Europe, Japan, Canada, Australia and New Zealand. | In a bid to further strengthen its portfolio, enhance geographical reach and save taxes, Mylan ( MYL ) inked an all stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in developed ex-U.S. markets for $5.3 billion (based on Mylan's closing price of $50.20 per share last Friday). Deal Structure According to the terms of the deal, Abbott will receive 105 million shares of the merged entity following the closure of the deal and own approximately 21% of the new company. Post merger, the new company will comprise Mylan's existing business and the generic pharmaceuticals business of Abbott in all developed ex-U.S. markets such as Europe, Japan, Canada, Australia and New Zealand. | In a bid to further strengthen its portfolio, enhance geographical reach and save taxes, Mylan ( MYL ) inked an all stock deal with Abbott Laboratories ( ABT ) to buy the latter's branded specialty and generics business in developed ex-U.S. markets for $5.3 billion (based on Mylan's closing price of $50.20 per share last Friday). The all stock deal, which has been cleared by Mylan's board of directors, is expected to close in the first quarter of 2015. The news impacted Mylan's stock price positively. |
34160.0 | 2014-07-15 00:00:00 UTC | Pre-Market Earnings Report for July 16, 2014 : BAC, USB, ABT, BLK, PNC, ASML, SCHW, TSM, STJ, NTRS, TXT, FRC | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-july-16-2014-bac-usb-abt-blk-pnc-asml-schw-tsm-stj-ntrs-txt-frc | nan | nan | The following companies are expected to report earnings prior to market open on 07/16/2014. Visit our Earnings Calendar for a full list of expected earnings releases.
Bank of America Corporation ( BAC ) is reporting for the quarter ending June 30, 2014. The bank company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.29. This value represents a 9.38% decrease compared to the same quarter last year. BAC missed the consensus earnings per share in the 1st calendar quarter of 2014 by -200%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BAC is 17.30 vs. an industry ratio of 14.30, implying that they will have a higher earnings growth than their competitors in the same industry.
U.S. Bancorp ( USB ) is reporting for the quarter ending June 30, 2014. The bank company's consensus earnings per share forecast from the 17 analysts that follow the stock is $0.77. This value represents a 1.32% increase compared to the same quarter last year. In the past year USB has met analyst expectations three times and beat the expectations the other quarter. Zacks Investment Research reports that the 2014 Price to Earnings ratio for USB is 13.89 vs. an industry ratio of 14.30.
Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2014. The large cap pharmaceutical company's consensus earnings per share forecast from the 12 analysts that follow the stock is $0.51. This value represents a 10.87% increase compared to the same quarter last year. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.92 vs. an industry ratio of 26.80.
BlackRock, Inc. ( BLK ) is reporting for the quarter ending June 30, 2014. The finance/investment management company's consensus earnings per share forecast from the 10 analysts that follow the stock is $4.46. This value represents a 7.47% increase compared to the same quarter last year. In the past year BLK has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BLK is 17.34 vs. an industry ratio of 20.70.
PNC Financial Services Group, Inc. ( PNC ) is reporting for the quarter ending June 30, 2014. The bank company's consensus earnings per share forecast from the 17 analysts that follow the stock is $1.77. This value represents a 11.06% decrease compared to the same quarter last year. In the past year PNC has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 9.64%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for PNC is 12.13 vs. an industry ratio of 14.30.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending June 30, 2014. The capital goods company's consensus earnings per share forecast from the 3 analysts that follow the stock is $1.03. This value represents a 53.73% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ASML is 24.01 vs. an industry ratio of 13.00, implying that they will have a higher earnings growth than their competitors in the same industry.
The Charles Schwab Corporation ( SCHW ) is reporting for the quarter ending June 30, 2014. The investment bankers company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.22. This value represents a 22.22% increase compared to the same quarter last year. SCHW missed the consensus earnings per share in the 2nd calendar quarter of 2013 by -5.26%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for SCHW is 28.64 vs. an industry ratio of 25.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Taiwan Semiconductor Manufacturing Company Ltd. ( TSM ) is reporting for the quarter ending June 30, 2014. The semi fab foundry company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.37. This value represents a 12.12% increase compared to the same quarter last year. In the past year TSM has met analyst expectations once and beat the expectations the other two quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for TSM is 14.43 vs. an industry ratio of 21.00.
St. Jude Medical, Inc. ( STJ ) is reporting for the quarter ending June 30, 2014. The medical products company's consensus earnings per share forecast from the 12 analysts that follow the stock is $1.00. This value represents a 4.17% increase compared to the same quarter last year. In the past year STJ has beat the expectations every quarter. The highest one was in the 1st calendar quarter where they beat the consensus by 1.05%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for STJ is 17.49 vs. an industry ratio of -1.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Northern Trust Corporation ( NTRS ) is reporting for the quarter ending June 30, 2014. The bank company's consensus earnings per share forecast from the 11 analysts that follow the stock is $0.84. This value represents a 7.69% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for NTRS is 19.47 vs. an industry ratio of 14.30, implying that they will have a higher earnings growth than their competitors in the same industry.
Textron Inc. ( TXT ) is reporting for the quarter ending June 30, 2014. The aerospace and defense company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.47. This value represents a 17.50% increase compared to the same quarter last year. Zacks Investment Research reports that the 2014 Price to Earnings ratio for TXT is 18.72 vs. an industry ratio of 16.80, implying that they will have a higher earnings growth than their competitors in the same industry.
FIRST REPUBLIC BANK ( FRC ) is reporting for the quarter ending June 30, 2014. The bank (west) company's consensus earnings per share forecast from the 10 analysts that follow the stock is $0.76. This value represents a 18.75% increase compared to the same quarter last year. FRC missed the consensus earnings per share in the 3rd calendar quarter of 2013 by -1.54%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for FRC is 17.55 vs. an industry ratio of 18.20.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.92 vs. an industry ratio of 26.80. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.92 vs. an industry ratio of 26.80. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.92 vs. an industry ratio of 26.80. | Abbott Laboratories ( ABT ) is reporting for the quarter ending June 30, 2014. In the past year ABT has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 18.92 vs. an industry ratio of 26.80. |
34161.0 | 2014-07-15 00:00:00 UTC | Will Abbott Laboratories (ABT) Miss This Earnings Season? - Analyst Blog | ABT | https://www.nasdaq.com/articles/will-abbott-laboratories-abt-miss-this-earnings-season-analyst-blog-2014-07-15 | nan | nan | Abbott Laboratories ( ABT ) is set to report second quarter 2014 results on Jul 16 before market opens. Last quarter, the company had posted an earnings surprise of +17.14%. Let's see how things are shaping up for this announcement.
Factors at Play
While the diagnostics division is expected to continue to grow in mid-to-high single digit operational sales for the established pharmaceuticals division is expected to grow in the low single digits. The global diabetes segment is also expected to reflect a low double-digit decline in sales.
Moreover, Abbott Labs' top-line will remain under pressure due to the disruption of nutrition product sales following a supplier recall in the international market in August last year. The company expects to return to pre-recall levels in the third quarter of 2014. Sales might be adversely affected by about 1.5% due to currency fluctuation.
On its first quarter call, the company said that it expects second quarter earnings in the range of 50 cents − 52 cents per share, reflecting double-digit growth at the midpoint of the range.
Earnings Whispers?
Our proven model does not conclusively show that Abbott Labs is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for this to happen. That is not the case here as you will see below.
Zacks ESP: The Earnings ESP for Abbott Labs is 0.00% since the Most Accurate Estimate stands at $0.51, in line with the Zacks Consensus Estimate.
Zacks Rank #3 (Hold): Abbott Labs' Zacks Rank #3 (Hold) has little effect on the predictive power of ESP because the Zacks Rank #3 when combined with a 0.00% ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some other companies you may want to consider as our model shows that they have the right combination of elements, i.e., a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or #3.
Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +2.19% and holds a Zacks Rank #1 (Strong Buy). Biogen will report second quarter earnings on Jul 23.
Mallinckrodt plc ( MNK ) has an Earnings ESP of +5.95% and holds a Zacks Rank #1. Mallinckrodt will report third quarter earnings on Aug 7.
Impax Laboratories Inc. ( IPXL ) has an Earnings ESP of +26.83% and holds a Zacks Rank #3. Impax will report second quarter earnings on Aug 6.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
IMPAX LABORATRS (IPXL): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
MALLINCKRODT PL (MNK): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is set to report second quarter 2014 results on Jul 16 before market opens. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, Abbott Labs' top-line will remain under pressure due to the disruption of nutrition product sales following a supplier recall in the international market in August last year. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is set to report second quarter 2014 results on Jul 16 before market opens. That is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for this to happen. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is set to report second quarter 2014 results on Jul 16 before market opens. Zacks Rank #3 (Hold): Abbott Labs' Zacks Rank #3 (Hold) has little effect on the predictive power of ESP because the Zacks Rank #3 when combined with a 0.00% ESP makes surprise prediction difficult. | Abbott Laboratories ( ABT ) is set to report second quarter 2014 results on Jul 16 before market opens. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, the company had posted an earnings surprise of +17.14%. |
34162.0 | 2014-07-14 00:00:00 UTC | Futures Higher on Active Merger Market, Citigroup Earnings | ABT | https://www.nasdaq.com/articles/futures-higher-on-active-merger-market-citigroup-earnings-2014-07-14 | nan | nan | Stock futures are building on Friday's conservative gains as a flurry of mergers in the pharmaceutical sector and better than expected earnings from Citigroup ( C ) overshadow weak production data from Japan and the EU-zone, as well as any lingering concerns about the future of Portugal's Banco Espirito Santo. Banking stocks are buoying both Dow and S&P futures while tech stocks such as Apple ( AAPL ) and Facebook ( FB ) are helping Nasdaq futures outperform.
In M&A activity, Mylan ( MYL ) offered to buy Abbott Laboratories' ( ABT ) specialty and branded generics business outside the U.S. in an all-stock transaction valued at approximately $5.3 billion, while Abbie (ABBV) upped its offer for Shire Plc (SHPG) to more than $53 billion. Outside of the health care sector, AECOM Technology (ACM) paid $56.31 per share for URS Corp (URS), Synchronoss Technologies (SNCR) paid $26 million for address book personal cloud solutions company Voxmobili, and ConAgra Foods (CAG) acquires Inner Mongolia potato processor TaiMei for $93 million.
Global equities were also trading higher thanks to Friday's gains in the U.S. and waning worries about the health of Portugal's banks. Not surprisingly, Germany DAX outperformed its European peers as euphoria swept through the financial markets after Germany's win over Argentina in the World Cup finals.
-Dow Jones Industrial up 0.45%
-S&P 500 futures up 0.42%
-Nasdaq 100 futures up 0.49%
SENTIMENT
Nikkei up 0.88%
Hang Seng up 0.49%
Shanghai Composite up 0.96%
FTSE-100 up 0.67%
DAX-30 up 0.82%
PRE-MARKET SECTOR WATCH
(+) Large cap tech: higher
(+) Chip stocks: higher
(+) Software stocks: higher
(+) Hardware stocks: higher
(+) Internet stocks: higher
(+) Drug stocks: higher
(+) Financial stocks: higher
(+) Retail stocks: higher
(+) Industrial stocks: higher
(+) Airlines: higher
(+) Autos higher
UPSIDE MOVERS:
(+) URS (+8.23%) To be acquired by AECOM Techology (ACM) for $56.31 per share
(+) PGNX (+12.74%) FDA approved Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals' RELISTOR
(+) EXEL (+11.88%) Positive results on Phase 3 Trial of melanoma treatment
(+) C (+3.60%) Q2 Results top expectations, settlement reached with Justice Department
DOWNSIDE MOVERS:
(-) RVBD (-4.77%) Lowers Q2 guidance below street, sees EPS at lower end of outlook
(-) HLIT (-12.90%) Cuts Q2 guidance below prior view, street estimates
(-) ABBV (-2.71%) Specialty and branded generics business sold to Mylan ( MYL ) for $5.3 billion
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In M&A activity, Mylan ( MYL ) offered to buy Abbott Laboratories' ( ABT ) specialty and branded generics business outside the U.S. in an all-stock transaction valued at approximately $5.3 billion, while Abbie (ABBV) upped its offer for Shire Plc (SHPG) to more than $53 billion. Outside of the health care sector, AECOM Technology (ACM) paid $56.31 per share for URS Corp (URS), Synchronoss Technologies (SNCR) paid $26 million for address book personal cloud solutions company Voxmobili, and ConAgra Foods (CAG) acquires Inner Mongolia potato processor TaiMei for $93 million. Global equities were also trading higher thanks to Friday's gains in the U.S. and waning worries about the health of Portugal's banks. | In M&A activity, Mylan ( MYL ) offered to buy Abbott Laboratories' ( ABT ) specialty and branded generics business outside the U.S. in an all-stock transaction valued at approximately $5.3 billion, while Abbie (ABBV) upped its offer for Shire Plc (SHPG) to more than $53 billion. Outside of the health care sector, AECOM Technology (ACM) paid $56.31 per share for URS Corp (URS), Synchronoss Technologies (SNCR) paid $26 million for address book personal cloud solutions company Voxmobili, and ConAgra Foods (CAG) acquires Inner Mongolia potato processor TaiMei for $93 million. (+) Large cap tech: higher (+) Chip stocks: higher (+) Software stocks: higher (+) Hardware stocks: higher (+) Internet stocks: higher (+) Drug stocks: higher (+) Financial stocks: higher (+) Retail stocks: higher (+) Industrial stocks: higher (+) Airlines: higher (+) Autos higher | In M&A activity, Mylan ( MYL ) offered to buy Abbott Laboratories' ( ABT ) specialty and branded generics business outside the U.S. in an all-stock transaction valued at approximately $5.3 billion, while Abbie (ABBV) upped its offer for Shire Plc (SHPG) to more than $53 billion. Nikkei up 0.88% Hang Seng up 0.49% Shanghai Composite up 0.96% FTSE-100 up 0.67% DAX-30 up 0.82% (+) Large cap tech: higher (+) Chip stocks: higher (+) Software stocks: higher (+) Hardware stocks: higher (+) Internet stocks: higher (+) Drug stocks: higher (+) Financial stocks: higher (+) Retail stocks: higher (+) Industrial stocks: higher (+) Airlines: higher (+) Autos higher | In M&A activity, Mylan ( MYL ) offered to buy Abbott Laboratories' ( ABT ) specialty and branded generics business outside the U.S. in an all-stock transaction valued at approximately $5.3 billion, while Abbie (ABBV) upped its offer for Shire Plc (SHPG) to more than $53 billion. Stock futures are building on Friday's conservative gains as a flurry of mergers in the pharmaceutical sector and better than expected earnings from Citigroup ( C ) overshadow weak production data from Japan and the EU-zone, as well as any lingering concerns about the future of Portugal's Banco Espirito Santo. Banking stocks are buoying both Dow and S&P futures while tech stocks such as Apple ( AAPL ) and Facebook ( FB ) are helping Nasdaq futures outperform. |
34163.0 | 2014-07-14 00:00:00 UTC | Sector Update: Health Care | ABT | https://www.nasdaq.com/articles/sector-update-health-care-2014-07-14-0 | nan | nan | Health-care shares were flat to higher in pre-market trade Monday.
In health-care stocks news, Abbott ( ABT ) shares were up about 1% after it said it will sell its developed markets branded generics pharmaceuticals business to Mylan ( MYL ) for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company.
The deal represents a value of approximately $5.3 billion based on Mylan's closing stock price on Friday. The developed markets portion of this business generated approximately $2 billion in sales in 2013. Abbott will retain its branded generics pharmaceuticals business and products in emerging markets. Abbott also retains its other businesses and products in developed markets.
And, Synergy Pharmaceuticals ( SGYP ) said it has reached the halfway mark for total enrollment in the first pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation. The company plans to release top-line data from the first phase 3 CIC trial in the second quarter of 2015.
Finally, Salix Pharmaceuticals ( SLXP ) and Progenics Pharmaceuticals ( PGNX ) have announced the Food and Drug Administration (FDA) has informed Salix that its RELISTOR subcutaneous injection, 20 mg/ml, has been approved on the data submitted in the supplemental NDA (sNDA), for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Abbott ( ABT ) shares were up about 1% after it said it will sell its developed markets branded generics pharmaceuticals business to Mylan ( MYL ) for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company. The deal represents a value of approximately $5.3 billion based on Mylan's closing stock price on Friday. And, Synergy Pharmaceuticals ( SGYP ) said it has reached the halfway mark for total enrollment in the first pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation. | In health-care stocks news, Abbott ( ABT ) shares were up about 1% after it said it will sell its developed markets branded generics pharmaceuticals business to Mylan ( MYL ) for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company. Abbott will retain its branded generics pharmaceuticals business and products in emerging markets. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In health-care stocks news, Abbott ( ABT ) shares were up about 1% after it said it will sell its developed markets branded generics pharmaceuticals business to Mylan ( MYL ) for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company. Abbott will retain its branded generics pharmaceuticals business and products in emerging markets. Finally, Salix Pharmaceuticals ( SLXP ) and Progenics Pharmaceuticals ( PGNX ) have announced the Food and Drug Administration (FDA) has informed Salix that its RELISTOR subcutaneous injection, 20 mg/ml, has been approved on the data submitted in the supplemental NDA (sNDA), for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain. | In health-care stocks news, Abbott ( ABT ) shares were up about 1% after it said it will sell its developed markets branded generics pharmaceuticals business to Mylan ( MYL ) for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company. The developed markets portion of this business generated approximately $2 billion in sales in 2013. And, Synergy Pharmaceuticals ( SGYP ) said it has reached the halfway mark for total enrollment in the first pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation. |
34164.0 | 2014-07-14 00:00:00 UTC | Close Update: Stocks Rally on Citigroup Earnings Beat, M&A Activity | ABT | https://www.nasdaq.com/articles/close-update%3A-stocks-rally-on-citigroup-earnings-beat-ma-activity-2014-07-14 | nan | nan | Encouraged by upbeat earnings from Citigroup ( C ) and multi-billion dollar deals in the pharmaceutical sector, investors shrugged off geo-political pressures and poured back into equities on Monday, driving the Dow Industrials to another record high.
Last week's losses tied to Portugal's banking crisis and worries over Q2 earnings were reversed after Citigroup shares jumped higher on an earnings beat despite a $7 billion judgement levied against the bank by the Justice Department. Health care and industrials were given a shot-in-the arm by M&A deals between Mylan ( MYL ) and Abbott Labs ( ABT ), AbbVie ( ABBV ) and Shire Plc ( SHPG ),and ConAgra Foods (CAG) and Inner Mongolia potato processor TaiMei.
In commodities, gold put in its worst performance this year as the risk-aversion to equities dissipated. The precious metal f | Health care and industrials were given a shot-in-the arm by M&A deals between Mylan ( MYL ) and Abbott Labs ( ABT ), AbbVie ( ABBV ) and Shire Plc ( SHPG ),and ConAgra Foods (CAG) and Inner Mongolia potato processor TaiMei. Encouraged by upbeat earnings from Citigroup ( C ) and multi-billion dollar deals in the pharmaceutical sector, investors shrugged off geo-political pressures and poured back into equities on Monday, driving the Dow Industrials to another record high. In commodities, gold put in its worst performance this year as the risk-aversion to equities dissipated. | Health care and industrials were given a shot-in-the arm by M&A deals between Mylan ( MYL ) and Abbott Labs ( ABT ), AbbVie ( ABBV ) and Shire Plc ( SHPG ),and ConAgra Foods (CAG) and Inner Mongolia potato processor TaiMei. Encouraged by upbeat earnings from Citigroup ( C ) and multi-billion dollar deals in the pharmaceutical sector, investors shrugged off geo-political pressures and poured back into equities on Monday, driving the Dow Industrials to another record high. Last week's losses tied to Portugal's banking crisis and worries over Q2 earnings were reversed after Citigroup shares jumped higher on an earnings beat despite a $7 billion judgement levied against the bank by the Justice Department. | Health care and industrials were given a shot-in-the arm by M&A deals between Mylan ( MYL ) and Abbott Labs ( ABT ), AbbVie ( ABBV ) and Shire Plc ( SHPG ),and ConAgra Foods (CAG) and Inner Mongolia potato processor TaiMei. Encouraged by upbeat earnings from Citigroup ( C ) and multi-billion dollar deals in the pharmaceutical sector, investors shrugged off geo-political pressures and poured back into equities on Monday, driving the Dow Industrials to another record high. Last week's losses tied to Portugal's banking crisis and worries over Q2 earnings were reversed after Citigroup shares jumped higher on an earnings beat despite a $7 billion judgement levied against the bank by the Justice Department. | Health care and industrials were given a shot-in-the arm by M&A deals between Mylan ( MYL ) and Abbott Labs ( ABT ), AbbVie ( ABBV ) and Shire Plc ( SHPG ),and ConAgra Foods (CAG) and Inner Mongolia potato processor TaiMei. Encouraged by upbeat earnings from Citigroup ( C ) and multi-billion dollar deals in the pharmaceutical sector, investors shrugged off geo-political pressures and poured back into equities on Monday, driving the Dow Industrials to another record high. Last week's losses tied to Portugal's banking crisis and worries over Q2 earnings were reversed after Citigroup shares jumped higher on an earnings beat despite a $7 billion judgement levied against the bank by the Justice Department. |
34165.0 | 2014-07-11 00:00:00 UTC | Abbott Labs, Fonterra Collaborate for Dairy Farm Hub in China - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-fonterra-collaborate-for-dairy-farm-hub-in-china-analyst-blog-2014-07-11 | nan | nan | Abbott Laboratories ( ABT ) announced that it has signed an agreement with New Zealand-based Fonterra Co-operative Group Ltd. for the development of a proposed dairy farm hub in China. The alliance, pending regulatory approval in China, will leverage Fonterra's expertise in dairy nutrition and farming in China.
Upon approval, Abbott Labs and Fonterra will form a joint venture to invest a combined $300 million into the farm hub. The hub will contain up to five dairy farms and more than 16,000 dairy milking cattle in production. Abbott Labs expects the development of the first farm to be complete and operational in the first half of 2017 while the remaining farms will commence production in 2018.
The alliance is a step forward in Abbott Labs' strategic decision to invest in China in the long term. Abbott Labs expects to invest $400 million in its China operations in 2014.
In Jun 2014, Abbott Labs opened a state-of-the-art nutritional manufacturing facility in Jiaxin. In addition, it opened two research and development centers in Shanghai earlier in the year.
China is a key emerging market for Abbott Labs. We note that Abbott Labs' international nutrition sales were adversely impacted by a supplier recall initiated in Aug 2013 in China and two other markets for certain pediatric nutritional products. Although there were no quality issues with the recalled products and the supplier subsequently determined the products were safe for consumption, sales were disrupted.
Abbott Labs, a large-cap pharma, currently, carries a Zacks Rank #2 (Buy). Other large cap pharmas which look attractive include AbbVie ( ABBV ), Allergan ( AGN ) and Johnson & Johnson ( JNJ ). All three carry a Zacks Rank #2.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) announced that it has signed an agreement with New Zealand-based Fonterra Co-operative Group Ltd. for the development of a proposed dairy farm hub in China. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Upon approval, Abbott Labs and Fonterra will form a joint venture to invest a combined $300 million into the farm hub. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) announced that it has signed an agreement with New Zealand-based Fonterra Co-operative Group Ltd. for the development of a proposed dairy farm hub in China. Other large cap pharmas which look attractive include AbbVie ( ABBV ), Allergan ( AGN ) and Johnson & Johnson ( JNJ ). | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) announced that it has signed an agreement with New Zealand-based Fonterra Co-operative Group Ltd. for the development of a proposed dairy farm hub in China. Abbott Labs expects the development of the first farm to be complete and operational in the first half of 2017 while the remaining farms will commence production in 2018. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) announced that it has signed an agreement with New Zealand-based Fonterra Co-operative Group Ltd. for the development of a proposed dairy farm hub in China. Abbott Labs expects to invest $400 million in its China operations in 2014. |
34166.0 | 2014-07-08 00:00:00 UTC | Novo Nordisk Gets FDA Nod for NovoSeven RT - Analyst Blog | ABT | https://www.nasdaq.com/articles/novo-nordisk-gets-fda-nod-for-novoseven-rt-analyst-blog-2014-07-08 | nan | nan | Novo Nordisk 's ( NVO ) NovoSeven RT (coagulation factor VIIa [recombinant]) received FDA approval for perioperative management and the treatment of bleeding episodes in patients suffering from Glanzmann's thrombasthenia (a rare genetic bleeding disorder) with refractoriness to platelet transfusions (with or without antibodies to platelets). NovoSeven RT is the first recombinant treatment to gain FDA approval for this indication.
According to the press release issued by Novo Nordisk, one out of a million is diagnosed with this disease globally, and suffers from a lifelong susceptibility towards bleeding episodes, which might be potentially life threatening.
NovoSeven RT is already approved for Glanzmann's thrombasthenia in the EU.
We note that NovoSeven is also approved for the treatment and prevention of bleeding in surgeries and procedures in adults and children suffering from hemophilia (A or B) with inhibitors, acquired hemophilia or congenital factor VII (FVII) deficiency. In Feb 2013, Novo Nordisk launched NovoSeven with a pre-filled syringe under the trade name 'NovoSeven RT with MixPro' in the U.S. and 'NovoSeven with pre-filled syringe' in the EU.
In 2013, NovoSeven generated total sales of DKK 9.3 million, up 3.6% y/y. We are pleased to see NovoSeven RT's approval in the U.S. for Glanzmann's thrombasthenia. This will expand the eligible customer base for the drug and strengthen its position in the market for coagulation factors.
Novo Nordisk carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the health care sector include Abbott Laboratories ( ABT ), AbbVie Inc. ( ABBV ) and Allergan Inc. ( AGN ). All these stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ALLERGAN INC (AGN): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the health care sector include Abbott Laboratories ( ABT ), AbbVie Inc. ( ABBV ) and Allergan Inc. ( AGN ). Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Novo Nordisk 's ( NVO ) NovoSeven RT (coagulation factor VIIa [recombinant]) received FDA approval for perioperative management and the treatment of bleeding episodes in patients suffering from Glanzmann's thrombasthenia (a rare genetic bleeding disorder) with refractoriness to platelet transfusions (with or without antibodies to platelets). | Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Abbott Laboratories ( ABT ), AbbVie Inc. ( ABBV ) and Allergan Inc. ( AGN ). Novo Nordisk 's ( NVO ) NovoSeven RT (coagulation factor VIIa [recombinant]) received FDA approval for perioperative management and the treatment of bleeding episodes in patients suffering from Glanzmann's thrombasthenia (a rare genetic bleeding disorder) with refractoriness to platelet transfusions (with or without antibodies to platelets). | Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the health care sector include Abbott Laboratories ( ABT ), AbbVie Inc. ( ABBV ) and Allergan Inc. ( AGN ). Novo Nordisk 's ( NVO ) NovoSeven RT (coagulation factor VIIa [recombinant]) received FDA approval for perioperative management and the treatment of bleeding episodes in patients suffering from Glanzmann's thrombasthenia (a rare genetic bleeding disorder) with refractoriness to platelet transfusions (with or without antibodies to platelets). | Some better-ranked stocks in the health care sector include Abbott Laboratories ( ABT ), AbbVie Inc. ( ABBV ) and Allergan Inc. ( AGN ). Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Novo Nordisk 's ( NVO ) NovoSeven RT (coagulation factor VIIa [recombinant]) received FDA approval for perioperative management and the treatment of bleeding episodes in patients suffering from Glanzmann's thrombasthenia (a rare genetic bleeding disorder) with refractoriness to platelet transfusions (with or without antibodies to platelets). |
34167.0 | 2014-07-07 00:00:00 UTC | Roche's Alectinib Approved in Japan - Analyst Blog | ABT | https://www.nasdaq.com/articles/roches-alectinib-approved-in-japan-analyst-blog-2014-07-07 | nan | nan | Roche ( RHHBY ) received positive news when the Japanese Ministry of Health, Labour and Welfare (MHLW) approved alectinib for the treatment of patients suffering from non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+).
The approval was based on encouraging results from a phase I/II clinical study (AF-001JP) conducted in Japan among patients whose tumors were advanced, recurrent or could not be removed completely through surgery.
The trial consisted of two phases - in phase I, the safety, tolerability, pharmacokinetic parameters and recommended dose (24 patients) of alectinib was evaluated and phase II evaluated the efficacy and safety of the recommended dose. The data from the study showed that 90% of the patients responded to the treatment with alectinib.
Alectinib will be available in Japan later this year. We note that alectinib was granted Breakthrough Therapy Designation by the FDA in Jun 2013 for patients suffering from ALK+ NSCLC who progressed on Xalkori.
Meanwhile, Roche is conducting clinical studies on a global basis to evaluate alectinib for this indication as well as in treatment-naïve patients. Roche expects to use the results of these studies for regulatory submissions in the U.S. and Europe.
We note that Roche's Avastin and Tarceva are already approved for the treatment of various types of lung cancer. The approval of alectinib in Japan and a potential approval in the U.S. and EU will further boost Roche's oncology franchise.
Roche specializes in oncology drugs. In particular, the company is a leader in breast cancer franchise and continues to innovate further to strengthen its already dominant position.
Roche currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the broader healthcare sector include Abbott Labs ( ABT ), Allergan ( AGN ) and Shire ( SHPG ). All three stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the broader healthcare sector include Abbott Labs ( ABT ), Allergan ( AGN ) and Shire ( SHPG ). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Roche ( RHHBY ) received positive news when the Japanese Ministry of Health, Labour and Welfare (MHLW) approved alectinib for the treatment of patients suffering from non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+). | Some better-ranked stocks in the broader healthcare sector include Abbott Labs ( ABT ), Allergan ( AGN ) and Shire ( SHPG ). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the broader healthcare sector include Abbott Labs ( ABT ), Allergan ( AGN ) and Shire ( SHPG ). Roche ( RHHBY ) received positive news when the Japanese Ministry of Health, Labour and Welfare (MHLW) approved alectinib for the treatment of patients suffering from non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+). | Some better-ranked stocks in the broader healthcare sector include Abbott Labs ( ABT ), Allergan ( AGN ) and Shire ( SHPG ). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The approval was based on encouraging results from a phase I/II clinical study (AF-001JP) conducted in Japan among patients whose tumors were advanced, recurrent or could not be removed completely through surgery. |
34168.0 | 2014-06-30 00:00:00 UTC | IYH, PFE, GILD, ABT: Large Inflows Detected at ETF | ABT | https://www.nasdaq.com/articles/iyh-pfe-gild-abt-large-inflows-detected-etf-2014-06-30 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $32.1 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 19,800,000 to 20,050,000). Among the largest underlying components of IYH, in trading today Pfizer Inc (Symbol: PFE) is up about 0.1%, Gilead Sciences, Inc. (Symbol: GILD) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 1.4%. The chart below shows the one year price performance of IYH, versus its 200 day moving average:
Looking at the chart above, IYH's low point in its 52 week range is $99.75 per share, with $128.94 as the 52 week high point - that compares with a last trade of $128.70. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Pfizer Inc (Symbol: PFE) is up about 0.1%, Gilead Sciences, Inc. (Symbol: GILD) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 1.4%. The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $99.75 per share, with $128.94 as the 52 week high point - that compares with a last trade of $128.70. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IYH, in trading today Pfizer Inc (Symbol: PFE) is up about 0.1%, Gilead Sciences, Inc. (Symbol: GILD) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 1.4%. The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $99.75 per share, with $128.94 as the 52 week high point - that compares with a last trade of $128.70. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IYH, in trading today Pfizer Inc (Symbol: PFE) is up about 0.1%, Gilead Sciences, Inc. (Symbol: GILD) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $32.1 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 19,800,000 to 20,050,000). The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $99.75 per share, with $128.94 as the 52 week high point - that compares with a last trade of $128.70. | Among the largest underlying components of IYH, in trading today Pfizer Inc (Symbol: PFE) is up about 0.1%, Gilead Sciences, Inc. (Symbol: GILD) is up about 1.1%, and Abbott Laboratories (Symbol: ABT) is up by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Healthcare ETF (Symbol: IYH) where we have detected an approximate $32.1 million dollar inflow -- that's a 1.3% increase week over week in outstanding units (from 19,800,000 to 20,050,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. |
34169.0 | 2014-06-24 00:00:00 UTC | Abbott Labs to Buy Russia-Based Veropharm - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-to-buy-russia-based-veropharm-analyst-blog-2014-06-24 | nan | nan | Abbott Laboratories ( ABT ) announced a definitive agreement to acquire Russia-based pharmaceutical manufacturer Veropharm for approximately $395 million - $495 million (13.6 billion rubles - 17 billion rubles).
As per the terms of the agreement, Abbott Labs will acquire Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm.
The purchase price is dependent on Garden Hills' stake in Veropharm at the time of the closure of the deal.
We note that Garden Hills currently has more than 80% stake in Veropharm but is expected to own more than 95% by the time the transaction is closed. In addition, Abbott Labs will also assume net debt of approximately $136 million.
The acquisition of Veropharm will provide Abbott Labs a portfolio of medicines, which will complement its current pharmaceutical therapeutic focus areas of women's health, central nervous system, cardiovascular and gastroenterology.
Additionally, Abbott Labs will establish a manufacturing presence in Russia upon the closure of the transaction through its ownership of Veropharm's existing production facilities. It will also acquire ownership of a new state-of-the-art manufacturing facility that is currently being developed by Veropharm. Abbott Labs also intends to leverage its manufacturing expertise to expand Veropharm's capabilities and boost the existing infrastructure.
The acquisition is expected to add approximately $150 million to the top line in 2015. The transaction is expected to close in the fourth quarter and will not impact Abbott Labs' results in 2014.
Our Take
Abbott Labs currently carries a Zacks Rank #3 (Hold). Emerging markets are key focus areas for Abbott Labs. The acquisition of Veropharm will broaden Abbott Labs presence in Russian markets.
We remind investors that Abbott Labs became a diversified medical products company, focusing on branded generic pharmaceutical, medical devices, diagnostic and nutritional businesses following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc . ( ABBV ), in Jan 2013.
The business environment was challenging in 2013 due to austerity measures undertaken by developed markets. Hence, Abbott Labs' efforts to broaden its presence in the emerging markets will help the company to combat the challenging business environment elsewhere in the world and maintain top-line growth.
Some better-ranked stocks in the broader healthcare sector include Allergan ( AGN ) and Bayer ( BAYRY ). While Allergan carries a Zacks Rank #1 (Strong Buy), Bayer is a Zacks Rank #2 (Buy) stock.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) announced a definitive agreement to acquire Russia-based pharmaceutical manufacturer Veropharm for approximately $395 million - $495 million (13.6 billion rubles - 17 billion rubles). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition of Veropharm will provide Abbott Labs a portfolio of medicines, which will complement its current pharmaceutical therapeutic focus areas of women's health, central nervous system, cardiovascular and gastroenterology. | Abbott Laboratories ( ABT ) announced a definitive agreement to acquire Russia-based pharmaceutical manufacturer Veropharm for approximately $395 million - $495 million (13.6 billion rubles - 17 billion rubles). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. While Allergan carries a Zacks Rank #1 (Strong Buy), Bayer is a Zacks Rank #2 (Buy) stock. | Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) announced a definitive agreement to acquire Russia-based pharmaceutical manufacturer Veropharm for approximately $395 million - $495 million (13.6 billion rubles - 17 billion rubles). As per the terms of the agreement, Abbott Labs will acquire Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm. | Abbott Laboratories ( ABT ) announced a definitive agreement to acquire Russia-based pharmaceutical manufacturer Veropharm for approximately $395 million - $495 million (13.6 billion rubles - 17 billion rubles). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Garden Hills currently has more than 80% stake in Veropharm but is expected to own more than 95% by the time the transaction is closed. |
34170.0 | 2014-06-17 00:00:00 UTC | iShares U.S. Medical Devices ETF Experiences Big Outflow | ABT | https://www.nasdaq.com/articles/ishares-us-medical-devices-etf-experiences-big-outflow-2014-06-17 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $15.0 million dollar outflow -- that's a 2.1% decrease week over week (from 7,150,000 to 7,000,000). Among the largest underlying components of IHI, in trading today Medtronic, Inc. (Symbol: MDT) is up about 1.4%, Abbott Laboratories (Symbol: ABT) is off about 0.3%, and Baxter International Inc. (Symbol: BAX) is lower by about 0.2%. The chart below shows the one year price performance of IHI, versus its 200 day moving average:
Looking at the chart above, IHI's low point in its 52 week range is $76.93 per share, with $101.76 as the 52 week high point - that compares with a last trade of $100.53. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of IHI, in trading today Medtronic, Inc. (Symbol: MDT) is up about 1.4%, Abbott Laboratories (Symbol: ABT) is off about 0.3%, and Baxter International Inc. (Symbol: BAX) is lower by about 0.2%. The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $76.93 per share, with $101.76 as the 52 week high point - that compares with a last trade of $100.53. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of IHI, in trading today Medtronic, Inc. (Symbol: MDT) is up about 1.4%, Abbott Laboratories (Symbol: ABT) is off about 0.3%, and Baxter International Inc. (Symbol: BAX) is lower by about 0.2%. The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $76.93 per share, with $101.76 as the 52 week high point - that compares with a last trade of $100.53. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of IHI, in trading today Medtronic, Inc. (Symbol: MDT) is up about 1.4%, Abbott Laboratories (Symbol: ABT) is off about 0.3%, and Baxter International Inc. (Symbol: BAX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $15.0 million dollar outflow -- that's a 2.1% decrease week over week (from 7,150,000 to 7,000,000). The chart below shows the one year price performance of IHI, versus its 200 day moving average: Looking at the chart above, IHI's low point in its 52 week range is $76.93 per share, with $101.76 as the 52 week high point - that compares with a last trade of $100.53. | Among the largest underlying components of IHI, in trading today Medtronic, Inc. (Symbol: MDT) is up about 1.4%, Abbott Laboratories (Symbol: ABT) is off about 0.3%, and Baxter International Inc. (Symbol: BAX) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares U.S. Medical Devices ETF (Symbol: IHI) where we have detected an approximate $15.0 million dollar outflow -- that's a 2.1% decrease week over week (from 7,150,000 to 7,000,000). Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. |
34171.0 | 2014-06-17 00:00:00 UTC | Sector Update: Healthcare Stocks Little Changed Today; Biolase Soars After Legal Fight Ends in CEO Ouster | ABT | https://www.nasdaq.com/articles/sector-update-healthcare-stocks-little-changed-today-biolase-soars-after-legal-fight-ends | nan | nan | Top Healthcare Stocks
JNJ -0.83%
PFE -0.30%
ABT -0.33%
MRK -0.09%
AMGN +0.36%
Healthcare stocks were narrowly mixed this afternoon with the NYSE Healthcare Sector Index climbing about 0.1% and shares of healthcare companies in the S&P 500 down about 0.1% as a group.
In company news, Biolase Inc. ( BIOL ) jumped to its best share price in nearly two months Tuesday after Federico Pignatelli stepped down as CEO and board chairman at the dental-laser company, less than a week after the Delaware Supreme Court upheld a lower court decision in a shareholder suit seeking to end a board deadlock over his tenure.
Oracle Partners, a Greenwich, Conn., hedge fund that owns about 16.4% of BIOL stock, and Pignatelli have been fighting over board composition and size, with a Court of Chancery judge late last month siding with Oracle Partners' bid to place its nominee on a six-member board. That decision was upheld last Thursday, June 12, by the Delaware high court, effectively ending Pignatelli's efforts to remain at the company helm.
Following Pignatelli's resignation, BIOL said new board member Jeffrey Nugent agreed to serve as interim CEO while the company looks for a permanent replacement. Nugent previously held several executive positions at Johnson & Johnson ( JNJ ), including leading the healthcare conglomerate's dental care franchise as well as Worldwide President and CEO of its Neutrogena skin care unit. He also was a past CEO at Revlon Inc ( REV ).
Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman.
BIOL shares recently were up nearly 23% at $2.31 apiece, earlier climbing to a session high of $2.44 a share. The stock has a 52-week range of $1.15 to $4.52 a share, falling over 47% over the past 12 months.
In other sector news,
(+) NVGN, (+10.5%) Announces pre-clinical drug, Trx-1, a success in proof-of-concept studies confirming the potency of its experimental ovarian cancer treatment, Trx-1, when delivered into the peritoneal cavity.
(-) ACOR, (-6.4%) Planning $300 mln public offering of convertible senior notes due 2021.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. That decision was upheld last Thursday, June 12, by the Delaware high court, effectively ending Pignatelli's efforts to remain at the company helm. Following Pignatelli's resignation, BIOL said new board member Jeffrey Nugent agreed to serve as interim CEO while the company looks for a permanent replacement. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. That decision was upheld last Thursday, June 12, by the Delaware high court, effectively ending Pignatelli's efforts to remain at the company helm. | Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. Healthcare stocks were narrowly mixed this afternoon with the NYSE Healthcare Sector Index climbing about 0.1% and shares of healthcare companies in the S&P 500 down about 0.1% as a group. In company news, Biolase Inc. ( BIOL ) jumped to its best share price in nearly two months Tuesday after Federico Pignatelli stepped down as CEO and board chairman at the dental-laser company, less than a week after the Delaware Supreme Court upheld a lower court decision in a shareholder suit seeking to end a board deadlock over his tenure. | Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. Healthcare stocks were narrowly mixed this afternoon with the NYSE Healthcare Sector Index climbing about 0.1% and shares of healthcare companies in the S&P 500 down about 0.1% as a group. In company news, Biolase Inc. ( BIOL ) jumped to its best share price in nearly two months Tuesday after Federico Pignatelli stepped down as CEO and board chairman at the dental-laser company, less than a week after the Delaware Supreme Court upheld a lower court decision in a shareholder suit seeking to end a board deadlock over his tenure. |
34172.0 | 2014-06-17 00:00:00 UTC | Sector Update: Healthcare | ABT | https://www.nasdaq.com/articles/sector-update-healthcare-2014-06-17 | nan | nan | Healthcare stocks were narrowly mixed this afternoon with the NYSE Healthcare Sector Index climbing about 0.1% and shares of healthcare companies in the S&P 500 down about 0.1% as a group.
In company news, Biolase Inc. ( BIOL ) jumped to its best share price in nearly two months Tuesday after Federico Pignatelli stepped down as CEO and board chairman at the dental-laser company, less than a week after the Delaware Supreme Court upheld a lower court decision in a shareholder suit seeking to end a board deadlock over his tenure.
Oracle Partners, a Greenwich, Conn., hedge fund that owns about 16.4% of BIOL stock, and Pignatelli have been fighting over board composition and size, with a Court of Chancery judge late last month siding with Oracle Partners' bid to place its nominee on a six-member board. That decision was upheld last Thursday, June 12, by the Delaware high court, effectively ending Pignatelli's efforts to remain at the company helm.
Following Pignatelli's resignation, BIOL said new board member Jeffrey Nugent agreed to serve as interim CEO while the company looks for a permanent replacement. Nugent previously held several executive positions at Johnson & Johnson ( JNJ ), including leading the healthcare conglomerate's dental care franchise as well as Worldwide President and CEO of its Neutrogena skin care unit. He also was a past CEO at Revlon Inc ( REV ).
Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman.
BIOL shares recently were up nearly 23% at $2.31 apiece, earlier climbing to a session high of $2.44 a share. The stock has a 52-week range of $1.15 to $4.52 a share, falling over 47% over the past 12 months.
In other sector news,
(+) NVGN, (+10.5%) Announces pre-clinical drug, Trx-1, a success in proof-of-concept studies confirming the potency of its experimental ovarian cancer treatment, Trx-1, when delivered into the peritoneal cavity.
(-) ACOR, (-6.4%) Planning $300 mln public offering of convertible senior notes due 2021.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. That decision was upheld last Thursday, June 12, by the Delaware high court, effectively ending Pignatelli's efforts to remain at the company helm. Following Pignatelli's resignation, BIOL said new board member Jeffrey Nugent agreed to serve as interim CEO while the company looks for a permanent replacement. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. That decision was upheld last Thursday, June 12, by the Delaware high court, effectively ending Pignatelli's efforts to remain at the company helm. | Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. Healthcare stocks were narrowly mixed this afternoon with the NYSE Healthcare Sector Index climbing about 0.1% and shares of healthcare companies in the S&P 500 down about 0.1% as a group. In company news, Biolase Inc. ( BIOL ) jumped to its best share price in nearly two months Tuesday after Federico Pignatelli stepped down as CEO and board chairman at the dental-laser company, less than a week after the Delaware Supreme Court upheld a lower court decision in a shareholder suit seeking to end a board deadlock over his tenure. | Also today, the company said former Abbott Labs ( ABT ) executive Paul Clark was selected new board chairman. Healthcare stocks were narrowly mixed this afternoon with the NYSE Healthcare Sector Index climbing about 0.1% and shares of healthcare companies in the S&P 500 down about 0.1% as a group. In company news, Biolase Inc. ( BIOL ) jumped to its best share price in nearly two months Tuesday after Federico Pignatelli stepped down as CEO and board chairman at the dental-laser company, less than a week after the Delaware Supreme Court upheld a lower court decision in a shareholder suit seeking to end a board deadlock over his tenure. |
34173.0 | 2014-06-13 00:00:00 UTC | Daily Dividend Report: ABT, EQR, RL, GGG, RAS | ABT | https://www.nasdaq.com/articles/daily-dividend-report-abt-eqr-rl-ggg-ras-2014-06-13 | nan | nan | This morning, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. Based on the current stock price, investors can expect a yield of about 2.2% going forward. On the news, shares of ABT were flat, trading just below $40 per share.
In other dividend news, Equity Residential ( EQR ) maintained its quarterly dividend of 50 cents per share. Ralph Lauren ( RL ) maintained its quarterly dividend of 45 cents per share. And Graco ( GGG ) maintained its quarterly dividend of 27.5 cents per share.
Among dividend increases, RAIT Financial Trust ( RAS ) announced its quarterly dividend of 18 cents per share, an increase of about 6% over its prior dividend.
VIDEO: Daily Dividend Report: ABT, EQR, RL, GGG, RAS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIDEO: Daily Dividend Report: ABT, EQR, RL, GGG, RAS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This morning, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. On the news, shares of ABT were flat, trading just below $40 per share. | VIDEO: Daily Dividend Report: ABT, EQR, RL, GGG, RAS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This morning, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. On the news, shares of ABT were flat, trading just below $40 per share. | VIDEO: Daily Dividend Report: ABT, EQR, RL, GGG, RAS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This morning, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. On the news, shares of ABT were flat, trading just below $40 per share. | VIDEO: Daily Dividend Report: ABT, EQR, RL, GGG, RAS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. This morning, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. On the news, shares of ABT were flat, trading just below $40 per share. |
34174.0 | 2014-06-13 00:00:00 UTC | Weekly Market Wrap: June 13, 2014 | ABT | https://www.nasdaq.com/articles/weekly-market-wrap-june-13-2014-2014-06-13 | nan | nan | The twenty fourth trading week of 2014 comes to a close with US markets higher in the last hour of trading.
Names such as OpenTable (OPEN), Express (EXPR), and Yelp (YELP) are leading the way higher.
Hi. I'm Sayoko Murase. Welcome to the 'Weekly Market Wrap' for June 13, 2014.
The Dow Jones Industrial Average, S&P 500, and NASDAQ Composite are all lower for the week.
Crude oil futures are significantly higher this week, trading at $106.66 per barrel on Friday afternoon.
And Gold futures are higher for the week, trading at $1276.98 an ounce on Friday afternoon.
In economic news, the U.S. Census Bureau announced that April 2014 sales of merchant wholesalers, except manufacturers' sales branches and offices, after adjustment for seasonal variations and trading-day differences but not for price changes, were $450.2 billion, up 1.3 percent from the revised March level and were up 7.8 percent from the April 2013 level. The March preliminary estimate was revised upward $0.9 billion or 0.2 percent. April sales of durable goods were up 1.7 percent from last month and were up 6.0 percent from a year ago.
Total inventories of merchant wholesalers, except manufacturers' sales branches and offices, after adjustment for seasonal variations but not for price changes, were $530.6 billion at the end of April, up 1.1 percent from the revised March level and were up 6.7 percent from the April 2013 level. The March preliminary estimate was revised downward $0.1 billion. April inventories of durable goods were up 0.9 percent from last month and were up 6.6 percent from a year ago.
In the week ending June 7, the advance figure for seasonally adjusted initial claims was 317,000, an increase of 4,000 from the previous week's revised level. The previous week's level was revised up by 1,000 from 312,000 to 313,000. The 4-week moving average was 315,250, an increase of 4,750 from the previous week's revised average. The previous week's average was revised up by 250 from 310,250 to 310,500.
The Producer Price Index for final demand fell 0.2 percent in May, seasonally adjusted, the U.S.
Bureau of Labor Statistics reported. This decline followed increases of 0.6 percent in April and 0.5 percent in March. On an unadjusted basis, the index for final demand advanced 2.0
percent for the 12 months ended in May.
In May, the 0.2-percent decrease in final demand prices can be traced to the indexes for final demand services and final demand goods, both of which also declined 0.2 percent.
Within intermediate demand, prices for processed goods edged down 0.1 percent, the index for unprocessed goods was unchanged, and prices for services fell 0.4 percent.
In highlights of corporate dividend news, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter.
United Technologies ( UTX ) declared, effective July 7, a dividend of 59 cents per common share payable September 10 to shareowners of record at the close of business August 15. The ex-dividend date is August 13.
Colgate-Palmolive ( CL ) declared quarterly cash dividends of $0.36 per common share, payable on August 15, 2014, to shareholders of record on July 18, 2014. The Company has paid uninterrupted dividends on its common stock since 1895.
Microsoft declared a quarterly dividend of $0.28 per share. The dividend is payable Sept. 11, 2014 to shareholders of record on Aug. 21, 2014. The ex-dividend date will be Aug. 19, 2014.
Philip Morris International ( PM ) declared a regular quarterly dividend of $0.94 per common share, payable on July 11, 2014, to shareholders of record as of June 26, 2014. The ex-dividend date is June 24, 2014.
And, The TJX Companies ( TJX ) announced the declaration of a quarterly dividend on its common stock of $.175 per share payable September 4, 2014, to shareholders of record on August 14, 2014.
This is the 'Weekly Market Wrap' for Friday, June 13, 2014. Please join us on Monday for the Week Ahead Market Report.
VIDEO: Weekly Market Wrap: June 13, 2014
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In highlights of corporate dividend news, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. The Producer Price Index for final demand fell 0.2 percent in May, seasonally adjusted, the U.S. Bureau of Labor Statistics reported. United Technologies ( UTX ) declared, effective July 7, a dividend of 59 cents per common share payable September 10 to shareowners of record at the close of business August 15. | In highlights of corporate dividend news, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. In economic news, the U.S. Census Bureau announced that April 2014 sales of merchant wholesalers, except manufacturers' sales branches and offices, after adjustment for seasonal variations and trading-day differences but not for price changes, were $450.2 billion, up 1.3 percent from the revised March level and were up 7.8 percent from the April 2013 level. Total inventories of merchant wholesalers, except manufacturers' sales branches and offices, after adjustment for seasonal variations but not for price changes, were $530.6 billion at the end of April, up 1.1 percent from the revised March level and were up 6.7 percent from the April 2013 level. | In highlights of corporate dividend news, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. In economic news, the U.S. Census Bureau announced that April 2014 sales of merchant wholesalers, except manufacturers' sales branches and offices, after adjustment for seasonal variations and trading-day differences but not for price changes, were $450.2 billion, up 1.3 percent from the revised March level and were up 7.8 percent from the April 2013 level. Total inventories of merchant wholesalers, except manufacturers' sales branches and offices, after adjustment for seasonal variations but not for price changes, were $530.6 billion at the end of April, up 1.1 percent from the revised March level and were up 6.7 percent from the April 2013 level. | In highlights of corporate dividend news, Abbott Labs ( ABT ) declared its quarterly dividend of 22 cents per share, maintaining the amount paid to shareholders the previous quarter. Total inventories of merchant wholesalers, except manufacturers' sales branches and offices, after adjustment for seasonal variations but not for price changes, were $530.6 billion at the end of April, up 1.1 percent from the revised March level and were up 6.7 percent from the April 2013 level. This decline followed increases of 0.6 percent in April and 0.5 percent in March. |
34175.0 | 2014-05-20 00:00:00 UTC | Company News for May 20, 2014 - Corporate Summary | ABT | https://www.nasdaq.com/articles/company-news-for-may-20-2014-corporate-summary-2014-05-20 | nan | nan | • Campbell Soup Company's (NYSE: CPB ) shares declined 2.4% after forecasting fiscal 2014 sales growth from continuing operations of 3%, lower than the previous forecast of 4% to 5%
• Shares of The Valspar Corporation (NYSE: VAL ) rose 1.4% after reporting fiscal second quarter earnings per share of $1.07, beating the Zacks Consensus Estimate of $1.04
• Abbott Laboratories's (NYSE: ABT ) shares increased 1.5% after the company announced it will buy Chile based CFR Pharmaceuticals for about $2.9 billion
• Shares of Johnson Controls Inc (NYSE: JCI ) jumped 4.3% after it said it will hive off its automotive-interiors business to form a joint venture with Yanfeng Automotive Trim Systems Co
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
CAMPBELL SOUP (CPB): Free Stock Analysis Report
JOHNSON CONTROL (JCI): Free Stock Analysis Report
VALSPAR CORP (VAL): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Campbell Soup Company's (NYSE: CPB ) shares declined 2.4% after forecasting fiscal 2014 sales growth from continuing operations of 3%, lower than the previous forecast of 4% to 5% • Shares of The Valspar Corporation (NYSE: VAL ) rose 1.4% after reporting fiscal second quarter earnings per share of $1.07, beating the Zacks Consensus Estimate of $1.04 • Abbott Laboratories's (NYSE: ABT ) shares increased 1.5% after the company announced it will buy Chile based CFR Pharmaceuticals for about $2.9 billion • Shares of Johnson Controls Inc (NYSE: JCI ) jumped 4.3% after it said it will hive off its automotive-interiors business to form a joint venture with Yanfeng Automotive Trim Systems Co Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CAMPBELL SOUP (CPB): Free Stock Analysis Report JOHNSON CONTROL (JCI): Free Stock Analysis Report VALSPAR CORP (VAL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Campbell Soup Company's (NYSE: CPB ) shares declined 2.4% after forecasting fiscal 2014 sales growth from continuing operations of 3%, lower than the previous forecast of 4% to 5% • Shares of The Valspar Corporation (NYSE: VAL ) rose 1.4% after reporting fiscal second quarter earnings per share of $1.07, beating the Zacks Consensus Estimate of $1.04 • Abbott Laboratories's (NYSE: ABT ) shares increased 1.5% after the company announced it will buy Chile based CFR Pharmaceuticals for about $2.9 billion • Shares of Johnson Controls Inc (NYSE: JCI ) jumped 4.3% after it said it will hive off its automotive-interiors business to form a joint venture with Yanfeng Automotive Trim Systems Co Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CAMPBELL SOUP (CPB): Free Stock Analysis Report JOHNSON CONTROL (JCI): Free Stock Analysis Report VALSPAR CORP (VAL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Campbell Soup Company's (NYSE: CPB ) shares declined 2.4% after forecasting fiscal 2014 sales growth from continuing operations of 3%, lower than the previous forecast of 4% to 5% • Shares of The Valspar Corporation (NYSE: VAL ) rose 1.4% after reporting fiscal second quarter earnings per share of $1.07, beating the Zacks Consensus Estimate of $1.04 • Abbott Laboratories's (NYSE: ABT ) shares increased 1.5% after the company announced it will buy Chile based CFR Pharmaceuticals for about $2.9 billion • Shares of Johnson Controls Inc (NYSE: JCI ) jumped 4.3% after it said it will hive off its automotive-interiors business to form a joint venture with Yanfeng Automotive Trim Systems Co Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CAMPBELL SOUP (CPB): Free Stock Analysis Report JOHNSON CONTROL (JCI): Free Stock Analysis Report VALSPAR CORP (VAL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | • Campbell Soup Company's (NYSE: CPB ) shares declined 2.4% after forecasting fiscal 2014 sales growth from continuing operations of 3%, lower than the previous forecast of 4% to 5% • Shares of The Valspar Corporation (NYSE: VAL ) rose 1.4% after reporting fiscal second quarter earnings per share of $1.07, beating the Zacks Consensus Estimate of $1.04 • Abbott Laboratories's (NYSE: ABT ) shares increased 1.5% after the company announced it will buy Chile based CFR Pharmaceuticals for about $2.9 billion • Shares of Johnson Controls Inc (NYSE: JCI ) jumped 4.3% after it said it will hive off its automotive-interiors business to form a joint venture with Yanfeng Automotive Trim Systems Co Want the latest recommendations from Zacks Investment Research? Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report CAMPBELL SOUP (CPB): Free Stock Analysis Report JOHNSON CONTROL (JCI): Free Stock Analysis Report VALSPAR CORP (VAL): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. |
34176.0 | 2014-05-19 00:00:00 UTC | Abbott to Buy CFR Pharma - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-to-buy-cfr-pharma-analyst-blog-2014-05-19 | nan | nan | In a move to broaden its presence in the Latin American market, Abbott Labs ( ABT ) announced that it has entered into a definitive agreement to acquire Latin American pharmaceutical company, CFR Pharmaceuticals.
As per the terms of the agreement, Abbott Labs will acquire the holding company that owns a 73% stake in CFR Pharmaceuticals. Abbott Labs will also conduct a public cash tender offer for all of the outstanding shares of CFR Pharmaceuticals following necessary regulatory approvals.
The total purchase price comes to approximately $2.9 billion assuming all publicly-held shares are tendered to the offer along with the assumption of net debt of approximately $430 million.
The transaction is expected to close by the third quarter of 2014. The acquisition is expected to add approximately $900 million to Abbott Labs' top line in the first full year post acquisition (2015).
Thereafter, Abbott Labs expects double-digit sales growth over the next several years.
The transaction is also expected to be accretive to bottom line in 2015.
Headquartered in Chile, CFR Pharmaceuticals has a comprehensive product portfolio with operations in 15 Latin American markets. The acquisition is expected to be complementary to Abbott Labs' current pharmaceutical therapeutic areas of focus including women's health, central nervous system, cardiovascular and respiratory diseases.
Our Take
Abbott Labs currently carries a Zacks Rank #3 (Hold). Emerging markets are key focus areas for Abbott Labs. The CFR Pharmaceuticals acquisition will double Abbott Labs' branded generics pharmaceutical sales and presence in one of the fast growing markets. As per IMS forecasts, the Latin American pharmaceutical market will grow to $73 billion in 2014 and jump to $124 billion by 2018. Annual growth rates in these markets are expected to be two to three times that of developed markets over the coming years.
We remind investors that Abbott Labs became a diversified medical products company focusing on branded generic pharmaceutical, medical devices, diagnostic and nutritional businesses following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc . ( ABBV ), in Jan 2013.
The business environment was challenging in 2013 due to austerity measures undertaken by developed markets.
Hence, Abbott Labs' efforts to broaden its presence in the emerging markets will help the company to combat the challenging business environment elsewhere in the world and maintain top-line growth.
Some better-ranked stocks in the broader healthcare sector include Allergan ( AGN ) and Shire ( SHPG ). While Allergan is a rank #1 (Strong Buy), Shire is a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In a move to broaden its presence in the Latin American market, Abbott Labs ( ABT ) announced that it has entered into a definitive agreement to acquire Latin American pharmaceutical company, CFR Pharmaceuticals. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs will also conduct a public cash tender offer for all of the outstanding shares of CFR Pharmaceuticals following necessary regulatory approvals. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. In a move to broaden its presence in the Latin American market, Abbott Labs ( ABT ) announced that it has entered into a definitive agreement to acquire Latin American pharmaceutical company, CFR Pharmaceuticals. The CFR Pharmaceuticals acquisition will double Abbott Labs' branded generics pharmaceutical sales and presence in one of the fast growing markets. | In a move to broaden its presence in the Latin American market, Abbott Labs ( ABT ) announced that it has entered into a definitive agreement to acquire Latin American pharmaceutical company, CFR Pharmaceuticals. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The CFR Pharmaceuticals acquisition will double Abbott Labs' branded generics pharmaceutical sales and presence in one of the fast growing markets. | In a move to broaden its presence in the Latin American market, Abbott Labs ( ABT ) announced that it has entered into a definitive agreement to acquire Latin American pharmaceutical company, CFR Pharmaceuticals. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The acquisition is expected to add approximately $900 million to Abbott Labs' top line in the first full year post acquisition (2015). |
34177.0 | 2014-05-16 00:00:00 UTC | Sector Update: Healthcares | ABT | https://www.nasdaq.com/articles/sector-update-healthcares-2014-05-16 | nan | nan | Healthcare shares were generally lower in pre-market trade on Friday.
In healthcare stocks news, Kamada ( KMDA ) is lower after the company announced preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of its proprietary inhaled Alpha-1 Antitrypsin ( AAT ) therapy to treat Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema).
And, Abbott ( ABT ) edged lower in recent pre-market trading on Friday after saying it has signed a definitive agreement to buy Latin American pharmaceutical company CFR Pharmaceuticals for approximately $2.9 billion, plus the assumption of debt of approximately $430 million.
ABT closed down to $39.24 Thursday, in a 52-week range of $32.70 - $40.49.
And, Bovie Medical ( BVX ) said late Thursday that Q1 sales were $6.5 million, up 14% from a year ago. Adjusted net loss was $0.01 per share, down from a loss of $0.02 last year.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And, Abbott ( ABT ) edged lower in recent pre-market trading on Friday after saying it has signed a definitive agreement to buy Latin American pharmaceutical company CFR Pharmaceuticals for approximately $2.9 billion, plus the assumption of debt of approximately $430 million. ABT closed down to $39.24 Thursday, in a 52-week range of $32.70 - $40.49. In healthcare stocks news, Kamada ( KMDA ) is lower after the company announced preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of its proprietary inhaled Alpha-1 Antitrypsin ( AAT ) therapy to treat Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema). | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And, Abbott ( ABT ) edged lower in recent pre-market trading on Friday after saying it has signed a definitive agreement to buy Latin American pharmaceutical company CFR Pharmaceuticals for approximately $2.9 billion, plus the assumption of debt of approximately $430 million. ABT closed down to $39.24 Thursday, in a 52-week range of $32.70 - $40.49. | And, Abbott ( ABT ) edged lower in recent pre-market trading on Friday after saying it has signed a definitive agreement to buy Latin American pharmaceutical company CFR Pharmaceuticals for approximately $2.9 billion, plus the assumption of debt of approximately $430 million. ABT closed down to $39.24 Thursday, in a 52-week range of $32.70 - $40.49. In healthcare stocks news, Kamada ( KMDA ) is lower after the company announced preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of its proprietary inhaled Alpha-1 Antitrypsin ( AAT ) therapy to treat Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema). | ABT closed down to $39.24 Thursday, in a 52-week range of $32.70 - $40.49. And, Abbott ( ABT ) edged lower in recent pre-market trading on Friday after saying it has signed a definitive agreement to buy Latin American pharmaceutical company CFR Pharmaceuticals for approximately $2.9 billion, plus the assumption of debt of approximately $430 million. Healthcare shares were generally lower in pre-market trade on Friday. |
34178.0 | 2014-05-13 00:00:00 UTC | Abbott's Promising Data on RADICAL Platform - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbotts-promising-data-on-radical-platform-analyst-blog-2014-05-13 | nan | nan | AbbottLaboratories ( ABT ) announced positive interim data from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. The RADICAL study analyzed samples from more than 180 critically ill patients with suspected severe infections and compared the results of Abbott's technology (IRIDICA) to the current standard of care.
The RADICAL study demonstrated that the testing platform - IRIDICA - produced results consistent with the current standard of care in just a few hours. We note that the diagnosis of serious infections as per methods currently in use takes several days.
After reviewing the interim data, physicians on a panel said that they would have prescribed a different course of treatment in more than 50% of the cases evaluated in the study. The interim results revealed that with IRIDICA physicians would be able to rule out the source of infection more confidently and quickly.
IRIDICA may be used to quickly identify microorganisms before lab cultures can detect similar results in critically ill patients with life threatening infections. IRIDICA is designed to produce results in approximately 8 hours versus days.
The RADICAL study will come to an end in late 2014 and IRIDICA will be available as a CE-marked in vitro diagnostic device in European countries within a year.
Our Take
Abbott Labs currently carries a Zacks Rank #3 (Hold). We note that Abbott Labs continues to invest in the development of next-generation instruments and other advanced technologies in its diagnostics business.
Diagnostics business sales increased 5.1% year over year (on an operational basis) to $1.1 billion in the first quarter of 2014. Abbott is investing in the development of multiple new instrument platforms to improve its diagnostic segment. The IRIDICA platform has the potential to identify life-threatening infections much faster than current methods. The approval of this testing platform will boost the diagnostic segment of the company.
Investors looking for better-ranked stocks may consider companies like Allergan ( AGN ), Alexion Pharmaceuticals, Inc. ( ALXN ) and Shire ( SHPG ). All three carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
ALEXION PHARMA (ALXN): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AbbottLaboratories ( ABT ) announced positive interim data from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The RADICAL study analyzed samples from more than 180 critically ill patients with suspected severe infections and compared the results of Abbott's technology (IRIDICA) to the current standard of care. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottLaboratories ( ABT ) announced positive interim data from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. The RADICAL study analyzed samples from more than 180 critically ill patients with suspected severe infections and compared the results of Abbott's technology (IRIDICA) to the current standard of care. | Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbottLaboratories ( ABT ) announced positive interim data from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. The RADICAL study analyzed samples from more than 180 critically ill patients with suspected severe infections and compared the results of Abbott's technology (IRIDICA) to the current standard of care. | AbbottLaboratories ( ABT ) announced positive interim data from the RApid Diagnosis of Infections in the CriticAlly IlL (RADICAL) study. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The RADICAL study demonstrated that the testing platform - IRIDICA - produced results consistent with the current standard of care in just a few hours. |
34179.0 | 2014-05-13 00:00:00 UTC | Abbott May Be Looking To Divest Part Of Generic Drug Business | ABT | https://www.nasdaq.com/articles/abbott-may-be-looking-divest-part-generic-drug-business-2014-05-13 | nan | nan | Abbott Laboratories ( ABT ) is reportedly considering divesting a significant part of its generic drug business, according to a recent Reuters report. The report also suggests that the healthcare major is working with Morgan Stanley to find a buyer for the business. Abbott joins the ranks of competitors such as Pfizer, GlaxoSmithKline, Sanofi and Merck, who may also be looking to divest their portfolios of generic (or 'mature') medicines.
Generic drugs are part of Abbott's Established Pharmaceutical division, which generated sales of about $5 billion in 2013. The division's sales have seen a low-to-mid single-digit decline in the last few years, owing to pricing pressures in developed markets such as Europe and Japan. By divesting a part of its business, the company could be looking to exit from the low-margin, low-growth generic drug market in developed regions to focus on the high-growth opportunity in emerging markets such as India and China. According to some sources privy to the matter, Abbott could be looking to divest about 40% of its Established Pharmaceutical businesses for more than $5 billion. The business under review for sale generated about $2 billion in revenue in 2013.
We have a price estimate of $40 for Abbott Labs , which is slightly above the current market price.
See our full analysis for Abbott Labs
Why Is Abbott Looking To Divest?
The most likely reason for Abbott to weigh the sale of a big chunk of its generic drug division could be to streamline its business and focus on higher-growth areas. Sales from the Established Pharmaceutical division have dipped in the last two years due to competitive pressures and unfavorable macroeconomic conditions in some developed markets, partially offset by strong sales in emerging markets. Operational sales in the company's 14 key emerging markets, which include Brazil, China, Russia and India, increased 6.3% in 2013 and 12.8% in 2012. In contrast, Abbott's generic drug sales in developed markets and other regions (excluding key emerging markets) declined 4% in 2013 and 5.6% in 2012.
We believe that Abbott is likely looking to divest its Established Pharma business in developed markets only, where the company has struggled to grow. In its 2013 annual report, the company reported that emerging markets accounted for about 50% of its overall sales, and this proportion is expected to increase to about 60% in the coming years. The sale of its branded generic dug business in developed markets could be a step in this direction.
Abbott spun its proprietary pharmaceutical business as Abbvie Inc. ( ABBV ) in 2013 but retained its portfolio of branded generic medicines. This portfolio currently comprises of well-known drugs such as Creon, Biaxin, Klacid, Klaricid, Influvac, Serc, Brufen, Synthroid, Duspatal, Dicetel, and Duphaston.
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
Get Trefis Technology
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reportedly considering divesting a significant part of its generic drug business, according to a recent Reuters report. The division's sales have seen a low-to-mid single-digit decline in the last few years, owing to pricing pressures in developed markets such as Europe and Japan. The most likely reason for Abbott to weigh the sale of a big chunk of its generic drug division could be to streamline its business and focus on higher-growth areas. | Abbott Laboratories ( ABT ) is reportedly considering divesting a significant part of its generic drug business, according to a recent Reuters report. Generic drugs are part of Abbott's Established Pharmaceutical division, which generated sales of about $5 billion in 2013. In contrast, Abbott's generic drug sales in developed markets and other regions (excluding key emerging markets) declined 4% in 2013 and 5.6% in 2012. | Abbott Laboratories ( ABT ) is reportedly considering divesting a significant part of its generic drug business, according to a recent Reuters report. By divesting a part of its business, the company could be looking to exit from the low-margin, low-growth generic drug market in developed regions to focus on the high-growth opportunity in emerging markets such as India and China. Sales from the Established Pharmaceutical division have dipped in the last two years due to competitive pressures and unfavorable macroeconomic conditions in some developed markets, partially offset by strong sales in emerging markets. | Abbott Laboratories ( ABT ) is reportedly considering divesting a significant part of its generic drug business, according to a recent Reuters report. Generic drugs are part of Abbott's Established Pharmaceutical division, which generated sales of about $5 billion in 2013. By divesting a part of its business, the company could be looking to exit from the low-margin, low-growth generic drug market in developed regions to focus on the high-growth opportunity in emerging markets such as India and China. |
34180.0 | 2014-05-08 00:00:00 UTC | XLF, HDG: Big ETF Outflows | ABT | https://www.nasdaq.com/articles/xlf-hdg-big-etf-outflows-2014-05-08 | nan | nan | Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Financial Select Sector SPDR Fund ( XLF ), where 23,350,000 units were destroyed, or a 2.8% decrease week over week. Among the largest underlying components of XLF, in morning trading today Wells Fargo & Company ( WFC ) is trading flat, and Berkshire Hathaway Class B (BRK.B) is lower by about 0.6%.
And on a percentage change basis, the ETF with the biggest outflow was the Proshares Hedge Replication ETF ( HDG ), which lost 150,000 of its units, representing a 16.7% decline in outstanding units compared to the week prior. Among the largest underlying components of HDG, in morning trading today 3M Company ( MMM ) is up about 0.3%, and Abbott Labs ( ABT ) is higher by about 0.5%.
VIDEO: XLF, HDG: Big ETF Outflows
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of HDG, in morning trading today 3M Company ( MMM ) is up about 0.3%, and Abbott Labs ( ABT ) is higher by about 0.5%. Among the largest underlying components of XLF, in morning trading today Wells Fargo & Company ( WFC ) is trading flat, and Berkshire Hathaway Class B (BRK.B) is lower by about 0.6%. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Hedge Replication ETF ( HDG ), which lost 150,000 of its units, representing a 16.7% decline in outstanding units compared to the week prior. | Among the largest underlying components of HDG, in morning trading today 3M Company ( MMM ) is up about 0.3%, and Abbott Labs ( ABT ) is higher by about 0.5%. Among the largest underlying components of XLF, in morning trading today Wells Fargo & Company ( WFC ) is trading flat, and Berkshire Hathaway Class B (BRK.B) is lower by about 0.6%. VIDEO: XLF, HDG: Big ETF Outflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of HDG, in morning trading today 3M Company ( MMM ) is up about 0.3%, and Abbott Labs ( ABT ) is higher by about 0.5%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Financial Select Sector SPDR Fund ( XLF ), where 23,350,000 units were destroyed, or a 2.8% decrease week over week. And on a percentage change basis, the ETF with the biggest outflow was the Proshares Hedge Replication ETF ( HDG ), which lost 150,000 of its units, representing a 16.7% decline in outstanding units compared to the week prior. | Among the largest underlying components of HDG, in morning trading today 3M Company ( MMM ) is up about 0.3%, and Abbott Labs ( ABT ) is higher by about 0.5%. Looking at units outstanding versus one week prior within the universe of ETFs covered at ETF Channel, the biggest outflow was seen in the Financial Select Sector SPDR Fund ( XLF ), where 23,350,000 units were destroyed, or a 2.8% decrease week over week. Among the largest underlying components of XLF, in morning trading today Wells Fargo & Company ( WFC ) is trading flat, and Berkshire Hathaway Class B (BRK.B) is lower by about 0.6%. |
34181.0 | 2014-05-06 00:00:00 UTC | Tuesday's ETF with Unusual Volume: BSCF | ABT | https://www.nasdaq.com/articles/tuesdays-etf-unusual-volume-bscf-2014-05-06 | nan | nan | The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 470,000 shares traded versus three month average volume of about 121,000. Shares of BSCF were off about 0.1% on the day.
Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading off about 1.5% with over 44.6 million shares changing hands so far this session, and Astrazeneca ( AZN ), down about 0.8% on volume of over 4.2 million shares. Abbott Labs ( ABT ) is the component faring the best Tuesday, lower by about 0.3% on the day, while Metlife ( MET ) is lagging other components of the Guggenheim BulletShares 2015 Corporate Bond ETF, trading lower by about 2.3%.
VIDEO: Tuesday's ETF with Unusual Volume: BSCF
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) is the component faring the best Tuesday, lower by about 0.3% on the day, while Metlife ( MET ) is lagging other components of the Guggenheim BulletShares 2015 Corporate Bond ETF, trading lower by about 2.3%. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 470,000 shares traded versus three month average volume of about 121,000. Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading off about 1.5% with over 44.6 million shares changing hands so far this session, and Astrazeneca ( AZN ), down about 0.8% on volume of over 4.2 million shares. | Abbott Labs ( ABT ) is the component faring the best Tuesday, lower by about 0.3% on the day, while Metlife ( MET ) is lagging other components of the Guggenheim BulletShares 2015 Corporate Bond ETF, trading lower by about 2.3%. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 470,000 shares traded versus three month average volume of about 121,000. VIDEO: Tuesday's ETF with Unusual Volume: BSCF The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) is the component faring the best Tuesday, lower by about 0.3% on the day, while Metlife ( MET ) is lagging other components of the Guggenheim BulletShares 2015 Corporate Bond ETF, trading lower by about 2.3%. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 470,000 shares traded versus three month average volume of about 121,000. Components of that ETF with the highest volume on Tuesday were Bank of America ( BAC ), trading off about 1.5% with over 44.6 million shares changing hands so far this session, and Astrazeneca ( AZN ), down about 0.8% on volume of over 4.2 million shares. | Abbott Labs ( ABT ) is the component faring the best Tuesday, lower by about 0.3% on the day, while Metlife ( MET ) is lagging other components of the Guggenheim BulletShares 2015 Corporate Bond ETF, trading lower by about 2.3%. The Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) is seeing unusually high volume in afternoon trading Tuesday, with over 470,000 shares traded versus three month average volume of about 121,000. Shares of BSCF were off about 0.1% on the day. |
34182.0 | 2014-05-02 00:00:00 UTC | Medical Devices Face Onslaught Of Pricing Pressure | ABT | https://www.nasdaq.com/articles/medical-devices-face-onslaught-pricing-pressure-2014-05-02 | nan | nan | Makers of medical devices are coming under increasing pressure, owing to a fundamental power shift in American medicine favoring insurance companies, hospitals and their patients.
The change, according to Moty Avisar, president of medical systems maker Surgical Theater, is based on patients being forced by soaring medical costs to take control of their health care.
"Let's say a patient is told by his family doctor he needs heart surgery," said Avisar, whose company makes a surgery simulator that lets surgeons practice in a no-risk setting.
"The patient's doctor recommends a surgeon. The patient goes in and interviews the surgeon and then goes down the street to interview the next surgeon on his list so he can compare prices and services," Avisar told IBD.
As a result, medical technology device makers' "customer base is shifting as (insurance) payers, health systems and patients become more influential than they have been in the past," according to Ernst & Young's Medical Technology Report 2013, released on June 30 of that year.
The shift undermines what has been the fundamental business model for many medtech operators, the report says.
The companies are forced to find new ways to create, deliver and capture value.
The industry's challenges are encroaching on three fronts.
First, skyrocketing health costs have led to the rise of value-based health care.
Hospitals are not buying new equipment unless it's absolutely necessary and proven, ISI Group analyst Vijay Kumar said.
"Most health care costs have been unmanageable," Kumar said. And much as the Great Depression changed spending habits, the Great Recession of 2008-09 has made consumers savvier about negotiating medical costs.
A second line of fire is the rising regulatory pressure that medical device makers feel from tighter federal guidelines.
These costs are at least partly related to the Affordable Care Act, commonly called ObamaCare.
This fact was underscored by an April 17 advisory from the Food and Drug Administration. The release warned surgeons that a technique called power morcellation was likely to increase the risk of spreading cancerous cells.
The laproscopic procedure is reportedly used on tens of thousands of women each year. It involves using specialized equipment for cutting tissue -- often uterine fibroid tumors -- into small pieces for removal.
On April 30, diversified medical companyJohnson & Johnson ( JNJ ) said that it was, for the time being, discontinuing the worldwide sales, distribution and promotion of its market-leading morcellator devices.
The third factor: funding. Younger medtech companies, a powerful source of innovation, find themselves resource-constrained as venture capital migrates to what investors see as hotter territories, such as biotech drugs.
Meet The Medtechs
Pressure from the shift was evident inIntuitive Surgical 's ( ISRG ) first-quarter report after the market's close on April 22.
In the following session, investors sent shares of Intuitive down 11%. By far the largest company in the 63-company Medical-Systems/Equipment Group, Intuitive has a market capitalization of $15.8 billion, nearly twice the size of No. 2Varian Medical Systems ( VAR ).
Intuitive makes the da Vinci robotic surgery system. Surgeons control the da Vinci tool while sitting at a remote console, viewing the the operation on a screen while conducting surgery through the use of mechanical hands. The hands reach into the patient, generally through small incisions.
On April 1, Intuitive announced its fourth-generation product, da Vinci Xi.
The new system operates via an overhead boom. Its arms rotate to let a surgeon operate on more than one area of the body at a time, opening the door to more complex procedures.
Doctors use Da Vinci systems for gynecological, cardiac and other surgeries. They are also used in the type of morcellator procedures named in the FDA's advisory, ratcheting up investor uncertainty regarding the stock.
Still, CEO Gary Guthart hopes the da Vinci Xi will shore up flagging sales of the high-tech systems, which cost upward of $1 million each. A three-quarter slump in sales accelerated during the first quarter, driven by weak procedure growth in America.
"The first quarter was a difficult one," Guthart said on the Q1 conference call, echoing his earlier comments that 2013 was challenging.
"Trends that emerged in the second quarter of 2013 continued through the balance of the year, including revenue uncertainties for United States customers due to pressure on gynecology surgery broadly; the implementation of the Affordable Care Act," which ratcheted up costs; and other factors, he had said in the January earnings call.
Baxter International ( BAX ), a diversified medical products maker, reported on April 17 that its first-quarter earnings rose 13% to $1.19 per share on a 15% hike in revenue to $3.95 billion. Both figures topped analyst expectations.
CEO Robert Parkinson in a conference call that day commented on the shift to value-based health care: "Pressure to control costs is enormous -- as is the need to expand access to quality care, which requires further investment of limited resources."
He added, "It is little wonder then that governments and insurers around the world are pursuing multiple levers to control expenses."
Baxter hopes to unlock value for its shareholders by splitting the company in two. One company will retain the Baxter International name and sell medical devices. It had revenue of $9.3 billion last year.
The other, as-yet-unnamed company, which had about $6 billion revenue in 2013, will start out with a portfolio of drugs to treat hemophilia and other bleeding disorders and develop treatments.
The split is expected to be completed by mid-2015.
Baxter shares climbed nearly 4% on March 27 after it announced the split-up, which follows in the footsteps of several other large medtech companies.
In January 2013,Abbott Laboratories ( ABT ) broke into two companies. One, a medical-device maker, retained the Abbott name. The other, a research-based drugmaker, is nowAbbVie (ABBV).
In March,Boston Scientific (BSX) announced it was considering a spinoff of businesses grouped under its Endosurgery division.
A number of analysts and investors have pushed for a similar carve-out atPfizer (PFE). Other divide and conquer candidates include Johnson & Johnson and the U.K.'sSmith & Nephew (SNN).
One thing that device makers aren't likely to spin off: their lawyers. Patent protection and litigation remain central concerns for medtech companies.
Align Technology (ALGN), the largest maker of transparent aligners for teeth, announced a major court victory April 3.
The International Trade Commission affirmed an earlier court decision that found rival ClearCorrect infringed on five of Align's key patents.
The ITC issued an order to ClearCorrect to cease using the technology. Shares of Align, which is on the IBD 50 list of top-rated stocks, climbed 2.3% the next day.
Challenges
Anemic industry revenue growth has narrowed venture capital interest in the market. Total sales among U.S. medical technology makers rose just 2% in 2012 to $210.1 billion.
U.S. venture capital investment in medtech has responded by sliding to its lowest level in at least seven years.
After a slight rebound in 2011-12 from recession lows, "the total amount of U.S. medtech venture funding slid 19% to $3 billion in the 12-month period ended June 2013," the E&Y report said.
The number of new medical-system companies scrambling for a piece of that shrinking pie is growing. Initial public offerings doubled from three to six in the year ended June 2013. Total value was up 20% to $155 million.
Meanwhile, the medtech industry is consolidating elsewhere.
"All signs point to deals," Ernst & Young said in its report.
Johnson & Johnson in June 2012 bought Swiss medical device maker Synthes Holding in a $20 billion cash and stock deal.
As the number of medtech acquisition targets in the U.S. and Europe dwindles, many Western companies are turning to China.
In the 12-month period ended June 2013, Western companies acquired nine Chinese firms for a bargain-basement total of $1.7 billion, E&Y said.
The seven years prior to 2012-13 saw a total of 25 deals. Combined value: $346 million.
For many, the big question is what will be the long-term impact of ObamaCare.
Until the effects of the medical overhaul are fully known, "hospitals today are being very selective with what they are buying," Surgical Theater head Avisar said.
The former Israeli air force pilot, who helped design the flight simulator for the U.S. Air Force's F-16 jet fighter, forecasts that "it will be a conservative year.
"We don't see a lot of growth of medical equipment sales. I think a lot of (medical) centers are sitting on the fence waiting to see in the first year of ObamaCare how revenue will play out."
Still, Ernst & Young said in its report, the industry is weathering the storm well, and "companies are adapting to a new health care ecosystem that values better health outcomes and cost-effectiveness."
Follow James DeTar on Twitter: @IBD_JDeTar .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In January 2013,Abbott Laboratories ( ABT ) broke into two companies. Makers of medical devices are coming under increasing pressure, owing to a fundamental power shift in American medicine favoring insurance companies, hospitals and their patients. "Trends that emerged in the second quarter of 2013 continued through the balance of the year, including revenue uncertainties for United States customers due to pressure on gynecology surgery broadly; the implementation of the Affordable Care Act," which ratcheted up costs; and other factors, he had said in the January earnings call. | In January 2013,Abbott Laboratories ( ABT ) broke into two companies. The change, according to Moty Avisar, president of medical systems maker Surgical Theater, is based on patients being forced by soaring medical costs to take control of their health care. As a result, medical technology device makers' "customer base is shifting as (insurance) payers, health systems and patients become more influential than they have been in the past," according to Ernst & Young's Medical Technology Report 2013, released on June 30 of that year. | In January 2013,Abbott Laboratories ( ABT ) broke into two companies. Makers of medical devices are coming under increasing pressure, owing to a fundamental power shift in American medicine favoring insurance companies, hospitals and their patients. The change, according to Moty Avisar, president of medical systems maker Surgical Theater, is based on patients being forced by soaring medical costs to take control of their health care. | In January 2013,Abbott Laboratories ( ABT ) broke into two companies. The change, according to Moty Avisar, president of medical systems maker Surgical Theater, is based on patients being forced by soaring medical costs to take control of their health care. It had revenue of $9.3 billion last year. |
34183.0 | 2014-05-01 00:00:00 UTC | MedTech's Partial Tax Repeal: Is It Enough? - Industry Outlook | ABT | https://www.nasdaq.com/articles/medtechs-partial-tax-repeal%3A-is-it-enough-industry-outlook-2014-05-01 | nan | nan | The medical devices industry, which was once acclaimed for its high-paying jobs and research and development opportunities, has been subject to the much controversial 2.3% medical device excise tax since its enactment in the beginning of 2013. Sequestration-related spending cuts to the U.S. federal budget have also undermined the medical devices industry's prospects. In fact, this has significantly restricted the industry's bottom-line improvement in the past year.
Partial Repeal: A Boon?
However, as a slight respite, in Jan 2014, the National Institutes of Health (NIH) got a $1 billion or 3.5% boost to its fiscal 2014 budget from the prior-year post-sequestration budget (according to fiscal 2014 Omnibus Appropriations bill, released on Jan 13, 2014). According to a statement by appropriators, this hike, although insignificant, is expected to result in 385 million new grant opportunities for researchers compared to 2013. We note that the sequestration, which resulted in a 5.5% cut in the NIH fiscal 2013 budget, resulted in 640 fewer grants in 2013.
Apart from NIH, the National Institutes of Standards and Technology, The National Science Foundation (NSF), health professions and nursing workforce development programs are some of the others to gain from this bill.
The U.S. Food and Drug Administration (FDA) has also managed to get $2.552 billion through this omnibus spending package, a $166 million (7%) increase over the fiscal 2013 post-sequestration funding level. The Centers for Disease Control and Prevention (CDC) received a $370 million or 6.8% increase over the year-ago post-sequestration funding level.
Situation Remains Bleak
Even more than three months after the Senate passed the Omnibus Appropriations bill, the research funding scenario continues to look bleak. Most economists are of the opinion that with cost of research rising astronomically, this nominal revision can hardly bring any reprieve. While the additional funding for NIH will help sustain current projects and begin funding for new research grants, this is still $714 million short of NIH's pre-sequestration budget.
Further, things are not at all cheery for the Centers for Medicare and Medicaid Services (CMS). While the bill included $3.7 billion for the CMS, this was $195 million less than what was enacted in the previous fiscal.
Unless totally repealed or replaced, these spending cuts will last through 2021. NIH expects sequestration to turn graver in the coming years leading to serious consequences like delaying progress in medical breakthroughs, deterioration in job creation and tempering of economic growth. An NBC news article recently noted that many new researchers, who were trained with the U.S. taxpayers' money, may have to move to Europe and Asia where government funding for medical research is on the rise.
Moreover, the medical device excise tax is taking a heavy toll on the MedTech sector, hurting pricing decisions of companies and subjecting them to tremendous margin pressure. The 2.3% excise tax (effective Jan 2013), which is imposed on the sales price instead of net profit, amounts to a sizable sum, wiping out almost a quarter of the profit at the med instrument owners.
The big players are trying out ways to change their business model and cost structure to accommodate the excise tax. These companies are undertaking various restructuring initiatives to counter costs incurred from the implementation of the new tax. Restructuring especially to offset the effect of the excise tax has already been adopted by several key players. The companies are also trying to focus on strategic mergers and acquisitions (M&A), emerging market expansion or are reducing operations in order to weather the tax burden.
M&A Activities
MedTech M&A continues unabated in 2014. Wary of an uncertain economy, MedTech giants have resorted to the acquisition route to harness their strengths and diversify offerings.
The first quarter earnings season in the medical device sector kicked off with such a mega acquisition announcement. Last week, on itsearnings call Zimmer Holdings ( ZMH ) disclosed that it has entered into a definitive agreement to acquire Biomet, Inc. -- a provider of surgical and non-surgical products -- for a transaction value of $13.35 billion. According to Zimmer, with the successful completion of this acquisition, it will be better able to capture the $45 billion musculoskeletal industry.
Another noteworthy move in recent times is the colossal $13.6 billion takeover of Life Technologies Corporation by its major peer Thermo Fisher Scientific ( TMO ) which closed in February. In the same month, artificial knee and hip maker Smith & Nephew plc ( SNN ), entered into an agreement to buy Arthrocare Corporation ( ARTC ) for $1.7 billion in order to expand its product line in sports medicines.
Global orthopedic device makers, Stryker Corporation ( SYK ) and Wright Medical Group, Inc. ( WMGI ) are also resorting to inorganic means to expand their businesses. In April, Stryker acquired German surgical tools firm, Berchtold Holding. In March, it acquired U.S.-based developer of hip arthroscopy products, Pivot Medical. In December last year, Stryker was in the headlines with its $1.65 billion acquisition of robotic assisted surgery developer, MAKO Surgical Corp.
Wright Medical to expand in the fast growing extremities market, announced a couple of acquisitions: Solana Surgical and OrthoPro. Earlier in November, Wright Medical completing the acquisition of French orthopedic extremities company Biotech International.
Some other significant newest buyouts include Covidien plc's ( COV ) $860 million acquisition of Israel-based diagnostic products maker Given Imaging (in February) and Quest Diagnostics' ( DGX ) takeover of Solstas Lab Partners Group and its subsidiaries for approximately $570 million (Mar 2014). Besides, to expand its dental business in Europe, in February, Henry Schein, Inc. ( HSIC ) acquired five companies from a Dutch company, Arseus NV.
There have been many more M&As in the MedTech space. Boston Scientific Corporation ( BSX ) closed the acquisition of Bard EP, the electrophysiology business of C.R. Bard, Inc. ( BCR ). Earlier in September, Baxter International ( BAX ) closed its $3.9 billion deal to acquire Gambro AB, a Sweden-based renal products company.
In the light of the discussion above, we see no slowing down of M&A deals in the MedTech space in rest of 2014. We also expect a significant pickup in in-licensing activities and collaborations for the development of pipeline candidates.
Divestments
With the medical device excise tax in force, leading to further contraction in profit margins, we have been observing a lot of divestments of late, particularly of non-core business segments. Divestments, specifically to offset the tax, have been announced by many key players. We expect this trend to continue in the rest of 2014.
MedTech giant Johnson & Johnson ( JNJ ), after its $1 billion acquisition of privately-held, pharmaceutical discovery and development company, Aragon Pharmaceuticals, Inc, in Apr 2014 announced its decision to sell off its Ortho-Clinical Diagnostics business to The Carlyle Group ( CG ) for about $4 billion. The divestment, which is expected to go through in mid-2014, will help the company increase its focus on the core pharma business.
Taking a cue from Abbott Laboratories ( ABT ), which separated its research-based pharmaceuticals business by creating a new company AbbVie ( ABBV ) last year, Baxter International revealed in Mar 2014 that it will split its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on these two businesses.
In January, Wright Medical exited the hip and knee implant market with the $290 million divestment of its OrthoRecon business to MicroPort Scientific Corporation and its affiliates. In January again, Covidien sold off its Confluent Surgical product line for approximately $235 million.
Novartis ( NVS ) has also entered into a definitive agreement to divest its blood transfusion diagnostics unit to Spain-based Grifols for $1.675 billion. Kimberly-Clark Corporation ( KMB ) on the other hand is working on a potential tax-free spin-off of the company's health care business. In November last year, Quest Diagnostics divested its Enterix colorectal cancer screening test business.
Emerging Markets
Although the U.S. still holds the leading position with almost one-third ofglobal marketshare, a gradual slowdown in established markets due to a number of lingering headwinds are forcing MedTech companies to look for opportunities in the developing world. Currently, with the growth rate remaining in low single digits in developed markets like the U.S., Europe and Japan, large-cap medical device makers are looking to invest more in the high-growth emerging regions.
Accordingly, emerging economies like Brazil, Russia, India and China (BRICs) as well as Turkey, Mexico, Malaysia, South Africa, South Korea and the Czech Republic are fast coming up in the medical devices space. These emerging economies are seeing an increasing uptake in medical devices largely due to growing medical awareness and economic prosperity.
An aging population, increasing wealth, government focus on healthcare infrastructure and expansion of medical insurance coverage make these markets a happy hunting ground for global medical device players. Expansion in emerging markets, especially those with double-digit annual growth rates, represents one of the best potential avenues for growth in 2014 and beyond.
Among the BRIC members, Brazil is currently the largest healthcare market in Latin America, covering almost one-fourth of the population. Though India has one of the largest and fastest growing healthcare markets in the world, it is considered to have the least developed healthcare infrastructure and spends relatively little in this area. In order to reverse the trend, during the 12th Plan (2012-2017), the Indian government planned to spend 2.5% of its GDP (up from 1.2% earlier) on health care and raise it to at least 3% by 2022.
Accordingly, big players in the MedTech sector are vying to expand their presence in BRIC and other emerging markets. These companies are also looking to establish their manufacturing facilities abroad.
Abbott continues to lead the trend with about 40% of sales coming in from the emerging markets. The company expects this contribution to increase to 50% by 2015. Johnson & Johnson showed 13% growth in the BRIC nations during the first quarter of 2014 and is currently working to increase its presence in these regions.
The company has already set up manufacturing and R&D centers in Brazil, China and India and expects to expand further in China on the back of the Synthes acquisition.
Becton, Dickinson and Company ( BDX ), with about 58% of revenues from international markets, witnessed double-digit sales growth in emerging geographies during the first quarter with China growing over 25% at constant exchange rate (CER). For Medtronic, emerging market grew a robust 12% (at CER) in its third quarter fiscal 2014, representing more than 13% of the company's total sales mix. Management is targeting 20% of its revenues from emerging markets, adding incremental revenues of $2.5 billion over the long term with mid-teens growth for the current fiscal.
Against the backdrop of flattening or declining sales growth in developed markets, Boston Scientific achieved 8% international growth in the first quarter of 2014 on the back of 22% growth in emerging markets, which represented 9% of total company sales.
Stryker, with 7% sales coming from emerging markets in the first quarter of 2014, is expected to grow market share further in key geographies like China and India. Orthopedic major, Smith & Nephew, continued to gain double-digit sales growth in emerging markets.
Thermo Fisher is also expanding its presence in emerging markets. It expects to garner 25% of total revenues from the high-growth Asia-Pacific region and emerging markets by 2016, up from 19% in 2011. According to the company, China with its rapid industrialization, increasing focus on healthcare, new BioPharma R&D centers and government sponsored research has robust growth potential.
Zacks Industry Rank
Within the Zacks Industry classification, MedTech is broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into four industries at the expanded level: med instruments, med products, med/dental-supp and medical info systems.
We rank all the 260-plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry. To learn more visit: About Zacks Industry Rank .
As a guideline, the outlook for industries with Zacks Industry Rank of #88 and lower is 'Positive,' between #89 and #176 is 'Neutral' and #177 and higher is 'Negative.'
The Zacks Industry Rank for med instruments is #101, med products is #161, med/dental-supp is #164, while the medical info systems is #216. Analyzing the Zacks Industry Rank for different MedTech segments, it is obvious that while the outlook for medical info systems stocks is negative, that for med instruments, med products and med/dental-supp is neutral.
Earnings Trend of the Sector
So far, 41.2% of the Medical sector participants have reported first quarter results which have been fairly good with respect to beat ratios (percentage of companies coming out with positive surprises). We note that the results were not impressive in terms of year-over-year growth.
The earnings "beat ratio" was 76.2%, while the revenue "beat ratio" was 38.1% in the first quarter. Total earnings for the companies in this sector increased a strong 15.2% year over year on revenue growth of 16.2%. In fact, earnings and revenues showed a massive improvement from the fourth quarter 2013 performance.
The earnings is expected to increase by 3.1% in the second quarter 2014. The sector is expected to register an impressive growth of 8.1% for the full-year 2014 and 16.2% in the full-year 2015. In terms of revenue expectation, the sector is expected to register 7.3% year-over-year growth in the second quarter of the year, resulting in an annual growth rate of 7.4%.
For more information about earnings for this sector and others, please read our 'Earnings Trends' report .
OPPORTUNITIES
In spite of several core market challenges, the big three medical device players -- Medtronic, Boston Scientific and St. Jude Medical, Inc. ( STJ ) -- are striving to gain share in the ICD market through new product launches. With gradual stability in the ICD market, these players should be able to revive their top line. In the first quarter of 2014, St. Jude Medical's ICD revenues increased 2.1% (3% in constant-currency).
Although Boston Scientific posted another quarter of weak ICD sales with 3.1% year-over-year decline, it is taking several initiatives to revive its top line. We also wait for a better-than-expected ICD performance from Medtronic which is slated to report its fourth quarter and fiscal 2014 results on May 20.
The Cooper Companies Inc. ( COO ) holding a Zacks Rank #2 (Buy) represents a value proposition based on factors such as margin expansion, acquisitions, product line expansion and geographical reach as well as share buybacks. Johnson & Johnson holding a Zacks Rank #2 has been trying to offset the declining sales of some of its important products by bringing in new products through in-licensing deals and acquisitions.
Beyond the MedTech majors, we are also optimistic about the Zacks Ranked #3 orthopedic device players, Zimmer Holdings and Stryker Corporation. The percentage of population over 65 in the U.S., Europe, Japan and other regions is expected to nearly double by the year 2030. We believe the orthopedic giants stand to benefit from this aging demography.
Among scientific instrument makers, Thermo Fisher Scientific has been successfully expanding operating margins over the past few quarters on the back of operational efficiency. Apart from the newest incorporated segment Life Sciences Solution segment with the buyout of Life Technologies, Thermo Fisher's market leading portfolio of analytical technologies demonstrated strong performance with growth in the Life Sciences Mass Spec and Chromatography businesses.
Among other MedTech stocks, Mead Johnson Nutrition Company ( MJN ), Covance Inc. ( CVD ), Cardinal Health, Inc. ( CAH ), Illumina Inc. ( ILMN ) and Hologic Inc. ( HOLX ) carrying a Zacks Rank #2 (Buy) also look attractive.
CHALLENGES AND WEAKNESSES
Coming to the weakest link in the MedTech sector, we advise investors against names that offer little growth/opportunity over the near term. These include companies for which estimate revision trends for 2014 reflect a bearish sentiment.
Stocks which do not look inspiring are Intuitive Surgical ( ISRG ) sporting a Zacks Rank #5 (Strong Sell), Wright Medical, Volcano Corporation ( VOLC ), CareFusion Corporation ( CFN ), Haemonetics Corporation ( HAE ), Patterson Companies, Inc. ( PDCO ) and DENTSPLY International Inc. ( XRAY ), all carrying the Zacks Rank #4 (Sell).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ARTHROCARE CORP (ARTC): Free Stock Analysis Report
BAXTER INTL (BAX): Free Stock Analysis Report
BARD C R INC (BCR): Free Stock Analysis Report
BECTON DICKINSO (BDX): Free Stock Analysis Report
BOSTON SCIENTIF (BSX): Free Stock Analysis Report
CARDINAL HEALTH (CAH): Free Stock Analysis Report
CAREFUSION CORP (CFN): Free Stock Analysis Report
CARLYLE GROUP (CG): Free Stock Analysis Report
COOPER COS (COO): Free Stock Analysis Report
COVIDIEN PLC (COV): Free Stock Analysis Report
COVANCE INC (CVD): Free Stock Analysis Report
QUEST DIAGNOSTC (DGX): Free Stock Analysis Report
HAEMONETICS CP (HAE): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
HENRY SCHEIN IN (HSIC): Free Stock Analysis Report
ILLUMINA INC (ILMN): Free Stock Analysis Report
INTUITIVE SURG (ISRG): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
KIMBERLY CLARK (KMB): Free Stock Analysis Report
MEAD JOHNSON NU (MJN): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
PATTERSON COS (PDCO): Free Stock Analysis Report
SMITH & NEPHEW (SNN): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
STRYKER CORP (SYK): Free Stock Analysis Report
THERMO FISHER (TMO): Free Stock Analysis Report
VOLCANO CORP (VOLC): Free Stock Analysis Report
WRIGHT MEDICAL (WMGI): Free Stock Analysis Report
DENTSPLY INTL (XRAY): Free Stock Analysis Report
ZIMMER HOLDINGS (ZMH): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Taking a cue from Abbott Laboratories ( ABT ), which separated its research-based pharmaceuticals business by creating a new company AbbVie ( ABBV ) last year, Baxter International revealed in Mar 2014 that it will split its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on these two businesses. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ARTHROCARE CORP (ARTC): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report BARD C R INC (BCR): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report CARDINAL HEALTH (CAH): Free Stock Analysis Report CAREFUSION CORP (CFN): Free Stock Analysis Report CARLYLE GROUP (CG): Free Stock Analysis Report COOPER COS (COO): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report COVANCE INC (CVD): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report HAEMONETICS CP (HAE): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report HENRY SCHEIN IN (HSIC): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report KIMBERLY CLARK (KMB): Free Stock Analysis Report MEAD JOHNSON NU (MJN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report SMITH & NEPHEW (SNN): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZIMMER HOLDINGS (ZMH): Free Stock Analysis Report To read this article on Zacks.com click here. In the same month, artificial knee and hip maker Smith & Nephew plc ( SNN ), entered into an agreement to buy Arthrocare Corporation ( ARTC ) for $1.7 billion in order to expand its product line in sports medicines. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ARTHROCARE CORP (ARTC): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report BARD C R INC (BCR): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report CARDINAL HEALTH (CAH): Free Stock Analysis Report CAREFUSION CORP (CFN): Free Stock Analysis Report CARLYLE GROUP (CG): Free Stock Analysis Report COOPER COS (COO): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report COVANCE INC (CVD): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report HAEMONETICS CP (HAE): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report HENRY SCHEIN IN (HSIC): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report KIMBERLY CLARK (KMB): Free Stock Analysis Report MEAD JOHNSON NU (MJN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report SMITH & NEPHEW (SNN): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZIMMER HOLDINGS (ZMH): Free Stock Analysis Report To read this article on Zacks.com click here. Taking a cue from Abbott Laboratories ( ABT ), which separated its research-based pharmaceuticals business by creating a new company AbbVie ( ABBV ) last year, Baxter International revealed in Mar 2014 that it will split its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on these two businesses. Among other MedTech stocks, Mead Johnson Nutrition Company ( MJN ), Covance Inc. ( CVD ), Cardinal Health, Inc. ( CAH ), Illumina Inc. ( ILMN ) and Hologic Inc. ( HOLX ) carrying a Zacks Rank #2 (Buy) also look attractive. | Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ARTHROCARE CORP (ARTC): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report BARD C R INC (BCR): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report CARDINAL HEALTH (CAH): Free Stock Analysis Report CAREFUSION CORP (CFN): Free Stock Analysis Report CARLYLE GROUP (CG): Free Stock Analysis Report COOPER COS (COO): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report COVANCE INC (CVD): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report HAEMONETICS CP (HAE): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report HENRY SCHEIN IN (HSIC): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report KIMBERLY CLARK (KMB): Free Stock Analysis Report MEAD JOHNSON NU (MJN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report SMITH & NEPHEW (SNN): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZIMMER HOLDINGS (ZMH): Free Stock Analysis Report To read this article on Zacks.com click here. Taking a cue from Abbott Laboratories ( ABT ), which separated its research-based pharmaceuticals business by creating a new company AbbVie ( ABBV ) last year, Baxter International revealed in Mar 2014 that it will split its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on these two businesses. Against the backdrop of flattening or declining sales growth in developed markets, Boston Scientific achieved 8% international growth in the first quarter of 2014 on the back of 22% growth in emerging markets, which represented 9% of total company sales. | Taking a cue from Abbott Laboratories ( ABT ), which separated its research-based pharmaceuticals business by creating a new company AbbVie ( ABBV ) last year, Baxter International revealed in Mar 2014 that it will split its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on these two businesses. Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ARTHROCARE CORP (ARTC): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report BARD C R INC (BCR): Free Stock Analysis Report BECTON DICKINSO (BDX): Free Stock Analysis Report BOSTON SCIENTIF (BSX): Free Stock Analysis Report CARDINAL HEALTH (CAH): Free Stock Analysis Report CAREFUSION CORP (CFN): Free Stock Analysis Report CARLYLE GROUP (CG): Free Stock Analysis Report COOPER COS (COO): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report COVANCE INC (CVD): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report HAEMONETICS CP (HAE): Free Stock Analysis Report HOLOGIC INC (HOLX): Free Stock Analysis Report HENRY SCHEIN IN (HSIC): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report KIMBERLY CLARK (KMB): Free Stock Analysis Report MEAD JOHNSON NU (MJN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PATTERSON COS (PDCO): Free Stock Analysis Report SMITH & NEPHEW (SNN): Free Stock Analysis Report ST JUDE MEDICAL (STJ): Free Stock Analysis Report STRYKER CORP (SYK): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report VOLCANO CORP (VOLC): Free Stock Analysis Report WRIGHT MEDICAL (WMGI): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZIMMER HOLDINGS (ZMH): Free Stock Analysis Report To read this article on Zacks.com click here. Total earnings for the companies in this sector increased a strong 15.2% year over year on revenue growth of 16.2%. |
34184.0 | 2014-04-21 00:00:00 UTC | Noteworthy ETF Outflows: SSO, ABT, ACN, ACE | ABT | https://www.nasdaq.com/articles/noteworthy-etf-outflows-sso-abt-acn-ace-2014-04-21 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $47.0 million dollar outflow -- that's a 1.4% decrease week over week (from 31,500,000 to 31,050,000). Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.7%, Accenture plc (Symbol: ACN) is up about 0.2%, and ACE, Ltd. (Symbol: ACE) is relatively unchanged. The chart below shows the one year price performance of SSO, versus its 200 day moving average:
Looking at the chart above, SSO's low point in its 52 week range is $70.11 per share, with $108.35 as the 52 week high point - that compares with a last trade of $104.66. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs experienced notable outflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.7%, Accenture plc (Symbol: ACN) is up about 0.2%, and ACE, Ltd. (Symbol: ACE) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $47.0 million dollar outflow -- that's a 1.4% decrease week over week (from 31,500,000 to 31,050,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $70.11 per share, with $108.35 as the 52 week high point - that compares with a last trade of $104.66. | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.7%, Accenture plc (Symbol: ACN) is up about 0.2%, and ACE, Ltd. (Symbol: ACE) is relatively unchanged. The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $70.11 per share, with $108.35 as the 52 week high point - that compares with a last trade of $104.66. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.7%, Accenture plc (Symbol: ACN) is up about 0.2%, and ACE, Ltd. (Symbol: ACE) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $47.0 million dollar outflow -- that's a 1.4% decrease week over week (from 31,500,000 to 31,050,000). The chart below shows the one year price performance of SSO, versus its 200 day moving average: Looking at the chart above, SSO's low point in its 52 week range is $70.11 per share, with $108.35 as the 52 week high point - that compares with a last trade of $104.66. | Among the largest underlying components of SSO, in trading today Abbott Laboratories (Symbol: ABT) is off about 0.7%, Accenture plc (Symbol: ACN) is up about 0.2%, and ACE, Ltd. (Symbol: ACE) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Proshares Ultra S&P500 (Symbol: SSO) where we have detected an approximate $47.0 million dollar outflow -- that's a 1.4% decrease week over week (from 31,500,000 to 31,050,000). Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. |
34185.0 | 2014-04-17 00:00:00 UTC | Abbott Earnings Preview: Emerging Markets & New Products Likely To Drive Sales | ABT | https://www.nasdaq.com/articles/abbott-earnings-preview-emerging-markets-new-products-likely-drive-sales-2014-04-17 | nan | nan | Abbott Labs ( ABT ) is scheduled to release its Q1 2014 earnings on Wednesday, April 16. In the previous quarter, operational sales increased 3.3% year-over-year (y-o-y) to $5.7 billion, driven by robust sales of its Diagnostics, Vascular and Medical Optics products. Nutritionals, the company's largest business segment, continued to be impacted by the supplier recall that was initiated in international markets in August of last year and reported a marginal 1.1% y-o-y increase in operational sales. On the cost side, the healthcare conglomerate improved its gross margins by 60 basis points to 55.4% on the back of improving operating margins in the Nutritionals and Diagnostics businesses.
In the company's first quarter earnings, we expect operational sales to grow in the mid-single digits, driven by continued growth in Diagnostics and a marginal improvement in Nutritionals. Abbott's management stated in the previousearnings callthat the company expected adjusted gross margins to decline to about 54% in the first quarter of 2014 on account of increasing competition, foreign exchange impacts and the supplier recall in Nutritionals. We expect gross margins to match company estimates.
Emerging markets contributed about 40% of total sales in the fourth quarter last year. We expect this to increase going forward as Abbott increases its presence in emerging markets such as China, India and Brazil, anticipating higher growth prospects compared to developed regions. The company introduced several new products last year and they are likely to contribute significantly to sales in the near future.
We have a price estimate of $40 for Abbott Labs , implying a premium of over 5% to the current market price.
See our full analysis for Abbott Labs
Emerging Markets To Drive Growth In Sales
Sales in emerging markets grew 9% y-o-y in the previous quarter driven by strong performance in the Adult Nutrition business, Diagnostics and Established Pharmaceuticals (generic drugs). Together, the Nutritionals, Diagnostics and Established Pharmaceuticals divisions account for over 75% of Abbott's revenue and are likely to derive most of their future growth from emerging markets.
Countries such as China, India, Russia and Brazil continue to grow at a faster rate than most developed economies, and have a rapidly growing middle class population. McKinsey & Company predicts that the urban household income in China will double by 2022 and that the majority of its urban consumers will earn between $9,000 and $34,000 annually by that time. As the middle class continues to grow in these markets, people are likely to increase their discretionary spending on nutritional products (such as food supplements) and point-of-care diagnostics.
New Products Could Boost Sales
In 2013, Abbott launched several new products across its diversified businesses to boost sales and tap into new markets. This included over 70 new products in the Nutritionals, Diagnostics and Vascular divisions. Going forward, these new products are expected to significantly contribute to the company's sales. Some of these new products are as follows:
XIENCE Xpedition drug-eluting stent - This is part of the Endovascular division and currently sold in international markets such as Japan and China. It is expected to contribute significantly to Abbott's efforts in increasing its global share in the stent market, along with its ABSORB product.
MitraClip- This device is used to treat mitral (a valve in the heart) regurgitation. Its markets include the U.S. and Europe. It generated sales of about $130 million in 2013 and is expected to grow to $200 million by the end of this year.
SUPERA Veritas- It is a stent used for treating blockages in blood vessels due to peripheral artery disease (PAD), a sickness that ails 27 million people in Europe and North America. It is also under FDA review for superficial femoral artery (SFA) treatment in the U.S. This is the flagship product of IDEV Technologies, a company which Abbott acquired in August 2013.
Catalys- This optics product allows surgeons to replace manual steps in cataract surgery with computer-guided laser technology. Abbott acquired this product as part of its acquisition of OptiMedica Corporation in 2013 and it provides Abbott an entry point in the large and fast-growing laser cataract surgery market.
Similac's Triple [ph] Pack- The company launched its flagship Similac infant formula product with an enhanced packaging solution for the online market in China. This is an example of innovation within existing products to tap into new markets and boost sales. (( Abbott Reports Fourth-Quarter 2013 Results , Abbott Labs, January 22, 2014))
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) is scheduled to release its Q1 2014 earnings on Wednesday, April 16. Nutritionals, the company's largest business segment, continued to be impacted by the supplier recall that was initiated in international markets in August of last year and reported a marginal 1.1% y-o-y increase in operational sales. Abbott's management stated in the previousearnings callthat the company expected adjusted gross margins to decline to about 54% in the first quarter of 2014 on account of increasing competition, foreign exchange impacts and the supplier recall in Nutritionals. | Abbott Labs ( ABT ) is scheduled to release its Q1 2014 earnings on Wednesday, April 16. In the previous quarter, operational sales increased 3.3% year-over-year (y-o-y) to $5.7 billion, driven by robust sales of its Diagnostics, Vascular and Medical Optics products. Nutritionals, the company's largest business segment, continued to be impacted by the supplier recall that was initiated in international markets in August of last year and reported a marginal 1.1% y-o-y increase in operational sales. | Abbott Labs ( ABT ) is scheduled to release its Q1 2014 earnings on Wednesday, April 16. Nutritionals, the company's largest business segment, continued to be impacted by the supplier recall that was initiated in international markets in August of last year and reported a marginal 1.1% y-o-y increase in operational sales. See our full analysis for Abbott Labs Emerging Markets To Drive Growth In Sales Sales in emerging markets grew 9% y-o-y in the previous quarter driven by strong performance in the Adult Nutrition business, Diagnostics and Established Pharmaceuticals (generic drugs). | Abbott Labs ( ABT ) is scheduled to release its Q1 2014 earnings on Wednesday, April 16. Nutritionals, the company's largest business segment, continued to be impacted by the supplier recall that was initiated in international markets in August of last year and reported a marginal 1.1% y-o-y increase in operational sales. In the company's first quarter earnings, we expect operational sales to grow in the mid-single digits, driven by continued growth in Diagnostics and a marginal improvement in Nutritionals. |
34186.0 | 2014-04-16 00:00:00 UTC | Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-tops-earnings-misses-sales-est-analyst-blog-2014-04-16 | nan | nan | Abbott Laboratories ( ABT ) reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.
Earnings were down 2.4% from the year-ago quarter but above the management's guidance range of 34-36 cents. Including one-time items, first quarter earnings came in at 22 cents per share, down from 34 cents in the year-ago quarter.
Abbott Labs generated sales of $5.2 billion in the first quarter of 2014, down 2.5% year over year and short of the Zacks Consensus Estimate of $5.4 billion.
The disruption in Abbott Labs' international nutrition business in Aug 2013 and the timing of supply of key products in Established Pharmaceuticals segment due to an expected plant shutdown for capacity expansion purposes negatively impacted sales by 2.6% points.
First Quarter in Detail
Abbott Labs operates through four segments, namely Established Pharmaceuticals Division (EPD), Medical Devices, Diagnostics and Nutrition.
EPD sales declined 6.6% year over year to $1.1 billion including a negative impact of 5.9% due to currency fluctuations. Sales in key emerging markets edged up 0.2% on an operational basis (excluding foreign currency fluctuations) driven by growth in Brazil, Russia and China. However, sales from developed and other markets declined 1.5% on an operational basis.
Even though sales in this division was impacted by the timing of supply of key products in women's health portfolio due to an expected plant shutdown for capacity expansion purposes, Abbott Labs' expects sales growth from key emerging markets to accelerate in 2014.
The Medical Devices business generated sales of $1.3 billion, down 1.2% year over year. Diabetes Care sales were down 10.5% due to the implementation of CMS or the competitive bidding for Medicare patients in the U.S. The Vascular business was down 0.5% despite continued uptake of drug eluting stent systems Xience Xpedition and Absorb in key geographies.
On a positive note, Medical Optics business was up 7.6%. Cataract sales, accounting for more than 65% of total Medical Optics sales, outpaced the overall market and recorded double-digit growth propelled by a number of new products launched in 2013, including the Tecnis OptiBlue IOL in Japan and the Tecnis Toric IOL in the U.S. along with further penetration of the Catalys Precision Laser System for cataract surgery.
As expected, the Nutrition business was down 4.0% year over year to $1.6 billion. Pediatric Nutrition sales declined 8.5% as sales in this business were adversely impacted by a supplier recall in early Aug 2013 in certain international markets. This sales disruption is estimated to have reduced sales by approximately $75 million in the first quarter in international Pediatric Nutrition business. Adult Nutrition sales grew 2.2%, driven by solid growth of its key brand Ensure.
Diagnostics business sales increased 2.6% year over year to $1.1 billion. Key areas of focus in this division include the Core Laboratory Diagnostics, Molecular Diagnostics and Point of Care Diagnostics businesses. Core Laboratory sales increased 2.4% and Point of Care Diagnostics increased 2.2%. Worldwide sales of Molecular Diagnostics were up 4.6%.
2014 Outlook Reiterated
Abbott Labs continues to expect earnings per share in the range of $2.16 to $2.26 in 2014. The Zacks Consensus Estimate currently stands at $2.20 per share, well within the company's guidance. Shares were up in pre-market trading .
Our View
Abbott Labs currently carries a Zacks Rank #3 (Hold). Even though earnings were above expectations in the first quarter, sales fell short. The supply constraints in the EPD segment continue to pull down the sales growth of the division. We were disappointed by the disruption in international markets of the Nutrition business which was one of the fastest growing businesses for Abbott Labs. The disruption is likely to stretch into the first half of 2014.
Nevertheless, Abbott Labs plans to launch a number of new products globally in 2014 to recapture its lost market share in the nutrition business, including a new infant formula, Eleva, recently launched in China. The company intends to increase its global capacity to meet demand with three new manufacturing facilities scheduled to be operational in China, India and the U.S. in the second quarter.
We believe that Abbott Labs is extremely diversified with its presence in nutrition, diagnostics, generic pharmaceuticals and medical devices markets after having separated its proprietary pharmaceutical business into a new company called AbbVie ( ABBV ) in early 2013.
Some better-ranked stocks in the healthcare sector include Allergan ( AGN ) and Biodel Inc. ( BIOD ). Both carry a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ALLERGAN INC (AGN): Free Stock Analysis Report
BIODEL INC (BIOD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIODEL INC (BIOD): Free Stock Analysis Report To read this article on Zacks.com click here. The disruption in Abbott Labs' international nutrition business in Aug 2013 and the timing of supply of key products in Established Pharmaceuticals segment due to an expected plant shutdown for capacity expansion purposes negatively impacted sales by 2.6% points. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIODEL INC (BIOD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents. The disruption in Abbott Labs' international nutrition business in Aug 2013 and the timing of supply of key products in Established Pharmaceuticals segment due to an expected plant shutdown for capacity expansion purposes negatively impacted sales by 2.6% points. | Abbott Laboratories ( ABT ) reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIODEL INC (BIOD): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs generated sales of $5.2 billion in the first quarter of 2014, down 2.5% year over year and short of the Zacks Consensus Estimate of $5.4 billion. | Abbott Laboratories ( ABT ) reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIODEL INC (BIOD): Free Stock Analysis Report To read this article on Zacks.com click here. Core Laboratory sales increased 2.4% and Point of Care Diagnostics increased 2.2%. |
34187.0 | 2014-04-16 00:00:00 UTC | Prestige Brands Gains on Product Acquisition News - Analyst Blog | ABT | https://www.nasdaq.com/articles/prestige-brands-gains-on-product-acquisition-news-analyst-blog-2014-04-16 | nan | nan | Prestige Brands Holdings, Inc. 's ( PBH ) shares gained 5.94% immediately after the company announced that it has signed a purchase agreement with Australia-based The Hydration Pharmaceuticals Trust of Victoria to acquire their over-the-counter (OTC) oral rehydration brand, Hydralyte. The acquisition is slated to close by Jun 2014. Financial details were not provided.
With the acquisition of Hydralyte, Prestige Brands expects annual revenues of its Australian subsidiary, Care Pharmaceuticals, to double to nearly $50 million (AUD) in fiscal 2015.
Our Take
This deal marks Prestige Brands' efforts towards strengthening its OTC portfolio. We note that prior to the Hydralyte deal, Prestige Brands had made four other similar acquisitions in the last five years. Last year, the company acquired Care Pharmaceuticals to boost its OTC healthcare segment.
We remind investors that fiscal 2014 is a transition year for Prestige Brands and that the company intends to focus on the growth of its core OTC segment.
The upcoming acquisition of Hydralyte will help Prestige Brands expand its business in the Austral-Asia region. With Hydralyte's leading-OTC-brand status in the market for oral rehydration following diarrhea, vomiting, fever, heat and other ailments in Australia and New Zealand, the addition of Hydralyte to Prestige Brands' portfolio will be immediately accretive to its fiscal 2015 earnings.
Some approved oral rehydration therapies include Sanofi 's ( SNY ) Dioralyte and Abbott Laboratories ' ( ABT ) Pedialyte.
Prestige Brands carries a Zacks Rank #4 (Sell). A better-ranked stock in the health care sector is Central Garden & Pet Company ( CENT ) carrying a Zacks Rank #2 (Buy).
ABBOTT LABS (ABT): Free Stock Analysis Report
CENTRAL GARDEN (CENT): Free Stock Analysis Report
PRESTIGE BRANDS (PBH): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some approved oral rehydration therapies include Sanofi 's ( SNY ) Dioralyte and Abbott Laboratories ' ( ABT ) Pedialyte. ABBOTT LABS (ABT): Free Stock Analysis Report CENTRAL GARDEN (CENT): Free Stock Analysis Report PRESTIGE BRANDS (PBH): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. With the acquisition of Hydralyte, Prestige Brands expects annual revenues of its Australian subsidiary, Care Pharmaceuticals, to double to nearly $50 million (AUD) in fiscal 2015. | ABBOTT LABS (ABT): Free Stock Analysis Report CENTRAL GARDEN (CENT): Free Stock Analysis Report PRESTIGE BRANDS (PBH): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Some approved oral rehydration therapies include Sanofi 's ( SNY ) Dioralyte and Abbott Laboratories ' ( ABT ) Pedialyte. Prestige Brands Holdings, Inc. 's ( PBH ) shares gained 5.94% immediately after the company announced that it has signed a purchase agreement with Australia-based The Hydration Pharmaceuticals Trust of Victoria to acquire their over-the-counter (OTC) oral rehydration brand, Hydralyte. | ABBOTT LABS (ABT): Free Stock Analysis Report CENTRAL GARDEN (CENT): Free Stock Analysis Report PRESTIGE BRANDS (PBH): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Some approved oral rehydration therapies include Sanofi 's ( SNY ) Dioralyte and Abbott Laboratories ' ( ABT ) Pedialyte. Prestige Brands Holdings, Inc. 's ( PBH ) shares gained 5.94% immediately after the company announced that it has signed a purchase agreement with Australia-based The Hydration Pharmaceuticals Trust of Victoria to acquire their over-the-counter (OTC) oral rehydration brand, Hydralyte. | Some approved oral rehydration therapies include Sanofi 's ( SNY ) Dioralyte and Abbott Laboratories ' ( ABT ) Pedialyte. ABBOTT LABS (ABT): Free Stock Analysis Report CENTRAL GARDEN (CENT): Free Stock Analysis Report PRESTIGE BRANDS (PBH): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. We note that prior to the Hydralyte deal, Prestige Brands had made four other similar acquisitions in the last five years. |
34188.0 | 2014-04-16 00:00:00 UTC | Sector Update: Healthcare Shares Higher Pre-Market; St. Jude Q1 Earnings Top Street View | ABT | https://www.nasdaq.com/articles/sector-update-healthcare-shares-higher-pre-market-st-jude-q1-earnings-top-street-view-2014 | nan | nan | Top Healthcare stocks:
JNJ: +0.58%
PFE: +0.37%
ABT: +1.29%
MRK: +0.54%
AMGN: +0.50%
Healthcare shares were generally higher in pre-market trade on Wednesday.
In healthcare stocks news, St. Jude Medical ( STJ ) reported Q1 earnings that exceeded analysts' expectations by one cent and sales that were in line with estimates while the guidance for Q2 and FY14 straddled the consensus.
The maker of cardiovascular medical devices said adjusted Q1 earnings were $278 million or $0.95 per share, up from $0.92 the year earlier and exceeding the $0.95 average estimate from analysts polled by Capital IQ. Reported net earnings rose to $249 million from $223 million a year ago.
And, Abbott Laboratories ( ABT ) reported a Q1 EPS of $0.96, which beat the analyst consensus by $0.01. Revenue of $1.36 billion was on par with the Street view.
ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And, Abbott Laboratories ( ABT ) reported a Q1 EPS of $0.96, which beat the analyst consensus by $0.01. ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. In healthcare stocks news, St. Jude Medical ( STJ ) reported Q1 earnings that exceeded analysts' expectations by one cent and sales that were in line with estimates while the guidance for Q2 and FY14 straddled the consensus. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And, Abbott Laboratories ( ABT ) reported a Q1 EPS of $0.96, which beat the analyst consensus by $0.01. ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. | And, Abbott Laboratories ( ABT ) reported a Q1 EPS of $0.96, which beat the analyst consensus by $0.01. ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. In healthcare stocks news, St. Jude Medical ( STJ ) reported Q1 earnings that exceeded analysts' expectations by one cent and sales that were in line with estimates while the guidance for Q2 and FY14 straddled the consensus. | And, Abbott Laboratories ( ABT ) reported a Q1 EPS of $0.96, which beat the analyst consensus by $0.01. ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. Healthcare shares were generally higher in pre-market trade on Wednesday. |
34189.0 | 2014-04-16 00:00:00 UTC | Sector Update: Healthcare | ABT | https://www.nasdaq.com/articles/sector-update-healthcare-2014-04-16 | nan | nan | Healthcare shares were generally higher in pre-market trade on Wednesday.
In healthcare stocks news, St. Jude Medical ( STJ ) reported Q1 earnings that exceeded analysts' expectations by one cent and sales that were in line with estimates while the guidance for Q2 and FY14 straddled the consensus.
The maker of cardiovascular medical devices said adjusted Q1 earnings were $278 million or $0.95 per share, up from $0.92 the year earlier and exceeding the $0.95 average estimate from analysts polled by Capital IQ. Reported net earnings rose to $249 million from $223 million a year ago.
And, Abbott Laboratories ( ABT ) reported Q1 EPS of $0.96, which beat the analyst consensus by $0.01. Revenue of $1.36 billion was on par with the Street view.
ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And, Abbott Laboratories ( ABT ) reported Q1 EPS of $0.96, which beat the analyst consensus by $0.01. ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. In healthcare stocks news, St. Jude Medical ( STJ ) reported Q1 earnings that exceeded analysts' expectations by one cent and sales that were in line with estimates while the guidance for Q2 and FY14 straddled the consensus. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And, Abbott Laboratories ( ABT ) reported Q1 EPS of $0.96, which beat the analyst consensus by $0.01. ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. | And, Abbott Laboratories ( ABT ) reported Q1 EPS of $0.96, which beat the analyst consensus by $0.01. ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. In healthcare stocks news, St. Jude Medical ( STJ ) reported Q1 earnings that exceeded analysts' expectations by one cent and sales that were in line with estimates while the guidance for Q2 and FY14 straddled the consensus. | ABT was up 1.29% at $38.46 in pre-market trade with a 52-week range of $32.70 to $40.49. And, Abbott Laboratories ( ABT ) reported Q1 EPS of $0.96, which beat the analyst consensus by $0.01. In healthcare stocks news, St. Jude Medical ( STJ ) reported Q1 earnings that exceeded analysts' expectations by one cent and sales that were in line with estimates while the guidance for Q2 and FY14 straddled the consensus. |
34190.0 | 2014-04-15 00:00:00 UTC | Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog | ABT | https://www.nasdaq.com/articles/will-abbott-labs-abt-disappoint-this-quarter-analyst-blog-2014-04-15 | nan | nan | Abbott Laboratories ( ABT ) is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014.
Last quarter, Abbott Labs reported break-even earnings. On an average, Abbott Labs has posted a 6.20% positive surprise in the last four quarters. Let's see how things are shaping up for the first quarter.
Factors to Influence 1Q Results
Abbott Labs is an extremely diversified company with its presence in the diagnostics, nutrition, generics and medical devices markets after having separated its pharmaceutical business into a new company called AbbVie ( ABBV ) in Jan 2013.
However, the business environment continues to be challenging due to austerity measures in developed markets and weak economic conditions in the developing markets.
Moreover, we were disappointed by the disruption in international nutrition sales in the third quarter of 2013. The disruption is likely to stretch into the first half of 2014. The nutrition division is the company's fastest growing business and hence a disruption in business will impact growth rates going forward.
Nevertheless, the Medical Devices and Diagnostics business look promising.
Earnings Whispers?
Our proven model does not conclusively show that Abbott Labs will beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, #2 or #3 to be able to beat consensus estimates. That is not the case here as you will see below.
Zacks ESP : The ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is -2.86%. This is because both the Most Accurate Estimate currently stands at 34 cents while the Zacks Consensus Estimate currently stands at 35 cents.
Zacks Rank #3 (Hold): Abbott Labs' Zacks Rank #3 (Hold) lowers the predictive power of ESP because the Zacks Rank #3 when combined with a negative ESP makes surprise prediction difficult.
We caution against stocks with Zacks Ranks #4 and #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks to Consider
Here are some other stocks in the broader healthcare sector that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this season:
Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +8.14% and holds a Zacks Rank #3 (Hold). Biogen will be reporting first quarter results on Apr 23.
Shire ( SHPG ) has an Earnings ESP of +1.79% and holds a Zacks Rank #2 (Buy). Shire will report first quarter results on May 1.
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Influence 1Q Results Abbott Labs is an extremely diversified company with its presence in the diagnostics, nutrition, generics and medical devices markets after having separated its pharmaceutical business into a new company called AbbVie ( ABBV ) in Jan 2013. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014. Zacks Rank #3 (Hold): Abbott Labs' Zacks Rank #3 (Hold) lowers the predictive power of ESP because the Zacks Rank #3 when combined with a negative ESP makes surprise prediction difficult. | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014. Zacks Rank #3 (Hold): Abbott Labs' Zacks Rank #3 (Hold) lowers the predictive power of ESP because the Zacks Rank #3 when combined with a negative ESP makes surprise prediction difficult. | Abbott Laboratories ( ABT ) is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Last quarter, Abbott Labs reported break-even earnings. |
34191.0 | 2014-04-15 00:00:00 UTC | Pre-Market Earnings Report for April 16, 2014 : BAC, USB, ABT, PNC, ASML, STJ, GWW, HBAN, FRC, ADTN | ABT | https://www.nasdaq.com/articles/pre-market-earnings-report-april-16-2014-bac-usb-abt-pnc-asml-stj-gww-hban-frc-adtn-2014 | nan | nan | The following companies are expected to report earnings prior to market open on 04/16/2014. Visit our Earnings Calendar for a full list of expected earnings releases.
Bank of America Corporation ( BAC ) is reporting for the quarter ending March 31, 2014. The bank company's consensus earnings per share forecast from the 14 analysts that follow the stock is $0.05. This value represents a 75.00% decrease compared to the same quarter last year. BAC missed the consensus earnings per share in the 1st calendar quarter of 2013 by -13.04%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BAC is 14.68 vs. an industry ratio of 13.40, implying that they will have a higher earnings growth than their competitors in the same industry.
U.S. Bancorp ( USB ) is reporting for the quarter ending March 31, 2014. The bank company's consensus earnings per share forecast from the 17 analysts that follow the stock is $0.73. This value represents a no change for the same quarter last year. In the past year USB has met analyst expectations three times and beat the expectations the other quarter. Zacks Investment Research reports that the 2014 Price to Earnings ratio for USB is 12.85 vs. an industry ratio of 13.40.
Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2014. The large cap pharmaceutical company's consensus earnings per share forecast from the 14 analysts that follow the stock is $0.35. This value represents a 16.67% decrease compared to the same quarter last year. In the past year ABT has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 17.15 vs. an industry ratio of 17.70.
PNC Financial Services Group, Inc. ( PNC ) is reporting for the quarter ending March 31, 2014. The bank company's consensus earnings per share forecast from the 16 analysts that follow the stock is $1.66. This value represents a 5.68% decrease compared to the same quarter last year. In the past year PNC has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 3.05%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for PNC is 11.66 vs. an industry ratio of 13.40.
ASML Holding N.V. ( ASML ) is reporting for the quarter ending March 31, 2014. The capital goods company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.81. This value represents a 65.31% increase compared to the same quarter last year. The days to cover, as reported in the 3/31/2014 short interest update, increased 149.68% from previous report on 3/14/2014. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ASML is 19.50 vs. an industry ratio of 19.30, implying that they will have a higher earnings growth than their competitors in the same industry.
St. Jude Medical, Inc. ( STJ ) is reporting for the quarter ending March 31, 2014. The medical products company's consensus earnings per share forecast from the 14 analysts that follow the stock is $0.95. This value represents a 3.26% increase compared to the same quarter last year. In the past year STJ has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for STJ is 15.72 vs. an industry ratio of 5.70, implying that they will have a higher earnings growth than their competitors in the same industry.
W.W. Grainger, Inc. ( GWW ) is reporting for the quarter ending March 31, 2014. The industrial services company's consensus earnings per share forecast from the 13 analysts that follow the stock is $2.97. This value represents a 1.02% increase compared to the same quarter last year. The last two quarters GWW had negative earnings surprises; the latest report they missed by -1.52%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for GWW is 19.76 vs. an industry ratio of 19.00, implying that they will have a higher earnings growth than their competitors in the same industry.
Huntington Bancshares Incorporated ( HBAN ) is reporting for the quarter ending March 31, 2014. The bank (midwest) company's consensus earnings per share forecast from the 16 analysts that follow the stock is $0.17. This value represents a no change for the same quarter last year. In the past year HBAN has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 11.76%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for HBAN is 13.01 vs. an industry ratio of 14.80.
FIRST REPUBLIC BANK ( FRC ) is reporting for the quarter ending March 31, 2014. The bank (west) company's consensus earnings per share forecast from the 8 analysts that follow the stock is $0.64. This value represents a 11.11% decrease compared to the same quarter last year. FRC missed the consensus earnings per share in the 3rd calendar quarter of 2013 by -1.54%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for FRC is 18.83 vs. an industry ratio of 17.80, implying that they will have a higher earnings growth than their competitors in the same industry.
ADTRAN, Inc. ( ADTN ) is reporting for the quarter ending March 31, 2014. The infrastructure company's consensus earnings per share forecast from the 5 analysts that follow the stock is $0.16. This value represents a 14.29% increase compared to the same quarter last year. In the past year ADTN has beat the expectations every quarter. The highest one was in the 4th calendar quarter where they beat the consensus by 50%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ADTN is 22.45 vs. an industry ratio of 132.10.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2014. In the past year ABT has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 17.15 vs. an industry ratio of 17.70. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2014. In the past year ABT has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 17.15 vs. an industry ratio of 17.70. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2014. In the past year ABT has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 17.15 vs. an industry ratio of 17.70. | Abbott Laboratories ( ABT ) is reporting for the quarter ending March 31, 2014. In the past year ABT has met analyst expectations twice and beat the expectations the other two quarters. Zacks Investment Research reports that the 2014 Price to Earnings ratio for ABT is 17.15 vs. an industry ratio of 17.70. |
34192.0 | 2014-04-11 00:00:00 UTC | Notable Two Hundred Day Moving Average Cross - ABT | ABT | https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-abt-2014-04-11 | nan | nan | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $36.83, changing hands as low as $36.65 per share. Abbott Laboratories shares are currently trading down about 0.3% on the day. The chart below shows the one year performance of ABT shares, versus its 200 day moving average:
Looking at the chart above, ABT's low point in its 52 week range is $32.70 per share, with $40.49 as the 52 week high point - that compares with a last trade of $36.93.
According to the ETF Finder at ETF Channel, ABT makes up 10.19% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading lower by about 0.6% on the day Friday.
Click here to find out which 9 other stocks recently crossed below their 200 day moving average »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $36.83, changing hands as low as $36.65 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $32.70 per share, with $40.49 as the 52 week high point - that compares with a last trade of $36.93. According to the ETF Finder at ETF Channel, ABT makes up 10.19% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading lower by about 0.6% on the day Friday. | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $36.83, changing hands as low as $36.65 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $32.70 per share, with $40.49 as the 52 week high point - that compares with a last trade of $36.93. According to the ETF Finder at ETF Channel, ABT makes up 10.19% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading lower by about 0.6% on the day Friday. | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $36.83, changing hands as low as $36.65 per share. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $32.70 per share, with $40.49 as the 52 week high point - that compares with a last trade of $36.93. According to the ETF Finder at ETF Channel, ABT makes up 10.19% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading lower by about 0.6% on the day Friday. | In trading on Friday, shares of Abbott Laboratories (Symbol: ABT) crossed below their 200 day moving average of $36.83, changing hands as low as $36.65 per share. According to the ETF Finder at ETF Channel, ABT makes up 10.19% of the iShares U.S. Medical Devices ETF (Symbol: IHI) which is trading lower by about 0.6% on the day Friday. The chart below shows the one year performance of ABT shares, versus its 200 day moving average: Looking at the chart above, ABT's low point in its 52 week range is $32.70 per share, with $40.49 as the 52 week high point - that compares with a last trade of $36.93. |
34193.0 | 2014-04-11 00:00:00 UTC | Abbott Labs Progresses with Absorb - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbott-labs-progresses-with-absorb-analyst-blog-2014-04-11 | nan | nan | Abbott Laboratories ( ABT ) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS) device.
The ABSORB III trial (n=2000) will evaluate the potential benefits of Absorb in people with coronary artery disease in the U.S. The trials are being conducted to support approvals of Absorb in the U.S, Japan and China.
The primary endpoint of ABSORB III trial is target lesion failure (TLF), a combined measure of the safety and effectiveness of Absorb versus Xience family of drug eluting stents at the end of first year. The trials in Japan and China also have the same primary endpoint.
The vascular portfolio of Abbott Labs has drug eluting stents such as the Xience series and Absorb. We note that Absorb already has a marketing approval in Europe and is available in more than 60 countries around the world.
We are encouraged by the recent positive updates on Abbott Labs' vascular portfolio. In Mar 2014, the U.S. Food and Drug Administration (FDA) approved Abbott Labs' Supera peripheral stent system for the treatment of people with blocked bl | Abbott Laboratories ( ABT ) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS) device. The vascular portfolio of Abbott Labs has drug eluting stents such as the Xience series and Absorb. In Mar 2014, the U.S. Food and Drug Administration (FDA) approved Abbott Labs' Supera peripheral stent system for the treatment of people with blocked bl | Abbott Laboratories ( ABT ) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS) device. The primary endpoint of ABSORB III trial is target lesion failure (TLF), a combined measure of the safety and effectiveness of Absorb versus Xience family of drug eluting stents at the end of first year. The vascular portfolio of Abbott Labs has drug eluting stents such as the Xience series and Absorb. | Abbott Laboratories ( ABT ) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS) device. The ABSORB III trial (n=2000) will evaluate the potential benefits of Absorb in people with coronary artery disease in the U.S. The primary endpoint of ABSORB III trial is target lesion failure (TLF), a combined measure of the safety and effectiveness of Absorb versus Xience family of drug eluting stents at the end of first year. | Abbott Laboratories ( ABT ) announced that it has completed enrollment of three clinical trials on Absorb, a drug-eluting coronary bioresorbable vascular scaffold (BVS) device. The trials in Japan and China also have the same primary endpoint. The vascular portfolio of Abbott Labs has drug eluting stents such as the Xience series and Absorb. |
34194.0 | 2014-04-10 00:00:00 UTC | Abbott Laboratories (ABT) Ex-Dividend Date Scheduled for April 11, 2014 | ABT | https://www.nasdaq.com/articles/abbott-laboratories-abt-ex-dividend-date-scheduled-april-11-2014-2014-04-10 | nan | nan | Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 11, 2014. A cash dividend payment of $0.22 per share is scheduled to be paid on May 15, 2014. Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. This represents an 57.14% increase over the same period a year ago. At the current stock price of $37.63, the dividend yield is 2.34%.
The previous trading day's last sale of ABT was $37.63, representing a -7.06% decrease from the 52 week high of $40.49 and a 15.08% increase over the 52 week low of $32.70.
ABT is a part of the Health Care sector, which includes companies such as Johnson & Johnson ( JNJ ) and Novartis AG ( NVS ). ABT's current earnings per share, an indicator of a company's profitability, is $1.62. Zacks Investment Research reports ABT's forecasted earnings growth in 2014 as 9.56%, compared to an industry average of -.7%.
For more information on the declaration, record and payment dates, visit the ABT Dividend History page. Our Dividend Calendar has the full list of stocks that have an ex-dividend today.
Interested in gaining exposure to ABT through an Exchange Traded Fund [ETF]?
The following ETF(s) have ABT as a top-10 holding:
Vanguard Dividend Appreciation ETF ( VIG )
WisdomTree Low P/E Fund ( EZY )
iShares U.S. Medical Devices ETF ( IHI )
Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF )
Schwab U.S. Large-Cap Value ETF ( SCHV ).
The top-performing ETF of this group is IHI with an increase of 8.49% over the last 100 days. VIG has the highest percent weighting of ABT at 3.91%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports ABT's forecasted earnings growth in 2014 as 9.56%, compared to an industry average of -.7%. For more information on the declaration, record and payment dates, visit the ABT Dividend History page. | The following ETF(s) have ABT as a top-10 holding: Vanguard Dividend Appreciation ETF ( VIG ) WisdomTree Low P/E Fund ( EZY ) iShares U.S. Medical Devices ETF ( IHI ) Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) Schwab U.S. Large-Cap Value ETF ( SCHV ). The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 11, 2014. | Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. The previous trading day's last sale of ABT was $37.63, representing a -7.06% decrease from the 52 week high of $40.49 and a 15.08% increase over the 52 week low of $32.70. The following ETF(s) have ABT as a top-10 holding: Vanguard Dividend Appreciation ETF ( VIG ) WisdomTree Low P/E Fund ( EZY ) iShares U.S. Medical Devices ETF ( IHI ) Guggenheim BulletShares 2015 Corporate Bond ETF ( BSCF ) Schwab U.S. Large-Cap Value ETF ( SCHV ). | Shareholders who purchased ABT stock prior to the ex-dividend date are eligible for the cash dividend payment. ABT's current earnings per share, an indicator of a company's profitability, is $1.62. Abbott Laboratories ( ABT ) will begin trading ex-dividend on April 11, 2014. |
34195.0 | 2014-04-02 00:00:00 UTC | Noteworthy ETF Inflows: VIG, ABT, CVX, WAG | ABT | https://www.nasdaq.com/articles/noteworthy-etf-inflows-vig-abt-cvx-wag-2014-04-02 | nan | nan | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $211.5 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 248,416,564 to 251,216,564). Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.1%, and Walgreen Co. (Symbol: WAG) is lower by about 0.2%. The chart below shows the one year price performance of VIG, versus its 200 day moving average:
Looking at the chart above, VIG's low point in its 52 week range is $64.83 per share, with $75.75 as the 52 week high point - that compares with a last trade of $75.68. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average » .
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Click here to find out which 9 other ETFs had notable inflows »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.1%, and Walgreen Co. (Symbol: WAG) is lower by about 0.2%. The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $64.83 per share, with $75.75 as the 52 week high point - that compares with a last trade of $75.68. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.1%, and Walgreen Co. (Symbol: WAG) is lower by about 0.2%. The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $64.83 per share, with $75.75 as the 52 week high point - that compares with a last trade of $75.68. Click here to find out which 9 other ETFs had notable inflows » The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.1%, and Walgreen Co. (Symbol: WAG) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $211.5 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 248,416,564 to 251,216,564). The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $64.83 per share, with $75.75 as the 52 week high point - that compares with a last trade of $75.68. | Among the largest underlying components of VIG, in trading today Abbott Laboratories (Symbol: ABT) is down about 0.3%, Chevron Corporation (Symbol: CVX) is off about 0.1%, and Walgreen Co. (Symbol: WAG) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Dividend Appreciation ETF (Symbol: VIG) where we have detected an approximate $211.5 million dollar inflow -- that's a 1.1% increase week over week in outstanding units (from 248,416,564 to 251,216,564). The chart below shows the one year price performance of VIG, versus its 200 day moving average: Looking at the chart above, VIG's low point in its 52 week range is $64.83 per share, with $75.75 as the 52 week high point - that compares with a last trade of $75.68. |
34196.0 | 2014-03-31 00:00:00 UTC | Abbott's Supera Stent Approved in the U.S. - Analyst Blog | ABT | https://www.nasdaq.com/articles/abbotts-supera-stent-approved-in-the-u.s.-analyst-blog-2014-03-31 | nan | nan | Abbott Laboratories ( ABT ) received a boost for its vascular portfolio when it announced that the U.S. Food and Drug Administration (FDA) approved its Supera peripheral stent system for the treatment of people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD).
The FDA approval was supported by encouraging data from the SUPERB trial which showed that the Supera stent was highly effective in opening up blocked blood vessels in the upper leg, even in difficult cases.
Moreover, it was observed that there were no stent fractures during the first year following the treatment with the Supera stent and at two years there was a very low stent fracture rate of 0.5%.
We note that Abbott Labs acquired Supera stent through the acquisition of IDEV Technologies in Aug 2013. The Supera stent already carries a CE mark in Europe for treating blocked blood vessels caused by PAD.
Hence, an approval in the U.S. will further boost vascular sales. The vascular business is an important part of Abbott Labs' product portfolio and generated sales of $3.0 billion in 2013, down 1.5% from 2012. The vascular portfolio of Abbott Labs already boasts of drug eluting stents such as Xience series and Absorb.
Abbott Labs is continuously working to boost its vascular products portfolio and expects to launch several products in the next few years. The continued rollout of Absorb and Xience Xpedition along with new products such as Supera stents will further strengthen Abbott Labs' vascular portfolio in 2014.
We remind investors that Abbott Labs became a diversified medical products company focusing on branded generic pharmaceutical, medical devices, diagnostic and nutritional businesses following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc. ( ABBV ), in Jan 2013.
The business environment was challenging in 2013 due to austerity measures undertaken by developed markets and weak economic conditions elsewhere. We believe Abbott Labs' diversification in varied business lines will enable the company to counter the challenging business environment and maintain top-line growth.
Abbott Labs currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Shire ( SHPG ) and Lannett Company, Inc. ( LCI ). Both carry a Zacks Rank #1 (Strong Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
LANNETT INC (LCI): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Laboratories ( ABT ) received a boost for its vascular portfolio when it announced that the U.S. Food and Drug Administration (FDA) approved its Supera peripheral stent system for the treatment of people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA approval was supported by encouraging data from the SUPERB trial which showed that the Supera stent was highly effective in opening up blocked blood vessels in the upper leg, even in difficult cases. | Abbott Laboratories ( ABT ) received a boost for its vascular portfolio when it announced that the U.S. Food and Drug Administration (FDA) approved its Supera peripheral stent system for the treatment of people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs is continuously working to boost its vascular products portfolio and expects to launch several products in the next few years. | Abbott Laboratories ( ABT ) received a boost for its vascular portfolio when it announced that the U.S. Food and Drug Administration (FDA) approved its Supera peripheral stent system for the treatment of people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The continued rollout of Absorb and Xience Xpedition along with new products such as Supera stents will further strengthen Abbott Labs' vascular portfolio in 2014. | Abbott Laboratories ( ABT ) received a boost for its vascular portfolio when it announced that the U.S. Food and Drug Administration (FDA) approved its Supera peripheral stent system for the treatment of people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The vascular business is an important part of Abbott Labs' product portfolio and generated sales of $3.0 billion in 2013, down 1.5% from 2012. |
34197.0 | 2014-03-28 00:00:00 UTC | Baxter Hits 52-Week High on Planned Business Split-Up - Analyst Blog | ABT | https://www.nasdaq.com/articles/baxter-hits-52-week-high-on-planned-business-split-up-analyst-blog-2014-03-28 | nan | nan | Baxter International Inc. ( BAX ) revealed that it will split-up its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on the two businesses, effectively commercialize product offerings, efficiently allocate resources to high growth areas, and bring flexibility in deciding on growth and investment strategies.
Following the announcement, shares of BAX reached new 52-week high of $75.68 to close at $72.80 on the same day.
BAX expects to complete splitting up the business in mid-2015. The transaction will take the form of a tax-free distribution to the company's shareholders of a new publicly traded stock in the new biopharmaceuticals company.
BAX expects to incur one-time charges due to the split up during the reporting periods preceding the separation. However, the company does not expect it to impact the financial guidance for 2014.
The Two Businesses
BAX's biopharmaceuticals/bioscience division includes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions. It contributed $6.6 billion or 43.0% to overall revenues in 2013.
Ludwig N. Hantson - the current president of BioScience division - will be named as the CEO of the new biopharmaceuticals company. Baxter director Wayne T. Hockmeyer will serve as nonexecutive chairman of the new unit.
BAX's medical products division manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics.
The medical products business contributed $8.7 million or 57% to BAX's overall revenues in 2013. The business will continue to integrate the $4 billion acquisition of Swedish dialysis maker Gambro AB, completed last September, which complements its existing renal therapies franchise.
BAX's current CEO and chairman, Robert L. Parkinson Jr., will lead the medical products business in the future, retaining its international name.
Moody's Reaction
Following the announcement, Moody's Investors Service - the credit rating arm of Moody's Corporation ( MCO ) - downgraded its outlook on the company to negative from stable, while keeping its A3 and Prime-2 ratings intact. The rating agency believes that the split-up will significantly hurt BAX's profitability.
Apart from losing economies of scale and business diversity, Moody's believes separating the key biopharmaceuticals division would significantly impact the company's margin as it generates over half of the company's profitability due to the presence of key pipeline products, despite a lower contribution to overall revenues compared to the other medical product division.
Recent Split-up in HealthcareIndustry
In early 2013, Abbott Laboratories ( ABT ) spun off its drug business into the new company, AbbVie. Abbott's remaining businesses market nutritional formula, generic drugs, medical implants and diagnostics.
Recently, there was a rumor that the biggest drug maker in the U.S., Pfizer Inc. ( PFE ) may split up its businesses into two or three companies. However, Pfizer negated the rumor, saying that it is not looking for any split-up until for a couple of years in the future.
Currently, Baxter retains a Zacks Rank #3 (Hold).
ABBOTT LABS (ABT): Free Stock Analysis Report
BAXTER INTL (BAX): Free Stock Analysis Report
MOODYS CORP (MCO): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Recent Split-up in HealthcareIndustry In early 2013, Abbott Laboratories ( ABT ) spun off its drug business into the new company, AbbVie. ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report MOODYS CORP (MCO): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Baxter International Inc. ( BAX ) revealed that it will split-up its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on the two businesses, effectively commercialize product offerings, efficiently allocate resources to high growth areas, and bring flexibility in deciding on growth and investment strategies. | ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report MOODYS CORP (MCO): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Recent Split-up in HealthcareIndustry In early 2013, Abbott Laboratories ( ABT ) spun off its drug business into the new company, AbbVie. Apart from losing economies of scale and business diversity, Moody's believes separating the key biopharmaceuticals division would significantly impact the company's margin as it generates over half of the company's profitability due to the presence of key pipeline products, despite a lower contribution to overall revenues compared to the other medical product division. | ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report MOODYS CORP (MCO): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Recent Split-up in HealthcareIndustry In early 2013, Abbott Laboratories ( ABT ) spun off its drug business into the new company, AbbVie. Baxter International Inc. ( BAX ) revealed that it will split-up its biopharmaceuticals and medical device segments into two independent companies in order to put greater management focus on the two businesses, effectively commercialize product offerings, efficiently allocate resources to high growth areas, and bring flexibility in deciding on growth and investment strategies. | Recent Split-up in HealthcareIndustry In early 2013, Abbott Laboratories ( ABT ) spun off its drug business into the new company, AbbVie. ABBOTT LABS (ABT): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report MOODYS CORP (MCO): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. BAX expects to complete splitting up the business in mid-2015. |
34198.0 | 2014-03-26 00:00:00 UTC | Sector Update: Healthcare | ABT | https://www.nasdaq.com/articles/sector-update-healthcare-2014-03-26 | nan | nan | Healthcare stocks were higher again with the NYSE Healthcare Sector Index advancing 0.4% and shares of healthcare companies in the S&P 500 also climbing 0.4% as a group.
In company news, Perrigo plc ( PRGO ) shares were off their worst levels of the session but remain underwater late in Wednesday's session after earlier announcing plans to work with a division of Golden State foods to produce a popular nutritional drink for older adults.
PRGO and Golden State's KanPak unit will partner to produce six varieties of Ensure nutritional drinks, the companies said. Additional details of the partnerships were not disclosed as well as any information on the companies' relationship with Abbott Laboratories ( ABT ), which markets Ensure through its Abbott Nutrition subsidiary.
PRGO shares were down nearly 1% at $156.57 each, or more than $1 above its intra-day low. The stock has a 52-week range of $111.37 to $162.35 a share. ABT was up 1.1% at $38.83 a share in late trade.
In other sector news,
(+) KOOL, Submits pre-Investigational Device Exemption information package to the U.S. Food and Drug Administration for the use of its SurgWerks CLI Therapy to treat no-option patients with late-stage, critical limb ischemia.
(-) INSM, Said its Arikayce inhaled antibiotic falls short of its primary goal in Phase II testing, failing to cause a statistically significant reduction in drug-resistant nontuberculous mycobacteria lung infections when compared to a placebo.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Additional details of the partnerships were not disclosed as well as any information on the companies' relationship with Abbott Laboratories ( ABT ), which markets Ensure through its Abbott Nutrition subsidiary. ABT was up 1.1% at $38.83 a share in late trade. PRGO and Golden State's KanPak unit will partner to produce six varieties of Ensure nutritional drinks, the companies said. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Additional details of the partnerships were not disclosed as well as any information on the companies' relationship with Abbott Laboratories ( ABT ), which markets Ensure through its Abbott Nutrition subsidiary. ABT was up 1.1% at $38.83 a share in late trade. | Additional details of the partnerships were not disclosed as well as any information on the companies' relationship with Abbott Laboratories ( ABT ), which markets Ensure through its Abbott Nutrition subsidiary. ABT was up 1.1% at $38.83 a share in late trade. Healthcare stocks were higher again with the NYSE Healthcare Sector Index advancing 0.4% and shares of healthcare companies in the S&P 500 also climbing 0.4% as a group. | Additional details of the partnerships were not disclosed as well as any information on the companies' relationship with Abbott Laboratories ( ABT ), which markets Ensure through its Abbott Nutrition subsidiary. ABT was up 1.1% at $38.83 a share in late trade. Healthcare stocks were higher again with the NYSE Healthcare Sector Index advancing 0.4% and shares of healthcare companies in the S&P 500 also climbing 0.4% as a group. |
34199.0 | 2014-03-26 00:00:00 UTC | Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews | ABT | https://www.nasdaq.com/articles/pharma-biotech-stock-outlook-march-2014-zacks-analyst-interviews-2014-03-26 | nan | nan | The pharmaceutical sector has been slowly but steadily recovering from the impact of the patent cliff being faced by several companies over the past few years. The worst of the patent cliff is over and the NYSE ARCA Pharmaceutical Index (^DRG) is up 21.4% over the last year. So far in 2014, the index is up 6.9%.
Several companies which had been struggling to post growth in the face of genericization over the past few years are now on the recovery path. New products should start contributing significantly to results, and increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector.
Products that lost exclusivity recently include Eli Lilly's ( LLY ) Cymbalta and Evista. AstraZeneca's ( AZN ) Nexium could also start facing generics from May 2014 in the U.S. where sales were $2.1 billion in 2013.
Collaborations, Acquisitions and Restructuring
The pharma sector witnessed major merger and acquisitions (M&A) activity over the last couple of years. Going forward, we expect small bolt-on acquisitions to continue. In-licensing activities and collaborations for the development of pipeline candidates have also increased significantly. Several pharma companies are focusing on in-licensing mid-to-late stage pipeline candidates that look promising, instead of developing a product from scratch, which involves a lot of funds and time.
Small biotech companies are open to in-licensing activities and collaborations. Most of these companies find it challenging to raise cash, thereby making it difficult for them to survive and continue with the development of promising pipeline candidates. Therefore, it makes sense for them to seek deals with pharma companies that are sitting on huge piles of cash.
We recommend biotech stocks that have attractive pipeline candidates or technology that can be used for the development of novel therapeutics. Therapeutic areas which could see a lot of in-licensing activity include immuno-oncology, oncology, central nervous system disorders, diabetes and immunology/inflammation. The hepatitis C virus (HCV) market is also attracting a lot of attention.
Some recent acquisitions/deals include Shire's ( SHPG ) acquisition of ViroPharma, Salix's ( SLXP ) acquisition of Santarus as well as the acquisition of Optimer Pharmaceuticals and Trius Therapeutics by Cubist Pharmaceuticals ( CBST ) and that of Elan by Perrigo Company ( PRGO ). A major acquisition agreement was announced recently -- that of Forest Labs ( FRX ) by Actavis ( ACT ). This deal shows the intention of generic companies to establish a strong position in the branded market. Another significant deal was the one signed between Celgene ( CELG ) and OncoMed Pharmaceuticals ( OMED ) for the joint development and commercialization of up to six anti-cancer stem cell candidates from OncoMed's biologics pipeline.
Another trend that we are seeing in recent months is the divestment of non-core business segments. Pfizer ( PFE ) sold its Capsugel unit and its Nutrition business in Aug 2011 and Nov 2012, respectively. Pfizer then spun off its animal health business into a new company, Zoetis ( ZTS ).
Meanwhile, GlaxoSmithKline ( GSK ) divested certain non-core brands from its Consumer Healthcare segment. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY ( XRAY ). The monetization of non-core assets will allow the pharma/biotech companies to focus on their areas of expertise. Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. Johnson & Johnson ( JNJ ) is also looking to divest its ortho-clinical diagnostics business. Vertex ( VRTX ) monetized its Incivo-related royalties; the company can use the cash generated from this deal for its cystic fibrosis program.
Restructuring activities are also gaining momentum as large pharma companies are looking to cut costs and streamline their operations. Most of these companies are re-evaluating their pipelines and discontinuing programs which do not have a favorable risk-benefit profile. Some of the companies that announced restructuring plans include Merck ( MRK ), Novartis ( NVS ), Eli Lilly, Shire and Sanofi ( SNY ).
Destination Ireland
Of late, several companies have been looking towards Ireland for acquisitions. The latest company to join the Irish club is Horizon Pharma ( HZNP ) which is doing a reverse merger with Dublin-based Vidara. Tax benefits are a major attraction for such deals. Other such recent acquisitions include that of Warner Chilcott by Actavis and Elan by Perrigo.
Emerging Markets and Biosimilars
Another trend seen in the pharmaceutical sector is a focus on emerging markets. Companies like Mylan ( MYL ), Pfizer, Merck, Eli Lilly, Glaxo and Sanofi are all looking to expand their presence in India, China, Brazil and other emerging markets.
Until recently, most of the commercialization efforts were focused on the U.S. -- the largest pharmaceutical market -- along with Europe and Japan. Emerging markets are slowly and steadily gaining more importance, and several companies are now shifting their focus to these areas.
However, while higher demand for medicines, government initiatives for healthcare, new patient population and increasing use of generics should help drive demand, we point out that emerging markets are also not immune to genericization. Moreover, investigations into bribery charges in China could put a lid on near-term growth.
Meanwhile, growth in Europe will continue to be pressurized by austerity and cost-containment measures.
We are also seeing several companies entering into deals for the development of biosimilars, generic versions of biologics. Companies like Merck, Amgen, Biogen ( BIIB ) and Actavis are all targeting the highly lucrative biosimilars market.
4Q Earnings
All companies falling under the Medical sector have reported fourth quarter and full year 2013 results. While earnings-beat and revenue-beat ratios (percentage of companies coming out with positive surprises) were pretty impressive, growth ratios were modest. Fourth quarter results were characterized by currency headwinds as well as the impact of generics.
Fourth quarter 2013 earnings "beat ratio" was 74.0% while the revenue "beat ratio" was 76.0%. Total earnings for this sector were up 1.1%, compared to 0.2% recorded in the third quarter of 2013. Total revenues moved up 5.3% in the quarter versus 5.8% growth in the third quarter of 2013.
Looking at the consensus earnings expectations for the first quarter, earnings are expected to decline 3.3%. Tough challenges for some companies, negative currency movement and a few patent expirees will affect first quarter growth. However, growth should pick up from the second quarter for which 1.6% earnings growth is expected.
Overall, 2014 earnings are expected to grow 6.5%. For a detailed look at the earnings outlook for the Medical and other sectors, please check our Zacks Earnings Trends report.
Focus on New Products
2013 saw the FDA approving 27 novel medicines, about one-third (33%) of which were identified by the FDA as "First-in-Class," meaning they use a new and unique mechanism of action for treating a medical condition. These include drugs like Invokana (type II diabetes), Kadcyla (HER2-positive late-stage breast cancer), Sovaldi (an interferon-free oral treatment for some patients with chronic hepatitis C) and Mekinist (metastatic melanoma).
Yet another one-third of the approved drugs fall under the rare or "orphan" disease category that affects 200,000 or fewer Americans. These include Imbruvica (mantle cell lymphoma), Gazyva (chronic lymphocytic leukemia), Kynamro (homozygous familial hypercholesterolemia) and Adempas and Opsumit (both for pulmonary arterial hypertension). Three of the approved drugs - Gazyva, Imbruvica and Sovaldi - had breakthrough therapy designation. Breakthrough status, a new designation that became effective after Jul 9, 2012, is designed to cut short the development time of promising new treatments.
Some important products approved in 2013 include:
Drugs like Tecfidera, Sovaldi and Imbruvica represent strong commercial potential.
So far in 2014, drugs that have gained approval include AstraZeneca's Myalept (complications of leptin deficiency) and Farxiga (type II diabetes), Chelsea Therapeutics' ( CHTP ) Northera (to treat neurogenic orthostatic hypotension), BioMarin's ( BMRN ) Vimizim (Morquio A syndrome) and Vanda Pharma's ( VNDA ) Hetlioz (non-24- hour sleep-wake disorder).
Upcoming events include FDA advisory panel review of the regulatory application for MannKind's ( MNKD ) experimental diabetes treatment, Afrezza. April should be an active month with the agency expected to deliver a response on the approvability of several experimental drugs including Afrezza, Glaxo's Eperzan (type II diabetes) and Arzerra (CLL).
Zacks Industry Rank
Within the Zacks Industry classification, pharma and biotech are broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into four industries at the expanded level: large-cap pharma, med-biomed/gene, med-drugs and med-generic drugs.
We rank all the 260-plus industries in the 16 Zacks sectors based on the earnings outlook and fundamental strength of the constituent companies in each industry. To learn more, visit: About Zacks Industry Rank .
As a point of reference, the outlook for industries with Zacks Industry Rank #88 and lower is 'Positive,' between #89 and #176 is 'Neutral' and #177 and higher is 'Negative.'
The Zacks Industry Rank for large-cap pharma is #225, med-biomed/gene is #69, med-drugs is #84, while the med-generic drugs is #8. Analyzing the Zacks Industry Rank for different medical segments, it is obvious that the outlook is Positive for med-drugs, med-biomed/gene and med-generic drugs and Negative for large-cap pharma stocks.
OPPORTUNITIES
While several companies will continue to face challenges like EU austerity measures and genericization, the pharma industry is out of the worst of its genericization phase. Many companies which had faced generic headwinds in the last couple of years should continue to see a sustained improvement in results this year. Cost-cutting, downsizing, streamlining of the pipeline, growth in emerging markets and new product launches should support growth.
Among pharma stocks, Shire, a Zacks Rank #1 (Strong Buy) stock, looks well-positioned for growth with the company expanding its product portfolio and pipeline through the acquisition of ViroPharma. Horizon Pharma, a Zacks Rank #2 (Buy) stock, also seems on the right path with the company announcing its plans to acquire Ireland-based Vidara.
In the biotech space, we are positive on Biogen. Tecfidera, the company's recently launched oral multiple sclerosis drug, is off to a strong start with the product delivering sales of $876 million (as of Dec 31, 2013) since its launch in early April 2013. While Tecfidera has gained the top spot in the oral multiple sclerosis market in the U.S., Avonex and Tysabri should continue contributing significantly to sales. Tecfidera gained EU approval recently. Biogen is also progressing with its hemophilia pipeline.
We are also positive on Amgen ( AMGN ). Amgen should be able to deliver on its long-term strategy based on expansion in key markets, launch of new manufacturing technologies, and pipeline development. Enbrel should continue performing well. Amgen's late-stage pipeline is also moving along. While Amgen is a Zacks Rank #2 stock, Biogen is a Zacks Rank #3 (Hold) stock.
Gilead, a Zacks Rank #1 stock, continues to do well in the HIV segment and has a potential blockbuster in its portfolio in the form of HCV treatment, Sovaldi.
Among generic companies, Actavis looks well-positioned. Actavis is slowly and steadily building its position in the branded market through acquisitions (Actavis Group, Warner Chilcott and the upcoming acquisition of Forest). With fewer major patent expiries slated to occur in the next few years, we are encouraged by Actavis' focus on building its branded and biosimilars pipeline. The company carries a Zacks Rank #2.
WEAKNESSES
We recommend avoiding names that offer little growth or opportunity for a take-out. These include companies which are developing drugs that are likely to face regulatory hurdles.
Among large-cap pharma companies, Eli Lilly is gearing up for another round of patent expiries -- Cymbalta in Dec 2013 and Evista this year. We prefer waiting on the sidelines until the company is able to emerge from the impact of genericization.
Companies that currently carry a Zacks Rank #4 (Sell) include Bayer ( BAYRY ), Sanofi and Glaxo among others. Sanofi, which is facing currency headwinds, was in the news recently related to the development of its PCSK9 inhibitor, alirocumab. The FDA has asked Sanofi and partner Regeneron ( REGN ) to evaluate potential neurocognitive adverse events across the global development program for alirocumab, especially in long-term studies. While results on PCSK9 inhibitors in development have been encouraging so far, this is the first time that serious safety concerns have been raised.
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ACTAVIS PLC (ACT): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
ASTRAZENECA PLC (AZN): Free Stock Analysis Report
BAYER A G -ADR (BAYRY): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
BIOMARIN PHARMA (BMRN): Free Stock Analysis Report
CUBIST PHARM (CBST): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
CHELSEA THERAP (CHTP): Free Stock Analysis Report
FOREST LABS A (FRX): Free Stock Analysis Report
GLAXOSMITHKLINE (GSK): Free Stock Analysis Report
HORIZON PHARMA (HZNP): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
MANNKIND CORP (MNKD): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
ONCOMED PHARMA (OMED): Free Stock Analysis Report
PFIZER INC (PFE): Free Stock Analysis Report
PERRIGO CO PLC (PRGO): Free Stock Analysis Report
REGENERON PHARM (REGN): Free Stock Analysis Report
SALIX PHARM-LTD (SLXP): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
VANDA PHARMACT (VNDA): Free Stock Analysis Report
VERTEX PHARM (VRTX): Free Stock Analysis Report
DENTSPLY INTL (XRAY): Free Stock Analysis Report
ZOETIS INC (ZTS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ONCOMED PHARMA (OMED): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. These include drugs like Invokana (type II diabetes), Kadcyla (HER2-positive late-stage breast cancer), Sovaldi (an interferon-free oral treatment for some patients with chronic hepatitis C) and Mekinist (metastatic melanoma). | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ONCOMED PHARMA (OMED): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. Some of the companies that announced restructuring plans include Merck ( MRK ), Novartis ( NVS ), Eli Lilly, Shire and Sanofi ( SNY ). | ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ONCOMED PHARMA (OMED): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. Zacks Industry Rank Within the Zacks Industry classification, pharma and biotech are broadly grouped into the Medical sector (one of 16 Zacks sectors) and further sub-divided into four industries at the expanded level: large-cap pharma, med-biomed/gene, med-drugs and med-generic drugs. | Abbott Labs ( ABT ) split into two separate publicly traded companies; while one company deals in diversified medical products, the other, AbbVie ( ABBV ), is focusing on research-based pharmaceuticals. ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report ONCOMED PHARMA (OMED): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report DENTSPLY INTL (XRAY): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Collaborations, Acquisitions and Restructuring The pharma sector witnessed major merger and acquisitions (M&A) activity over the last couple of years. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.